{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "8fc8fb81",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Id</th>\n",
       "      <th>Name</th>\n",
       "      <th>Applications__c</th>\n",
       "      <th>Brand_Name__c</th>\n",
       "      <th>Chemical_Name__c</th>\n",
       "      <th>Applicants__c</th>\n",
       "      <th>Funding_requested_for__c</th>\n",
       "      <th>Stage__c</th>\n",
       "      <th>Pharmaceutical__c</th>\n",
       "      <th>Community_URL__c</th>\n",
       "      <th>Therapeutic_group__c</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>a0ROZ000009J5Ev2AK</td>\n",
       "      <td>15-valent pneumococcal conjugate vaccine (PCV15)</td>\n",
       "      <td>A-04423</td>\n",
       "      <td>VAXNEUVANCE.</td>\n",
       "      <td>15-valent pneumococcal conjugate vaccine (PCV15)</td>\n",
       "      <td>MERCK SHARP &amp; DOHME (NEW ZEALAND) LIMITED</td>\n",
       "      <td>Prevention of invasive pneumococcal disease</td>\n",
       "      <td>Decision</td>\n",
       "      <td>15-valent pneumococcal conjugate vaccine (PCV1...</td>\n",
       "      <td>/apptracker/s/application-public/a102P00000BUmR1</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>a0ROZ000004CX2l2AG</td>\n",
       "      <td>Adjuvanted inactivated quadrivalent influenza ...</td>\n",
       "      <td>A-03341</td>\n",
       "      <td>FLUAD® QUAD</td>\n",
       "      <td>Adjuvanted inactivated quadrivalent influenza ...</td>\n",
       "      <td>Seqirus</td>\n",
       "      <td>influenza vaccination for people aged 65 years...</td>\n",
       "      <td>Decision</td>\n",
       "      <td>Adjuvanted inactivated quadrivalent influenza ...</td>\n",
       "      <td>/apptracker/s/application-public/a102P00000ACGT3</td>\n",
       "      <td>National Immunisation Schedule</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>a0ROZ00000Cn1xE2AR</td>\n",
       "      <td>Adjuvanted inactivated trivalent influenza vac...</td>\n",
       "      <td>A-00724</td>\n",
       "      <td>Fluad</td>\n",
       "      <td>Adjuvanted inactivated trivalent influenza vac...</td>\n",
       "      <td>Seqirus</td>\n",
       "      <td>Influenza vaccine for people 65 years of age a...</td>\n",
       "      <td>Options Compared</td>\n",
       "      <td>Adjuvanted inactivated trivalent influenza vac...</td>\n",
       "      <td>/apptracker/s/application-public/a10OZ000003tIqb</td>\n",
       "      <td>National Immunisation Schedule</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>a0R2P000000gVYDUA2</td>\n",
       "      <td>Bevacizumab and Human Papillomavirus (HPV) vac...</td>\n",
       "      <td>A-00655</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Bevacizumab and Human Papillomavirus (HPV) vac...</td>\n",
       "      <td>PHARMAC Initiated</td>\n",
       "      <td>Recurrent respiratory papillomatosis</td>\n",
       "      <td>Decision</td>\n",
       "      <td>Bevacizumab and Human Papillomavirus (HPV) vac...</td>\n",
       "      <td>/apptracker/s/application-public/a102P000008pu1t</td>\n",
       "      <td>Respiratory System and Allergies</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>a0R2P000000LmcWUAS</td>\n",
       "      <td>Diphtheria and tetanus vaccine</td>\n",
       "      <td>A-00221</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Diphtheria and tetanus vaccine</td>\n",
       "      <td>PHARMAC Initiated</td>\n",
       "      <td>Widening of access</td>\n",
       "      <td>Decision</td>\n",
       "      <td>Diphtheria and tetanus vaccine</td>\n",
       "      <td>/apptracker/s/application-public/a102P000008pu78</td>\n",
       "      <td>National Immunisation Schedule</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2010</th>\n",
       "      <td>a0ROZ00000083aG2AQ</td>\n",
       "      <td>AEON Sodium Chloride 5 Percent</td>\n",
       "      <td>A-04432</td>\n",
       "      <td>AEON</td>\n",
       "      <td>AEON Sodium Chloride 5 Percent</td>\n",
       "      <td>MEDIX 21 LIMITED</td>\n",
       "      <td>Corneal oedema relief</td>\n",
       "      <td>Seeking Clinical Advice</td>\n",
       "      <td>AEON Sodium Chloride 5 Percent (AEON)</td>\n",
       "      <td>/apptracker/s/application-public/a102P00000BZ6SB</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2011</th>\n",
       "      <td>a0ROZ00000DqVYD2A3</td>\n",
       "      <td>Pegunigalsidase alfa-iwxj</td>\n",
       "      <td>A-05325</td>\n",
       "      <td>ELFABRIO</td>\n",
       "      <td>Pegunigalsidase alfa-iwxj</td>\n",
       "      <td>CHIESI NEW ZEALAND LIMITED</td>\n",
       "      <td>Fabry Disease</td>\n",
       "      <td>Options Compared</td>\n",
       "      <td>Pegunigalsidase alfa-iwxj (ELFABRIO)</td>\n",
       "      <td>/apptracker/s/application-public/a10OZ00000466q1</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2012</th>\n",
       "      <td>a0ROZ000003nufF2AQ</td>\n",
       "      <td>Elemental Food (Elemental Gold)</td>\n",
       "      <td>A-04296</td>\n",
       "      <td>It is not a pharmaceutical. The brand name is ...</td>\n",
       "      <td>Elemental Food (Elemental Gold)</td>\n",
       "      <td>ENDOTHERAPEUTICS NZ LIMITED</td>\n",
       "      <td>Currently funded indications</td>\n",
       "      <td>Seeking Clinical Advice</td>\n",
       "      <td>Elemental Food (Elemental Gold) (It is not a p...</td>\n",
       "      <td>/apptracker/s/application-public/a10OZ000001dzUU</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2013</th>\n",
       "      <td>a0ROZ00000AQkoE2AT</td>\n",
       "      <td>SARS-CoV-2 rS (Omicron XBB.1.5)</td>\n",
       "      <td>A-04785</td>\n",
       "      <td>NUVAXOVID XBB.1.5</td>\n",
       "      <td>SARS-CoV-2 rS (Omicron XBB.1.5)</td>\n",
       "      <td>BIOCELECT NEW ZEALAND LIMITED</td>\n",
       "      <td>prevention of COVID-19</td>\n",
       "      <td>Options Compared</td>\n",
       "      <td>SARS-CoV-2 rS (Omicron XBB.1.5) (NUVAXOVID XBB...</td>\n",
       "      <td>/apptracker/s/application-public/a10OZ000000N49N</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2014</th>\n",
       "      <td>a0ROZ0000070NGj2AM</td>\n",
       "      <td>Elasomeran, Elasomeran and Davesomeran, Anduso...</td>\n",
       "      <td>A-04863</td>\n",
       "      <td>SPIKEVAX</td>\n",
       "      <td>Elasomeran, Elasomeran and Davesomeran, Anduso...</td>\n",
       "      <td>Moderna Australia Pty Ltd</td>\n",
       "      <td>active immunisation to prevent coronavirus dis...</td>\n",
       "      <td>Under Assessment</td>\n",
       "      <td>Elasomeran, Elasomeran and Davesomeran, Anduso...</td>\n",
       "      <td>/apptracker/s/application-public/a10OZ000000N8Cz</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>2015 rows × 11 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                      Id                                               Name  \\\n",
       "0     a0ROZ000009J5Ev2AK   15-valent pneumococcal conjugate vaccine (PCV15)   \n",
       "1     a0ROZ000004CX2l2AG  Adjuvanted inactivated quadrivalent influenza ...   \n",
       "2     a0ROZ00000Cn1xE2AR  Adjuvanted inactivated trivalent influenza vac...   \n",
       "3     a0R2P000000gVYDUA2  Bevacizumab and Human Papillomavirus (HPV) vac...   \n",
       "4     a0R2P000000LmcWUAS                     Diphtheria and tetanus vaccine   \n",
       "...                  ...                                                ...   \n",
       "2010  a0ROZ00000083aG2AQ                     AEON Sodium Chloride 5 Percent   \n",
       "2011  a0ROZ00000DqVYD2A3                          Pegunigalsidase alfa-iwxj   \n",
       "2012  a0ROZ000003nufF2AQ                    Elemental Food (Elemental Gold)   \n",
       "2013  a0ROZ00000AQkoE2AT                    SARS-CoV-2 rS (Omicron XBB.1.5)   \n",
       "2014  a0ROZ0000070NGj2AM  Elasomeran, Elasomeran and Davesomeran, Anduso...   \n",
       "\n",
       "     Applications__c                                      Brand_Name__c  \\\n",
       "0            A-04423                                       VAXNEUVANCE.   \n",
       "1            A-03341                                        FLUAD® QUAD   \n",
       "2            A-00724                                              Fluad   \n",
       "3            A-00655                                                NaN   \n",
       "4            A-00221                                                NaN   \n",
       "...              ...                                                ...   \n",
       "2010         A-04432                                               AEON   \n",
       "2011         A-05325                                           ELFABRIO   \n",
       "2012         A-04296  It is not a pharmaceutical. The brand name is ...   \n",
       "2013         A-04785                                  NUVAXOVID XBB.1.5   \n",
       "2014         A-04863                                           SPIKEVAX   \n",
       "\n",
       "                                       Chemical_Name__c  \\\n",
       "0      15-valent pneumococcal conjugate vaccine (PCV15)   \n",
       "1     Adjuvanted inactivated quadrivalent influenza ...   \n",
       "2     Adjuvanted inactivated trivalent influenza vac...   \n",
       "3     Bevacizumab and Human Papillomavirus (HPV) vac...   \n",
       "4                        Diphtheria and tetanus vaccine   \n",
       "...                                                 ...   \n",
       "2010                     AEON Sodium Chloride 5 Percent   \n",
       "2011                          Pegunigalsidase alfa-iwxj   \n",
       "2012                    Elemental Food (Elemental Gold)   \n",
       "2013                    SARS-CoV-2 rS (Omicron XBB.1.5)   \n",
       "2014  Elasomeran, Elasomeran and Davesomeran, Anduso...   \n",
       "\n",
       "                                  Applicants__c  \\\n",
       "0     MERCK SHARP & DOHME (NEW ZEALAND) LIMITED   \n",
       "1                                       Seqirus   \n",
       "2                                       Seqirus   \n",
       "3                             PHARMAC Initiated   \n",
       "4                             PHARMAC Initiated   \n",
       "...                                         ...   \n",
       "2010                           MEDIX 21 LIMITED   \n",
       "2011                 CHIESI NEW ZEALAND LIMITED   \n",
       "2012                ENDOTHERAPEUTICS NZ LIMITED   \n",
       "2013              BIOCELECT NEW ZEALAND LIMITED   \n",
       "2014                  Moderna Australia Pty Ltd   \n",
       "\n",
       "                               Funding_requested_for__c  \\\n",
       "0           Prevention of invasive pneumococcal disease   \n",
       "1     influenza vaccination for people aged 65 years...   \n",
       "2     Influenza vaccine for people 65 years of age a...   \n",
       "3                  Recurrent respiratory papillomatosis   \n",
       "4                                    Widening of access   \n",
       "...                                                 ...   \n",
       "2010                              Corneal oedema relief   \n",
       "2011                                      Fabry Disease   \n",
       "2012                       Currently funded indications   \n",
       "2013                             prevention of COVID-19   \n",
       "2014  active immunisation to prevent coronavirus dis...   \n",
       "\n",
       "                     Stage__c  \\\n",
       "0                    Decision   \n",
       "1                    Decision   \n",
       "2            Options Compared   \n",
       "3                    Decision   \n",
       "4                    Decision   \n",
       "...                       ...   \n",
       "2010  Seeking Clinical Advice   \n",
       "2011         Options Compared   \n",
       "2012  Seeking Clinical Advice   \n",
       "2013         Options Compared   \n",
       "2014         Under Assessment   \n",
       "\n",
       "                                      Pharmaceutical__c  \\\n",
       "0     15-valent pneumococcal conjugate vaccine (PCV1...   \n",
       "1     Adjuvanted inactivated quadrivalent influenza ...   \n",
       "2     Adjuvanted inactivated trivalent influenza vac...   \n",
       "3     Bevacizumab and Human Papillomavirus (HPV) vac...   \n",
       "4                        Diphtheria and tetanus vaccine   \n",
       "...                                                 ...   \n",
       "2010              AEON Sodium Chloride 5 Percent (AEON)   \n",
       "2011               Pegunigalsidase alfa-iwxj (ELFABRIO)   \n",
       "2012  Elemental Food (Elemental Gold) (It is not a p...   \n",
       "2013  SARS-CoV-2 rS (Omicron XBB.1.5) (NUVAXOVID XBB...   \n",
       "2014  Elasomeran, Elasomeran and Davesomeran, Anduso...   \n",
       "\n",
       "                                      Community_URL__c  \\\n",
       "0     /apptracker/s/application-public/a102P00000BUmR1   \n",
       "1     /apptracker/s/application-public/a102P00000ACGT3   \n",
       "2     /apptracker/s/application-public/a10OZ000003tIqb   \n",
       "3     /apptracker/s/application-public/a102P000008pu1t   \n",
       "4     /apptracker/s/application-public/a102P000008pu78   \n",
       "...                                                ...   \n",
       "2010  /apptracker/s/application-public/a102P00000BZ6SB   \n",
       "2011  /apptracker/s/application-public/a10OZ00000466q1   \n",
       "2012  /apptracker/s/application-public/a10OZ000001dzUU   \n",
       "2013  /apptracker/s/application-public/a10OZ000000N49N   \n",
       "2014  /apptracker/s/application-public/a10OZ000000N8Cz   \n",
       "\n",
       "                  Therapeutic_group__c  \n",
       "0                                  NaN  \n",
       "1       National Immunisation Schedule  \n",
       "2       National Immunisation Schedule  \n",
       "3     Respiratory System and Allergies  \n",
       "4       National Immunisation Schedule  \n",
       "...                                ...  \n",
       "2010                               NaN  \n",
       "2011                               NaN  \n",
       "2012                               NaN  \n",
       "2013                               NaN  \n",
       "2014                               NaN  \n",
       "\n",
       "[2015 rows x 11 columns]"
      ]
     },
     "execution_count": 1,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import pandas as pd\n",
    "from tqdm import tqdm\n",
    "from pprint import pprint\n",
    "tqdm.pandas()\n",
    "df = pd.read_csv(\"applications.csv\")\n",
    "df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "c92a1a50",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>text</th>\n",
       "      <th>position</th>\n",
       "      <th>name</th>\n",
       "      <th>last</th>\n",
       "      <th>events</th>\n",
       "      <th>dateString</th>\n",
       "      <th>collapsed</th>\n",
       "      <th>checked</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>&lt;p&gt;New funding applications are referred to on...</td>\n",
       "      <td>0</td>\n",
       "      <td>Application Received</td>\n",
       "      <td>False</td>\n",
       "      <td>[{'Summary': {'s': None, 'fs': None, 'change':...</td>\n",
       "      <td>Aug 2022</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>&lt;p&gt;Pharmac is identifying and gathering inform...</td>\n",
       "      <td>1</td>\n",
       "      <td>Seeking Clinical Advice</td>\n",
       "      <td>False</td>\n",
       "      <td>[{'Summary': {'s': None, 'fs': None, 'change':...</td>\n",
       "      <td>Sep 2022</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>&lt;p&gt;Following Clinical Advice, Pharmac staff co...</td>\n",
       "      <td>2</td>\n",
       "      <td>Under Assessment</td>\n",
       "      <td>False</td>\n",
       "      <td>[{'Summary': {'s': None, 'fs': None, 'change':...</td>\n",
       "      <td>Mar 2023</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>&lt;p&gt;Pharmac staff uses a prioritisation process...</td>\n",
       "      <td>3</td>\n",
       "      <td>Options Compared</td>\n",
       "      <td>False</td>\n",
       "      <td>[{'Summary': {'s': None, 'fs': None, 'change':...</td>\n",
       "      <td>Jun 2024</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>&lt;p&gt;Pharmac is consulting on a proposal to eith...</td>\n",
       "      <td>4</td>\n",
       "      <td>Under Consultation</td>\n",
       "      <td>False</td>\n",
       "      <td>[{'Summary': {'s': None, 'fs': None, 'change':...</td>\n",
       "      <td>Oct 2024</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>&lt;p&gt;Following the consultation process, Pharmac...</td>\n",
       "      <td>5</td>\n",
       "      <td>Reviewing Consultation Feedback</td>\n",
       "      <td>False</td>\n",
       "      <td>[{'Summary': {'s': None, 'fs': None, 'change':...</td>\n",
       "      <td>Nov 2024</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>&lt;p&gt;We refer to our decisions about whether and...</td>\n",
       "      <td>6</td>\n",
       "      <td>Decision</td>\n",
       "      <td>True</td>\n",
       "      <td>[{'Summary': {'s': None, 'fs': None, 'change':...</td>\n",
       "      <td>Jun 2025</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                text  position  \\\n",
       "0  <p>New funding applications are referred to on...         0   \n",
       "1  <p>Pharmac is identifying and gathering inform...         1   \n",
       "2  <p>Following Clinical Advice, Pharmac staff co...         2   \n",
       "3  <p>Pharmac staff uses a prioritisation process...         3   \n",
       "4  <p>Pharmac is consulting on a proposal to eith...         4   \n",
       "5  <p>Following the consultation process, Pharmac...         5   \n",
       "6  <p>We refer to our decisions about whether and...         6   \n",
       "\n",
       "                              name   last  \\\n",
       "0             Application Received  False   \n",
       "1          Seeking Clinical Advice  False   \n",
       "2                 Under Assessment  False   \n",
       "3                 Options Compared  False   \n",
       "4               Under Consultation  False   \n",
       "5  Reviewing Consultation Feedback  False   \n",
       "6                         Decision   True   \n",
       "\n",
       "                                              events dateString  collapsed  \\\n",
       "0  [{'Summary': {'s': None, 'fs': None, 'change':...   Aug 2022      False   \n",
       "1  [{'Summary': {'s': None, 'fs': None, 'change':...   Sep 2022      False   \n",
       "2  [{'Summary': {'s': None, 'fs': None, 'change':...   Mar 2023      False   \n",
       "3  [{'Summary': {'s': None, 'fs': None, 'change':...   Jun 2024      False   \n",
       "4  [{'Summary': {'s': None, 'fs': None, 'change':...   Oct 2024      False   \n",
       "5  [{'Summary': {'s': None, 'fs': None, 'change':...   Nov 2024      False   \n",
       "6  [{'Summary': {'s': None, 'fs': None, 'change':...   Jun 2025      False   \n",
       "\n",
       "   checked  \n",
       "0     True  \n",
       "1     True  \n",
       "2     True  \n",
       "3     True  \n",
       "4     True  \n",
       "5     True  \n",
       "6     True  "
      ]
     },
     "execution_count": 2,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "events = pd.read_json(f\"applications/{df['Id'].iloc[0]}.json\")\n",
    "events"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "80763d50",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[{'Event_Description': {'change': None,\n",
      "                        'fs': 'Clinical advice required',\n",
      "                        's': 'Clinical advice required'},\n",
      "  'Formatted_Date': {'change': None, 'fs': 'Sep 2022', 's': 'Sep 2022'},\n",
      "  'Links': {'change': None, 'fs': None, 's': None},\n",
      "  'Outcome': {'change': None, 'fs': None, 's': None},\n",
      "  'PTAC_Comments': {'change': None, 'fs': None, 's': None},\n",
      "  'Published_Application': {'change': None, 'fs': None, 's': None},\n",
      "  'Published_Discussion': {'change': None, 'fs': None, 's': None},\n",
      "  'Published_Recommendation': {'change': None, 'fs': None, 's': None},\n",
      "  'Summary': {'change': None, 'fs': None, 's': None},\n",
      "  'change': None,\n",
      "  'e': {'Event_Date__c': '2022-09-20',\n",
      "        'Event_Description__c': 'Clinical advice required',\n",
      "        'Formatted_Date__c': 'Sep 2022',\n",
      "        'Id': 'a0POZ00000Mc77B2AR',\n",
      "        'Stage__c': 'Seeking Clinical Advice',\n",
      "        'Status_History__c': 'a132P000000E3xnQAC',\n",
      "        'attributes': {'type': 'Application_Event__c',\n",
      "                       'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000Mc77B2AR'}}},\n",
      " {'Event_Description': {'change': None,\n",
      "                        'fs': 'Assigned to Immunisation Advisory Committee '\n",
      "                              'meeting to provide advice on Friday 9 September '\n",
      "                              '2022',\n",
      "                        's': 'Assigned to Immunisation Advisory Committee '\n",
      "                             'meeting to provide advice on Friday 9 September '\n",
      "                             '2022'},\n",
      "  'Formatted_Date': {'change': None, 'fs': 'Sep 2022', 's': 'Sep 2022'},\n",
      "  'Links': {'change': None, 'fs': None, 's': None},\n",
      "  'Outcome': {'change': None, 'fs': None, 's': None},\n",
      "  'PTAC_Comments': {'change': None, 'fs': None, 's': None},\n",
      "  'Published_Application': {'change': None, 'fs': None, 's': None},\n",
      "  'Published_Discussion': {'change': None, 'fs': None, 's': None},\n",
      "  'Published_Recommendation': {'change': None, 'fs': None, 's': None},\n",
      "  'Summary': {'change': None, 'fs': None, 's': None},\n",
      "  'change': None,\n",
      "  'e': {'Event_Date__c': '2022-09-20',\n",
      "        'Event_Description__c': 'Assigned to Immunisation Advisory Committee '\n",
      "                                'meeting to provide advice on Friday 9 '\n",
      "                                'September 2022',\n",
      "        'Formatted_Date__c': 'Sep 2022',\n",
      "        'Id': 'a0POZ00000Mc77C2AR',\n",
      "        'Stage__c': 'Seeking Clinical Advice',\n",
      "        'Status_History__c': 'a132P000000E3xxQAC',\n",
      "        'attributes': {'type': 'Application_Event__c',\n",
      "                       'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000Mc77C2AR'}}},\n",
      " {'Event_Description': {'change': None,\n",
      "                        'fs': 'Clinical advice received from Immunisation '\n",
      "                              'Advisory Committee at meeting Friday 9 '\n",
      "                              'September 2022.',\n",
      "                        's': 'Clinical advice received from Immunisation '\n",
      "                             'Advisory Committee at meeting Friday 9 September '\n",
      "                             '2022.'},\n",
      "  'Formatted_Date': {'change': None, 'fs': 'Dec 2022', 's': 'Dec 2022'},\n",
      "  'Links': {'change': None,\n",
      "            'fs': '<p><a '\n",
      "                  'href=\"https://pharmac.govt.nz/assets/2022-09-Immunisation-Advisory-Meeting-Record.pdf\" '\n",
      "                  'target=\"_blank\">Meeting record</a></p>',\n",
      "            's': '<p><a '\n",
      "                 'href=\"https://pharmac.govt.nz/assets/2022-09-Immunisation-Advisory-Meeting-Record.pdf\" '\n",
      "                 'target=\"_blank\">Meeting record</a></p>'},\n",
      "  'Outcome': {'change': None, 'fs': None, 's': None},\n",
      "  'PTAC_Comments': {'change': None, 'fs': None, 's': None},\n",
      "  'Published_Application': {'change': None, 'fs': None, 's': None},\n",
      "  'Published_Discussion': {'change': None, 'fs': None, 's': None},\n",
      "  'Published_Recommendation': {'change': None, 'fs': None, 's': None},\n",
      "  'Summary': {'change': None, 'fs': None, 's': None},\n",
      "  'change': None,\n",
      "  'e': {'Event_Date__c': '2022-12-09',\n",
      "        'Event_Description__c': 'Clinical advice received from Immunisation '\n",
      "                                'Advisory Committee at meeting Friday 9 '\n",
      "                                'September 2022.',\n",
      "        'Formatted_Date__c': 'Dec 2022',\n",
      "        'Id': 'a0POZ00000Mc77D2AR',\n",
      "        'Links__c': '<p><a '\n",
      "                    'href=\"https://pharmac.govt.nz/assets/2022-09-Immunisation-Advisory-Meeting-Record.pdf\" '\n",
      "                    'target=\"_blank\">Meeting record</a></p>',\n",
      "        'Stage__c': 'Seeking Clinical Advice',\n",
      "        'Status_History__c': 'a132P000000ED9pQAG',\n",
      "        'attributes': {'type': 'Application_Event__c',\n",
      "                       'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000Mc77D2AR'}}}]\n"
     ]
    }
   ],
   "source": [
    "pprint(events.events[1])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "02a4fb45",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 42%|████▏     | 844/2015 [00:04<00:05, 215.54it/s]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Dec', 'fs': 'Dec', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'fs': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000007JyAAUA0'}, 'Id': 'a0P2P000007JyAAUA0', 'Event_Description__c': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'Stage__c': 'Reviewing Consultation Feedback', 'Formatted_Date__c': 'Dec', 'Status_History__c': 'a132P000000Clc2QAC'}, 'change': None}\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "100%|██████████| 2015/2015 [00:09<00:00, 208.79it/s]\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Id</th>\n",
       "      <th>Name</th>\n",
       "      <th>Applications__c</th>\n",
       "      <th>Brand_Name__c</th>\n",
       "      <th>Chemical_Name__c</th>\n",
       "      <th>Applicants__c</th>\n",
       "      <th>Funding_requested_for__c</th>\n",
       "      <th>Stage__c</th>\n",
       "      <th>Pharmaceutical__c</th>\n",
       "      <th>Community_URL__c</th>\n",
       "      <th>...</th>\n",
       "      <th>Application Received date</th>\n",
       "      <th>Last Update date</th>\n",
       "      <th>Days elapsed between application and last update</th>\n",
       "      <th>Application Received dates</th>\n",
       "      <th>Seeking Clinical Advice dates</th>\n",
       "      <th>Under Assessment dates</th>\n",
       "      <th>Options Compared dates</th>\n",
       "      <th>Under Consultation dates</th>\n",
       "      <th>Reviewing Consultation Feedback dates</th>\n",
       "      <th>Decision dates</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>688</th>\n",
       "      <td>a0R2P000000LmkWUAS</td>\n",
       "      <td>Risperidone tablets</td>\n",
       "      <td>A-01127</td>\n",
       "      <td>Risperdal</td>\n",
       "      <td>Risperidone tablets</td>\n",
       "      <td>Janssen</td>\n",
       "      <td>Schizophrenia</td>\n",
       "      <td>Decision</td>\n",
       "      <td>Risperidone tablets (Risperdal)</td>\n",
       "      <td>/apptracker/s/application-public/a102P000008pugY</td>\n",
       "      <td>...</td>\n",
       "      <td>1994-04-01</td>\n",
       "      <td>1995-10-01</td>\n",
       "      <td>548</td>\n",
       "      <td>1994-04-01</td>\n",
       "      <td>1994-04-01,1994-06-01,1994-09-01,1994-10-01,19...</td>\n",
       "      <td>1994-12-01,1995-04-01,1995-05-01</td>\n",
       "      <td>1994-09-01,1994-10-01</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1995-10-01</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>584</th>\n",
       "      <td>a0R2P000000LmjmUAC</td>\n",
       "      <td>Gabapentin</td>\n",
       "      <td>A-01197</td>\n",
       "      <td>Neurontin</td>\n",
       "      <td>Gabapentin</td>\n",
       "      <td>Parke Davis</td>\n",
       "      <td>Partial seizures in patients who have not achi...</td>\n",
       "      <td>Decision</td>\n",
       "      <td>Gabapentin (Neurontin)</td>\n",
       "      <td>/apptracker/s/application-public/a102P000008pufT</td>\n",
       "      <td>...</td>\n",
       "      <td>1994-08-01</td>\n",
       "      <td>2001-03-01</td>\n",
       "      <td>2404</td>\n",
       "      <td>1994-08-01</td>\n",
       "      <td>1995-02-01,1995-03-01,2000-05-01</td>\n",
       "      <td>1995-03-01</td>\n",
       "      <td>1995-05-01,2000-03-01,2000-06-01</td>\n",
       "      <td>2001-01-01</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2001-03-01</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>982</th>\n",
       "      <td>a0R2P000000LmThUAK</td>\n",
       "      <td>Somatropin - Growth Hormone</td>\n",
       "      <td>A-01165</td>\n",
       "      <td>Genotropin</td>\n",
       "      <td>Somatropin - Growth Hormone</td>\n",
       "      <td>Clinician</td>\n",
       "      <td>Adult  and adolescent  patients with growth ho...</td>\n",
       "      <td>Decision</td>\n",
       "      <td>Somatropin - Growth Hormone (Genotropin)</td>\n",
       "      <td>/apptracker/s/application-public/a102P000008puMe</td>\n",
       "      <td>...</td>\n",
       "      <td>1995-09-01</td>\n",
       "      <td>2005-09-01</td>\n",
       "      <td>3653</td>\n",
       "      <td>1995-09-01</td>\n",
       "      <td>1995-09-01,1995-11-01,1996-09-01,1996-10-01,20...</td>\n",
       "      <td>1996-11-01</td>\n",
       "      <td>1995-11-01,1996-09-01,1998-01-01,2004-01-01,20...</td>\n",
       "      <td>2009-10-01</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2005-09-01,2006-05-01,2009-11-01</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>593</th>\n",
       "      <td>a0R2P000000Lmo2UAC</td>\n",
       "      <td>Interferon beta-1-beta</td>\n",
       "      <td>A-01183</td>\n",
       "      <td>Betaferon</td>\n",
       "      <td>Interferon beta-1-beta</td>\n",
       "      <td>Bayer</td>\n",
       "      <td>Relapsing remitting multiple sclerosis</td>\n",
       "      <td>Decision</td>\n",
       "      <td>Interferon beta-1-beta (Betaferon)</td>\n",
       "      <td>/apptracker/s/application-public/a102P000008ptra</td>\n",
       "      <td>...</td>\n",
       "      <td>1996-01-01</td>\n",
       "      <td>1999-07-01</td>\n",
       "      <td>1277</td>\n",
       "      <td>1996-01-01</td>\n",
       "      <td>1996-01-01,1996-03-01,1996-05-01</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1999-05-01</td>\n",
       "      <td>1999-05-01</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1999-07-01,1999-12-01</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1407</th>\n",
       "      <td>a0R2P000000LmqWUAS</td>\n",
       "      <td>Anastrozole</td>\n",
       "      <td>A-01169</td>\n",
       "      <td>Arimidex</td>\n",
       "      <td>Anastrozole</td>\n",
       "      <td>AstraZeneca</td>\n",
       "      <td>Third line treatment of advanced breast cancer</td>\n",
       "      <td>Decision</td>\n",
       "      <td>Anastrozole (Arimidex)</td>\n",
       "      <td>/apptracker/s/application-public/a102P000008puCL</td>\n",
       "      <td>...</td>\n",
       "      <td>1997-02-01</td>\n",
       "      <td>1998-12-01</td>\n",
       "      <td>668</td>\n",
       "      <td>1997-02-01</td>\n",
       "      <td>1997-02-01,1997-05-15,1997-08-01</td>\n",
       "      <td>1997-05-01</td>\n",
       "      <td>1998-10-01</td>\n",
       "      <td>1998-10-01</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1998-12-01</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1282</th>\n",
       "      <td>a0ROZ00000Dms532AB</td>\n",
       "      <td>Riociguat</td>\n",
       "      <td>A-05544</td>\n",
       "      <td>ADEMPAS</td>\n",
       "      <td>Riociguat</td>\n",
       "      <td>Clinician</td>\n",
       "      <td>Chronic Thromboembolic Pulmonary Hypertension ...</td>\n",
       "      <td>Seeking Clinical Advice</td>\n",
       "      <td>Riociguat (ADEMPAS)</td>\n",
       "      <td>/apptracker/s/application-public/a10OZ000007nf61</td>\n",
       "      <td>...</td>\n",
       "      <td>2025-10-28</td>\n",
       "      <td>2026-02-02</td>\n",
       "      <td>97</td>\n",
       "      <td>2025-10-28</td>\n",
       "      <td>2026-02-02</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1770</th>\n",
       "      <td>a0ROZ00000DL1uT2AT</td>\n",
       "      <td>Mepolizumab</td>\n",
       "      <td>A-05540</td>\n",
       "      <td>Nucala</td>\n",
       "      <td>Mepolizumab</td>\n",
       "      <td>GLAXOSMITHKLINE NZ LIMITED</td>\n",
       "      <td>Inadequately controlled chronic obstructive pu...</td>\n",
       "      <td>Seeking Clinical Advice</td>\n",
       "      <td>Mepolizumab (Nucala)</td>\n",
       "      <td>/apptracker/s/application-public/a10OZ000007O5H3</td>\n",
       "      <td>...</td>\n",
       "      <td>2025-10-31</td>\n",
       "      <td>2026-01-09</td>\n",
       "      <td>70</td>\n",
       "      <td>2025-10-31</td>\n",
       "      <td>2026-01-09</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1841</th>\n",
       "      <td>a0ROZ00000DGeA52AL</td>\n",
       "      <td>Upadacitinib</td>\n",
       "      <td>A-05543</td>\n",
       "      <td>Rinvoq</td>\n",
       "      <td>Upadacitinib</td>\n",
       "      <td>ABBVIE LIMITED</td>\n",
       "      <td>Giant cell ateritis (GCA), glucocorticoid tape...</td>\n",
       "      <td>Seeking Clinical Advice</td>\n",
       "      <td>Upadacitinib (Rinvoq)</td>\n",
       "      <td>/apptracker/s/application-public/a10OZ000007JUXp</td>\n",
       "      <td>...</td>\n",
       "      <td>2025-10-31</td>\n",
       "      <td>2026-01-05</td>\n",
       "      <td>66</td>\n",
       "      <td>2025-10-31</td>\n",
       "      <td>2026-01-05</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1919</th>\n",
       "      <td>a0ROZ00000DKizt2AD</td>\n",
       "      <td>pembrolizumab</td>\n",
       "      <td>A-05472</td>\n",
       "      <td>KEYTRUDA</td>\n",
       "      <td>pembrolizumab</td>\n",
       "      <td>MERCK SHARP &amp; DOHME (NEW ZEALAND) LIMITED</td>\n",
       "      <td>Squamous Cell Carcinoma of the Head and Neck, ...</td>\n",
       "      <td>Seeking Clinical Advice</td>\n",
       "      <td>pembrolizumab (KEYTRUDA)</td>\n",
       "      <td>/apptracker/s/application-public/a10OZ000007NtEH</td>\n",
       "      <td>...</td>\n",
       "      <td>2025-12-19</td>\n",
       "      <td>2026-01-09</td>\n",
       "      <td>21</td>\n",
       "      <td>2025-12-19</td>\n",
       "      <td>2026-01-09</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1126</th>\n",
       "      <td>a0ROZ00000DoZ9Z2AV</td>\n",
       "      <td>Emicizumab</td>\n",
       "      <td>A-05466</td>\n",
       "      <td>Hemlibra</td>\n",
       "      <td>Emicizumab</td>\n",
       "      <td>Clinician</td>\n",
       "      <td>Haemophilia A, moderate severity, severe bleed...</td>\n",
       "      <td>Seeking Clinical Advice</td>\n",
       "      <td>Emicizumab (Hemlibra)</td>\n",
       "      <td>/apptracker/s/application-public/a10OZ000007owj7</td>\n",
       "      <td>...</td>\n",
       "      <td>2026-01-14</td>\n",
       "      <td>2026-02-03</td>\n",
       "      <td>20</td>\n",
       "      <td>2026-01-14</td>\n",
       "      <td>2026-02-03</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>2015 rows × 21 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                      Id                         Name Applications__c  \\\n",
       "688   a0R2P000000LmkWUAS          Risperidone tablets         A-01127   \n",
       "584   a0R2P000000LmjmUAC                   Gabapentin         A-01197   \n",
       "982   a0R2P000000LmThUAK  Somatropin - Growth Hormone         A-01165   \n",
       "593   a0R2P000000Lmo2UAC       Interferon beta-1-beta         A-01183   \n",
       "1407  a0R2P000000LmqWUAS                  Anastrozole         A-01169   \n",
       "...                  ...                          ...             ...   \n",
       "1282  a0ROZ00000Dms532AB                    Riociguat         A-05544   \n",
       "1770  a0ROZ00000DL1uT2AT                  Mepolizumab         A-05540   \n",
       "1841  a0ROZ00000DGeA52AL                 Upadacitinib         A-05543   \n",
       "1919  a0ROZ00000DKizt2AD                pembrolizumab         A-05472   \n",
       "1126  a0ROZ00000DoZ9Z2AV                   Emicizumab         A-05466   \n",
       "\n",
       "     Brand_Name__c             Chemical_Name__c  \\\n",
       "688      Risperdal          Risperidone tablets   \n",
       "584      Neurontin                   Gabapentin   \n",
       "982     Genotropin  Somatropin - Growth Hormone   \n",
       "593      Betaferon       Interferon beta-1-beta   \n",
       "1407      Arimidex                  Anastrozole   \n",
       "...            ...                          ...   \n",
       "1282       ADEMPAS                    Riociguat   \n",
       "1770        Nucala                  Mepolizumab   \n",
       "1841        Rinvoq                 Upadacitinib   \n",
       "1919      KEYTRUDA                pembrolizumab   \n",
       "1126      Hemlibra                   Emicizumab   \n",
       "\n",
       "                                  Applicants__c  \\\n",
       "688                                     Janssen   \n",
       "584                                 Parke Davis   \n",
       "982                                   Clinician   \n",
       "593                                       Bayer   \n",
       "1407                                AstraZeneca   \n",
       "...                                         ...   \n",
       "1282                                  Clinician   \n",
       "1770                 GLAXOSMITHKLINE NZ LIMITED   \n",
       "1841                             ABBVIE LIMITED   \n",
       "1919  MERCK SHARP & DOHME (NEW ZEALAND) LIMITED   \n",
       "1126                                  Clinician   \n",
       "\n",
       "                               Funding_requested_for__c  \\\n",
       "688                                       Schizophrenia   \n",
       "584   Partial seizures in patients who have not achi...   \n",
       "982   Adult  and adolescent  patients with growth ho...   \n",
       "593              Relapsing remitting multiple sclerosis   \n",
       "1407     Third line treatment of advanced breast cancer   \n",
       "...                                                 ...   \n",
       "1282  Chronic Thromboembolic Pulmonary Hypertension ...   \n",
       "1770  Inadequately controlled chronic obstructive pu...   \n",
       "1841  Giant cell ateritis (GCA), glucocorticoid tape...   \n",
       "1919  Squamous Cell Carcinoma of the Head and Neck, ...   \n",
       "1126  Haemophilia A, moderate severity, severe bleed...   \n",
       "\n",
       "                     Stage__c                         Pharmaceutical__c  \\\n",
       "688                  Decision           Risperidone tablets (Risperdal)   \n",
       "584                  Decision                    Gabapentin (Neurontin)   \n",
       "982                  Decision  Somatropin - Growth Hormone (Genotropin)   \n",
       "593                  Decision        Interferon beta-1-beta (Betaferon)   \n",
       "1407                 Decision                    Anastrozole (Arimidex)   \n",
       "...                       ...                                       ...   \n",
       "1282  Seeking Clinical Advice                       Riociguat (ADEMPAS)   \n",
       "1770  Seeking Clinical Advice                      Mepolizumab (Nucala)   \n",
       "1841  Seeking Clinical Advice                     Upadacitinib (Rinvoq)   \n",
       "1919  Seeking Clinical Advice                  pembrolizumab (KEYTRUDA)   \n",
       "1126  Seeking Clinical Advice                     Emicizumab (Hemlibra)   \n",
       "\n",
       "                                      Community_URL__c  ...  \\\n",
       "688   /apptracker/s/application-public/a102P000008pugY  ...   \n",
       "584   /apptracker/s/application-public/a102P000008pufT  ...   \n",
       "982   /apptracker/s/application-public/a102P000008puMe  ...   \n",
       "593   /apptracker/s/application-public/a102P000008ptra  ...   \n",
       "1407  /apptracker/s/application-public/a102P000008puCL  ...   \n",
       "...                                                ...  ...   \n",
       "1282  /apptracker/s/application-public/a10OZ000007nf61  ...   \n",
       "1770  /apptracker/s/application-public/a10OZ000007O5H3  ...   \n",
       "1841  /apptracker/s/application-public/a10OZ000007JUXp  ...   \n",
       "1919  /apptracker/s/application-public/a10OZ000007NtEH  ...   \n",
       "1126  /apptracker/s/application-public/a10OZ000007owj7  ...   \n",
       "\n",
       "     Application Received date Last Update date  \\\n",
       "688                 1994-04-01       1995-10-01   \n",
       "584                 1994-08-01       2001-03-01   \n",
       "982                 1995-09-01       2005-09-01   \n",
       "593                 1996-01-01       1999-07-01   \n",
       "1407                1997-02-01       1998-12-01   \n",
       "...                        ...              ...   \n",
       "1282                2025-10-28       2026-02-02   \n",
       "1770                2025-10-31       2026-01-09   \n",
       "1841                2025-10-31       2026-01-05   \n",
       "1919                2025-12-19       2026-01-09   \n",
       "1126                2026-01-14       2026-02-03   \n",
       "\n",
       "     Days elapsed between application and last update  \\\n",
       "688                                               548   \n",
       "584                                              2404   \n",
       "982                                              3653   \n",
       "593                                              1277   \n",
       "1407                                              668   \n",
       "...                                               ...   \n",
       "1282                                               97   \n",
       "1770                                               70   \n",
       "1841                                               66   \n",
       "1919                                               21   \n",
       "1126                                               20   \n",
       "\n",
       "      Application Received dates  \\\n",
       "688                   1994-04-01   \n",
       "584                   1994-08-01   \n",
       "982                   1995-09-01   \n",
       "593                   1996-01-01   \n",
       "1407                  1997-02-01   \n",
       "...                          ...   \n",
       "1282                  2025-10-28   \n",
       "1770                  2025-10-31   \n",
       "1841                  2025-10-31   \n",
       "1919                  2025-12-19   \n",
       "1126                  2026-01-14   \n",
       "\n",
       "                          Seeking Clinical Advice dates  \\\n",
       "688   1994-04-01,1994-06-01,1994-09-01,1994-10-01,19...   \n",
       "584                    1995-02-01,1995-03-01,2000-05-01   \n",
       "982   1995-09-01,1995-11-01,1996-09-01,1996-10-01,20...   \n",
       "593                    1996-01-01,1996-03-01,1996-05-01   \n",
       "1407                   1997-02-01,1997-05-15,1997-08-01   \n",
       "...                                                 ...   \n",
       "1282                                         2026-02-02   \n",
       "1770                                         2026-01-09   \n",
       "1841                                         2026-01-05   \n",
       "1919                                         2026-01-09   \n",
       "1126                                         2026-02-03   \n",
       "\n",
       "                Under Assessment dates  \\\n",
       "688   1994-12-01,1995-04-01,1995-05-01   \n",
       "584                         1995-03-01   \n",
       "982                         1996-11-01   \n",
       "593                                NaN   \n",
       "1407                        1997-05-01   \n",
       "...                                ...   \n",
       "1282                               NaN   \n",
       "1770                               NaN   \n",
       "1841                               NaN   \n",
       "1919                               NaN   \n",
       "1126                               NaN   \n",
       "\n",
       "                                 Options Compared dates  \\\n",
       "688                               1994-09-01,1994-10-01   \n",
       "584                    1995-05-01,2000-03-01,2000-06-01   \n",
       "982   1995-11-01,1996-09-01,1998-01-01,2004-01-01,20...   \n",
       "593                                          1999-05-01   \n",
       "1407                                         1998-10-01   \n",
       "...                                                 ...   \n",
       "1282                                                NaN   \n",
       "1770                                                NaN   \n",
       "1841                                                NaN   \n",
       "1919                                                NaN   \n",
       "1126                                                NaN   \n",
       "\n",
       "     Under Consultation dates Reviewing Consultation Feedback dates  \\\n",
       "688                       NaN                                   NaN   \n",
       "584                2001-01-01                                   NaN   \n",
       "982                2009-10-01                                   NaN   \n",
       "593                1999-05-01                                   NaN   \n",
       "1407               1998-10-01                                   NaN   \n",
       "...                       ...                                   ...   \n",
       "1282                      NaN                                   NaN   \n",
       "1770                      NaN                                   NaN   \n",
       "1841                      NaN                                   NaN   \n",
       "1919                      NaN                                   NaN   \n",
       "1126                      NaN                                   NaN   \n",
       "\n",
       "                        Decision dates  \n",
       "688                         1995-10-01  \n",
       "584                         2001-03-01  \n",
       "982   2005-09-01,2006-05-01,2009-11-01  \n",
       "593              1999-07-01,1999-12-01  \n",
       "1407                        1998-12-01  \n",
       "...                                ...  \n",
       "1282                               NaN  \n",
       "1770                               NaN  \n",
       "1841                               NaN  \n",
       "1919                               NaN  \n",
       "1126                               NaN  \n",
       "\n",
       "[2015 rows x 21 columns]"
      ]
     },
     "execution_count": 4,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "rows = []\n",
    "for i, row in tqdm(df.iterrows(), total=len(df)):\n",
    "    events = pd.read_json(f\"applications/{row.Id}.json\").dropna()\n",
    "    start = pd.to_datetime(events.events.iloc[0][0][\"e\"][\"Event_Date__c\"])\n",
    "    end = pd.to_datetime(events.events.iloc[-1][0][\"e\"][\"Event_Date__c\"])\n",
    "    delta = end - start\n",
    "    row[\"Application Received date\"] = start\n",
    "    row[\"Last Update date\"] = end\n",
    "    row[\"Days elapsed between application and last update\"] = delta.days\n",
    "    for stage in events.events:\n",
    "        stage_events = []\n",
    "        for event in stage:\n",
    "            try:\n",
    "                stage_events.append(event[\"e\"][\"Event_Date__c\"])\n",
    "            except KeyError:\n",
    "                print(event)\n",
    "        row[event[\"e\"][\"Stage__c\"] + \" dates\"] = \",\".join(stage_events)\n",
    "    rows.append(row)\n",
    "\n",
    "df = pd.DataFrame(rows)\n",
    "df.sort_values(\"Application Received date\", inplace=True)\n",
    "df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "21420dec",
   "metadata": {},
   "outputs": [],
   "source": [
    "df.Community_URL__c = \"https://connect.pharmac.govt.nz/\" + df.Community_URL__c"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "aa4aa574",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['Id',\n",
       " 'Name',\n",
       " 'Applications__c',\n",
       " 'Brand_Name__c',\n",
       " 'Chemical_Name__c',\n",
       " 'Applicants__c',\n",
       " 'Funding_requested_for__c',\n",
       " 'Stage__c',\n",
       " 'Pharmaceutical__c',\n",
       " 'Community_URL__c',\n",
       " 'Therapeutic_group__c',\n",
       " 'Application Received date',\n",
       " 'Last Update date',\n",
       " 'Days elapsed between application and last update',\n",
       " 'Application Received dates',\n",
       " 'Seeking Clinical Advice dates',\n",
       " 'Under Assessment dates',\n",
       " 'Options Compared dates',\n",
       " 'Under Consultation dates',\n",
       " 'Reviewing Consultation Feedback dates',\n",
       " 'Decision dates']"
      ]
     },
     "execution_count": 6,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "cols = ['Id', 'Name', 'Applications__c', 'Brand_Name__c', 'Chemical_Name__c',\n",
    "       'Applicants__c', 'Funding_requested_for__c', 'Stage__c',\n",
    "       'Pharmaceutical__c', 'Community_URL__c', 'Therapeutic_group__c',\n",
    "       'Application Received date', 'Last Update date',\n",
    "       'Days elapsed between application and last update',\n",
    "       'Application Received dates', 'Seeking Clinical Advice dates',\n",
    "       'Under Assessment dates', 'Options Compared dates', \n",
    "       'Under Consultation dates', 'Reviewing Consultation Feedback dates', 'Decision dates']\n",
    "cols"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "id": "75a00661",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Id</th>\n",
       "      <th>Name</th>\n",
       "      <th>Applications__c</th>\n",
       "      <th>Brand_Name__c</th>\n",
       "      <th>Chemical_Name__c</th>\n",
       "      <th>Applicants__c</th>\n",
       "      <th>Funding_requested_for__c</th>\n",
       "      <th>Stage__c</th>\n",
       "      <th>Pharmaceutical__c</th>\n",
       "      <th>Community_URL__c</th>\n",
       "      <th>...</th>\n",
       "      <th>Application Received date</th>\n",
       "      <th>Last Update date</th>\n",
       "      <th>Days elapsed between application and last update</th>\n",
       "      <th>Application Received dates</th>\n",
       "      <th>Seeking Clinical Advice dates</th>\n",
       "      <th>Under Assessment dates</th>\n",
       "      <th>Options Compared dates</th>\n",
       "      <th>Under Consultation dates</th>\n",
       "      <th>Reviewing Consultation Feedback dates</th>\n",
       "      <th>Decision dates</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>688</th>\n",
       "      <td>a0R2P000000LmkWUAS</td>\n",
       "      <td>Risperidone tablets</td>\n",
       "      <td>A-01127</td>\n",
       "      <td>Risperdal</td>\n",
       "      <td>Risperidone tablets</td>\n",
       "      <td>Janssen</td>\n",
       "      <td>Schizophrenia</td>\n",
       "      <td>Decision</td>\n",
       "      <td>Risperidone tablets (Risperdal)</td>\n",
       "      <td>https://connect.pharmac.govt.nz//apptracker/s/...</td>\n",
       "      <td>...</td>\n",
       "      <td>1994-04-01</td>\n",
       "      <td>1995-10-01</td>\n",
       "      <td>548</td>\n",
       "      <td>1994-04-01</td>\n",
       "      <td>1994-04-01,1994-06-01,1994-09-01,1994-10-01,19...</td>\n",
       "      <td>1994-12-01,1995-04-01,1995-05-01</td>\n",
       "      <td>1994-09-01,1994-10-01</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1995-10-01</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>584</th>\n",
       "      <td>a0R2P000000LmjmUAC</td>\n",
       "      <td>Gabapentin</td>\n",
       "      <td>A-01197</td>\n",
       "      <td>Neurontin</td>\n",
       "      <td>Gabapentin</td>\n",
       "      <td>Parke Davis</td>\n",
       "      <td>Partial seizures in patients who have not achi...</td>\n",
       "      <td>Decision</td>\n",
       "      <td>Gabapentin (Neurontin)</td>\n",
       "      <td>https://connect.pharmac.govt.nz//apptracker/s/...</td>\n",
       "      <td>...</td>\n",
       "      <td>1994-08-01</td>\n",
       "      <td>2001-03-01</td>\n",
       "      <td>2404</td>\n",
       "      <td>1994-08-01</td>\n",
       "      <td>1995-02-01,1995-03-01,2000-05-01</td>\n",
       "      <td>1995-03-01</td>\n",
       "      <td>1995-05-01,2000-03-01,2000-06-01</td>\n",
       "      <td>2001-01-01</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2001-03-01</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>982</th>\n",
       "      <td>a0R2P000000LmThUAK</td>\n",
       "      <td>Somatropin - Growth Hormone</td>\n",
       "      <td>A-01165</td>\n",
       "      <td>Genotropin</td>\n",
       "      <td>Somatropin - Growth Hormone</td>\n",
       "      <td>Clinician</td>\n",
       "      <td>Adult  and adolescent  patients with growth ho...</td>\n",
       "      <td>Decision</td>\n",
       "      <td>Somatropin - Growth Hormone (Genotropin)</td>\n",
       "      <td>https://connect.pharmac.govt.nz//apptracker/s/...</td>\n",
       "      <td>...</td>\n",
       "      <td>1995-09-01</td>\n",
       "      <td>2005-09-01</td>\n",
       "      <td>3653</td>\n",
       "      <td>1995-09-01</td>\n",
       "      <td>1995-09-01,1995-11-01,1996-09-01,1996-10-01,20...</td>\n",
       "      <td>1996-11-01</td>\n",
       "      <td>1995-11-01,1996-09-01,1998-01-01,2004-01-01,20...</td>\n",
       "      <td>2009-10-01</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2005-09-01,2006-05-01,2009-11-01</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>593</th>\n",
       "      <td>a0R2P000000Lmo2UAC</td>\n",
       "      <td>Interferon beta-1-beta</td>\n",
       "      <td>A-01183</td>\n",
       "      <td>Betaferon</td>\n",
       "      <td>Interferon beta-1-beta</td>\n",
       "      <td>Bayer</td>\n",
       "      <td>Relapsing remitting multiple sclerosis</td>\n",
       "      <td>Decision</td>\n",
       "      <td>Interferon beta-1-beta (Betaferon)</td>\n",
       "      <td>https://connect.pharmac.govt.nz//apptracker/s/...</td>\n",
       "      <td>...</td>\n",
       "      <td>1996-01-01</td>\n",
       "      <td>1999-07-01</td>\n",
       "      <td>1277</td>\n",
       "      <td>1996-01-01</td>\n",
       "      <td>1996-01-01,1996-03-01,1996-05-01</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1999-05-01</td>\n",
       "      <td>1999-05-01</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1999-07-01,1999-12-01</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1407</th>\n",
       "      <td>a0R2P000000LmqWUAS</td>\n",
       "      <td>Anastrozole</td>\n",
       "      <td>A-01169</td>\n",
       "      <td>Arimidex</td>\n",
       "      <td>Anastrozole</td>\n",
       "      <td>AstraZeneca</td>\n",
       "      <td>Third line treatment of advanced breast cancer</td>\n",
       "      <td>Decision</td>\n",
       "      <td>Anastrozole (Arimidex)</td>\n",
       "      <td>https://connect.pharmac.govt.nz//apptracker/s/...</td>\n",
       "      <td>...</td>\n",
       "      <td>1997-02-01</td>\n",
       "      <td>1998-12-01</td>\n",
       "      <td>668</td>\n",
       "      <td>1997-02-01</td>\n",
       "      <td>1997-02-01,1997-05-15,1997-08-01</td>\n",
       "      <td>1997-05-01</td>\n",
       "      <td>1998-10-01</td>\n",
       "      <td>1998-10-01</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1998-12-01</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1282</th>\n",
       "      <td>a0ROZ00000Dms532AB</td>\n",
       "      <td>Riociguat</td>\n",
       "      <td>A-05544</td>\n",
       "      <td>ADEMPAS</td>\n",
       "      <td>Riociguat</td>\n",
       "      <td>Clinician</td>\n",
       "      <td>Chronic Thromboembolic Pulmonary Hypertension ...</td>\n",
       "      <td>Seeking Clinical Advice</td>\n",
       "      <td>Riociguat (ADEMPAS)</td>\n",
       "      <td>https://connect.pharmac.govt.nz//apptracker/s/...</td>\n",
       "      <td>...</td>\n",
       "      <td>2025-10-28</td>\n",
       "      <td>2026-02-02</td>\n",
       "      <td>97</td>\n",
       "      <td>2025-10-28</td>\n",
       "      <td>2026-02-02</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1770</th>\n",
       "      <td>a0ROZ00000DL1uT2AT</td>\n",
       "      <td>Mepolizumab</td>\n",
       "      <td>A-05540</td>\n",
       "      <td>Nucala</td>\n",
       "      <td>Mepolizumab</td>\n",
       "      <td>GLAXOSMITHKLINE NZ LIMITED</td>\n",
       "      <td>Inadequately controlled chronic obstructive pu...</td>\n",
       "      <td>Seeking Clinical Advice</td>\n",
       "      <td>Mepolizumab (Nucala)</td>\n",
       "      <td>https://connect.pharmac.govt.nz//apptracker/s/...</td>\n",
       "      <td>...</td>\n",
       "      <td>2025-10-31</td>\n",
       "      <td>2026-01-09</td>\n",
       "      <td>70</td>\n",
       "      <td>2025-10-31</td>\n",
       "      <td>2026-01-09</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1841</th>\n",
       "      <td>a0ROZ00000DGeA52AL</td>\n",
       "      <td>Upadacitinib</td>\n",
       "      <td>A-05543</td>\n",
       "      <td>Rinvoq</td>\n",
       "      <td>Upadacitinib</td>\n",
       "      <td>ABBVIE LIMITED</td>\n",
       "      <td>Giant cell ateritis (GCA), glucocorticoid tape...</td>\n",
       "      <td>Seeking Clinical Advice</td>\n",
       "      <td>Upadacitinib (Rinvoq)</td>\n",
       "      <td>https://connect.pharmac.govt.nz//apptracker/s/...</td>\n",
       "      <td>...</td>\n",
       "      <td>2025-10-31</td>\n",
       "      <td>2026-01-05</td>\n",
       "      <td>66</td>\n",
       "      <td>2025-10-31</td>\n",
       "      <td>2026-01-05</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1919</th>\n",
       "      <td>a0ROZ00000DKizt2AD</td>\n",
       "      <td>pembrolizumab</td>\n",
       "      <td>A-05472</td>\n",
       "      <td>KEYTRUDA</td>\n",
       "      <td>pembrolizumab</td>\n",
       "      <td>MERCK SHARP &amp; DOHME (NEW ZEALAND) LIMITED</td>\n",
       "      <td>Squamous Cell Carcinoma of the Head and Neck, ...</td>\n",
       "      <td>Seeking Clinical Advice</td>\n",
       "      <td>pembrolizumab (KEYTRUDA)</td>\n",
       "      <td>https://connect.pharmac.govt.nz//apptracker/s/...</td>\n",
       "      <td>...</td>\n",
       "      <td>2025-12-19</td>\n",
       "      <td>2026-01-09</td>\n",
       "      <td>21</td>\n",
       "      <td>2025-12-19</td>\n",
       "      <td>2026-01-09</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1126</th>\n",
       "      <td>a0ROZ00000DoZ9Z2AV</td>\n",
       "      <td>Emicizumab</td>\n",
       "      <td>A-05466</td>\n",
       "      <td>Hemlibra</td>\n",
       "      <td>Emicizumab</td>\n",
       "      <td>Clinician</td>\n",
       "      <td>Haemophilia A, moderate severity, severe bleed...</td>\n",
       "      <td>Seeking Clinical Advice</td>\n",
       "      <td>Emicizumab (Hemlibra)</td>\n",
       "      <td>https://connect.pharmac.govt.nz//apptracker/s/...</td>\n",
       "      <td>...</td>\n",
       "      <td>2026-01-14</td>\n",
       "      <td>2026-02-03</td>\n",
       "      <td>20</td>\n",
       "      <td>2026-01-14</td>\n",
       "      <td>2026-02-03</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>2015 rows × 21 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                      Id                         Name Applications__c  \\\n",
       "688   a0R2P000000LmkWUAS          Risperidone tablets         A-01127   \n",
       "584   a0R2P000000LmjmUAC                   Gabapentin         A-01197   \n",
       "982   a0R2P000000LmThUAK  Somatropin - Growth Hormone         A-01165   \n",
       "593   a0R2P000000Lmo2UAC       Interferon beta-1-beta         A-01183   \n",
       "1407  a0R2P000000LmqWUAS                  Anastrozole         A-01169   \n",
       "...                  ...                          ...             ...   \n",
       "1282  a0ROZ00000Dms532AB                    Riociguat         A-05544   \n",
       "1770  a0ROZ00000DL1uT2AT                  Mepolizumab         A-05540   \n",
       "1841  a0ROZ00000DGeA52AL                 Upadacitinib         A-05543   \n",
       "1919  a0ROZ00000DKizt2AD                pembrolizumab         A-05472   \n",
       "1126  a0ROZ00000DoZ9Z2AV                   Emicizumab         A-05466   \n",
       "\n",
       "     Brand_Name__c             Chemical_Name__c  \\\n",
       "688      Risperdal          Risperidone tablets   \n",
       "584      Neurontin                   Gabapentin   \n",
       "982     Genotropin  Somatropin - Growth Hormone   \n",
       "593      Betaferon       Interferon beta-1-beta   \n",
       "1407      Arimidex                  Anastrozole   \n",
       "...            ...                          ...   \n",
       "1282       ADEMPAS                    Riociguat   \n",
       "1770        Nucala                  Mepolizumab   \n",
       "1841        Rinvoq                 Upadacitinib   \n",
       "1919      KEYTRUDA                pembrolizumab   \n",
       "1126      Hemlibra                   Emicizumab   \n",
       "\n",
       "                                  Applicants__c  \\\n",
       "688                                     Janssen   \n",
       "584                                 Parke Davis   \n",
       "982                                   Clinician   \n",
       "593                                       Bayer   \n",
       "1407                                AstraZeneca   \n",
       "...                                         ...   \n",
       "1282                                  Clinician   \n",
       "1770                 GLAXOSMITHKLINE NZ LIMITED   \n",
       "1841                             ABBVIE LIMITED   \n",
       "1919  MERCK SHARP & DOHME (NEW ZEALAND) LIMITED   \n",
       "1126                                  Clinician   \n",
       "\n",
       "                               Funding_requested_for__c  \\\n",
       "688                                       Schizophrenia   \n",
       "584   Partial seizures in patients who have not achi...   \n",
       "982   Adult  and adolescent  patients with growth ho...   \n",
       "593              Relapsing remitting multiple sclerosis   \n",
       "1407     Third line treatment of advanced breast cancer   \n",
       "...                                                 ...   \n",
       "1282  Chronic Thromboembolic Pulmonary Hypertension ...   \n",
       "1770  Inadequately controlled chronic obstructive pu...   \n",
       "1841  Giant cell ateritis (GCA), glucocorticoid tape...   \n",
       "1919  Squamous Cell Carcinoma of the Head and Neck, ...   \n",
       "1126  Haemophilia A, moderate severity, severe bleed...   \n",
       "\n",
       "                     Stage__c                         Pharmaceutical__c  \\\n",
       "688                  Decision           Risperidone tablets (Risperdal)   \n",
       "584                  Decision                    Gabapentin (Neurontin)   \n",
       "982                  Decision  Somatropin - Growth Hormone (Genotropin)   \n",
       "593                  Decision        Interferon beta-1-beta (Betaferon)   \n",
       "1407                 Decision                    Anastrozole (Arimidex)   \n",
       "...                       ...                                       ...   \n",
       "1282  Seeking Clinical Advice                       Riociguat (ADEMPAS)   \n",
       "1770  Seeking Clinical Advice                      Mepolizumab (Nucala)   \n",
       "1841  Seeking Clinical Advice                     Upadacitinib (Rinvoq)   \n",
       "1919  Seeking Clinical Advice                  pembrolizumab (KEYTRUDA)   \n",
       "1126  Seeking Clinical Advice                     Emicizumab (Hemlibra)   \n",
       "\n",
       "                                       Community_URL__c  ...  \\\n",
       "688   https://connect.pharmac.govt.nz//apptracker/s/...  ...   \n",
       "584   https://connect.pharmac.govt.nz//apptracker/s/...  ...   \n",
       "982   https://connect.pharmac.govt.nz//apptracker/s/...  ...   \n",
       "593   https://connect.pharmac.govt.nz//apptracker/s/...  ...   \n",
       "1407  https://connect.pharmac.govt.nz//apptracker/s/...  ...   \n",
       "...                                                 ...  ...   \n",
       "1282  https://connect.pharmac.govt.nz//apptracker/s/...  ...   \n",
       "1770  https://connect.pharmac.govt.nz//apptracker/s/...  ...   \n",
       "1841  https://connect.pharmac.govt.nz//apptracker/s/...  ...   \n",
       "1919  https://connect.pharmac.govt.nz//apptracker/s/...  ...   \n",
       "1126  https://connect.pharmac.govt.nz//apptracker/s/...  ...   \n",
       "\n",
       "     Application Received date Last Update date  \\\n",
       "688                 1994-04-01       1995-10-01   \n",
       "584                 1994-08-01       2001-03-01   \n",
       "982                 1995-09-01       2005-09-01   \n",
       "593                 1996-01-01       1999-07-01   \n",
       "1407                1997-02-01       1998-12-01   \n",
       "...                        ...              ...   \n",
       "1282                2025-10-28       2026-02-02   \n",
       "1770                2025-10-31       2026-01-09   \n",
       "1841                2025-10-31       2026-01-05   \n",
       "1919                2025-12-19       2026-01-09   \n",
       "1126                2026-01-14       2026-02-03   \n",
       "\n",
       "     Days elapsed between application and last update  \\\n",
       "688                                               548   \n",
       "584                                              2404   \n",
       "982                                              3653   \n",
       "593                                              1277   \n",
       "1407                                              668   \n",
       "...                                               ...   \n",
       "1282                                               97   \n",
       "1770                                               70   \n",
       "1841                                               66   \n",
       "1919                                               21   \n",
       "1126                                               20   \n",
       "\n",
       "      Application Received dates  \\\n",
       "688                   1994-04-01   \n",
       "584                   1994-08-01   \n",
       "982                   1995-09-01   \n",
       "593                   1996-01-01   \n",
       "1407                  1997-02-01   \n",
       "...                          ...   \n",
       "1282                  2025-10-28   \n",
       "1770                  2025-10-31   \n",
       "1841                  2025-10-31   \n",
       "1919                  2025-12-19   \n",
       "1126                  2026-01-14   \n",
       "\n",
       "                          Seeking Clinical Advice dates  \\\n",
       "688   1994-04-01,1994-06-01,1994-09-01,1994-10-01,19...   \n",
       "584                    1995-02-01,1995-03-01,2000-05-01   \n",
       "982   1995-09-01,1995-11-01,1996-09-01,1996-10-01,20...   \n",
       "593                    1996-01-01,1996-03-01,1996-05-01   \n",
       "1407                   1997-02-01,1997-05-15,1997-08-01   \n",
       "...                                                 ...   \n",
       "1282                                         2026-02-02   \n",
       "1770                                         2026-01-09   \n",
       "1841                                         2026-01-05   \n",
       "1919                                         2026-01-09   \n",
       "1126                                         2026-02-03   \n",
       "\n",
       "                Under Assessment dates  \\\n",
       "688   1994-12-01,1995-04-01,1995-05-01   \n",
       "584                         1995-03-01   \n",
       "982                         1996-11-01   \n",
       "593                                NaN   \n",
       "1407                        1997-05-01   \n",
       "...                                ...   \n",
       "1282                               NaN   \n",
       "1770                               NaN   \n",
       "1841                               NaN   \n",
       "1919                               NaN   \n",
       "1126                               NaN   \n",
       "\n",
       "                                 Options Compared dates  \\\n",
       "688                               1994-09-01,1994-10-01   \n",
       "584                    1995-05-01,2000-03-01,2000-06-01   \n",
       "982   1995-11-01,1996-09-01,1998-01-01,2004-01-01,20...   \n",
       "593                                          1999-05-01   \n",
       "1407                                         1998-10-01   \n",
       "...                                                 ...   \n",
       "1282                                                NaN   \n",
       "1770                                                NaN   \n",
       "1841                                                NaN   \n",
       "1919                                                NaN   \n",
       "1126                                                NaN   \n",
       "\n",
       "     Under Consultation dates Reviewing Consultation Feedback dates  \\\n",
       "688                       NaN                                   NaN   \n",
       "584                2001-01-01                                   NaN   \n",
       "982                2009-10-01                                   NaN   \n",
       "593                1999-05-01                                   NaN   \n",
       "1407               1998-10-01                                   NaN   \n",
       "...                       ...                                   ...   \n",
       "1282                      NaN                                   NaN   \n",
       "1770                      NaN                                   NaN   \n",
       "1841                      NaN                                   NaN   \n",
       "1919                      NaN                                   NaN   \n",
       "1126                      NaN                                   NaN   \n",
       "\n",
       "                        Decision dates  \n",
       "688                         1995-10-01  \n",
       "584                         2001-03-01  \n",
       "982   2005-09-01,2006-05-01,2009-11-01  \n",
       "593              1999-07-01,1999-12-01  \n",
       "1407                        1998-12-01  \n",
       "...                                ...  \n",
       "1282                               NaN  \n",
       "1770                               NaN  \n",
       "1841                               NaN  \n",
       "1919                               NaN  \n",
       "1126                               NaN  \n",
       "\n",
       "[2015 rows x 21 columns]"
      ]
     },
     "execution_count": 7,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df[cols]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "id": "926ada7c",
   "metadata": {},
   "outputs": [],
   "source": [
    "df[cols].to_excel(\"Pharmac applications.xlsx\", index=False)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "id": "3b7e0fc2",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "count    2015.000000\n",
       "mean     1390.057072\n",
       "std      1372.478161\n",
       "min       -94.000000\n",
       "25%       485.000000\n",
       "50%       866.000000\n",
       "75%      1844.500000\n",
       "max      9922.000000\n",
       "Name: Days elapsed between application and last update, dtype: float64"
      ]
     },
     "execution_count": 9,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df[\"Days elapsed between application and last update\"].describe()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "id": "c6e0cba0",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<Axes: title={'center': 'Number of applications received per month'}, xlabel='Application Received date'>"
      ]
     },
     "execution_count": 10,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "iVBORw0KGgoAAAANSUhEUgAAA9oAAAIjCAYAAAD8/WMiAAAAOXRFWHRTb2Z0d2FyZQBNYXRwbG90bGliIHZlcnNpb24zLjkuMiwgaHR0cHM6Ly9tYXRwbG90bGliLm9yZy8hTgPZAAAACXBIWXMAAA9hAAAPYQGoP6dpAACvLUlEQVR4nOzdd3hUZfrG8XsmlXRCCKETekcFQQSxoBR773Vtu2LXtXfdxbK76iqK5bdiX9uqK6vYBekC0nsPJQmE9J6Z8/tj5pycKYGEGQg63891cYVMJpOTaTn3+7zv8zoMwzAEAAAAAADCwtncBwAAAAAAwO8JQRsAAAAAgDAiaAMAAAAAEEYEbQAAAAAAwoigDQAAAABAGBG0AQAAAAAII4I2AAAAAABhRNAGAAAAACCMCNoAAAAAAIQRQRsAfuN++uknORwOffzxx819KI2Sl5enc889V61atZLD4dBzzz3X3IcUVJcuXXTllVdan5v3808//dTsx4KGPfLII3I4HM3ys3mcDowuXbro1FNPbe7DAIAmIWgDQCNMmTJFDodD8fHx2r59e8DXjzvuOPXv378Zjuy357bbbtPXX3+te++9V2+//bbGjRvX3Id0SJg9e7YeeeQRFRUVNfehAAfdypUr9cgjj2jz5s3NfSgAEBYEbQBogurqaj355JPNfRi/aT/88IPOOOMM3Xnnnbr00kvVu3fv5j6kRhk1apQqKys1atSoA3L7s2fP1qOPPho0aK9Zs0avvfbaAfm5vzcPPPCAKisrm/sw0EQrV67Uo48+StAG8LtB0AaAJjjssMP02muvaceOHc19KAddeXl5WG4nPz9faWlpYbmtg8npdCo+Pl5O58H/0xkXF6eYmJiD/nP3V0VFRbP97OjoaMXHxzfbzz9UhOv1CgDYPwRtAGiC++67Ty6Xa59V7c2bN8vhcGjKlCkBX3M4HHrkkUesz801pWvXrtWll16q1NRUtW7dWg8++KAMw1BOTo7OOOMMpaSkKCsrS3//+9+D/kyXy6X77rtPWVlZSkxM1Omnn66cnJyA682bN0/jxo1TamqqEhISdOyxx2rWrFk+1zGPaeXKlbr44ovVsmVLjRw5cq+/88aNG3XeeecpPT1dCQkJOuqoo/S///3P+ro5/d4wDE2aNEkOh2Ofa2n/9re/6eijj1arVq3UokULDR48OOhadIfDoRtvvFHvvvuuevXqpfj4eA0ePFgzZswI+nutXr1a559/vlJSUtSqVSvdcsstqqqq2uuxNLRGe968eTr55JPVsmVLJSYmauDAgXr++eetry9dulRXXnmlunbtqvj4eGVlZekPf/iDCgoKfI7rz3/+syQpOzvbum/M6l6wtb/7ur/tx/zhhx/qL3/5izp06KD4+HiNHj1a69ev97nuunXrdM455ygrK0vx8fHq0KGDLrzwQhUXF+/1fjGXTSxcuFCjRo1SQkKC7rvvPkmeGSAPP/ywunfvrri4OHXs2FF33XWXqqurA27nnXfe0dChQ5WQkKCWLVtq1KhR+uabb3yu89VXX+mYY45RYmKikpOTdcopp2jFihU+1/Ffo92/f38df/zxAT/P7Xarffv2Ovfcc30ue+6559SvXz/Fx8erTZs2uv7661VYWOjzvYZh6IknnlCHDh2UkJCg448/PuA4GmK+N/ztb3/Ts88+q86dO6tFixY69thjtXz58oDrr169Wueee67S09MVHx+vIUOG6L///a/PdczX1vTp03XDDTcoMzNTHTp0aPAY7M+LRx99VO3bt1dycrLOPfdcFRcXq7q6WrfeeqsyMzOVlJSkq666KuAxq6ur0+OPP65u3bopLi5OXbp00X333RdwPXN99cyZMzV06FDFx8era9eueuutt3yO/7zzzpMkHX/88dbz3/+1trfbAIBDTXRzHwAA/JZkZ2fr8ssv12uvvaZ77rlH7dq1C9ttX3DBBerTp4+efPJJ/e9//9MTTzyh9PR0vfLKKzrhhBP01FNP6d1339Wdd96pI488MmAK81/+8hc5HA7dfffdys/P13PPPacTTzxRixcvVosWLSR5pm2PHz9egwcP1sMPPyyn06k33nhDJ5xwgn7++WcNHTrU5zbPO+889ejRQ3/9619lGEaDx56Xl6ejjz5aFRUVuvnmm9WqVSu9+eabOv300/Xxxx/rrLPO0qhRo/T222/rsssu00knnaTLL798n/fJ888/r9NPP12XXHKJampq9O9//1vnnXeepk6dqlNOOcXnutOnT9cHH3ygm2++WXFxcXrppZc0btw4zZ8/P2D9/Pnnn68uXbpo4sSJmjt3rv75z3+qsLCwySfu3377rU499VS1bdtWt9xyi7KysrRq1SpNnTpVt9xyi3WdjRs36qqrrlJWVpZWrFihV199VStWrNDcuXPlcDh09tlna+3atXr//ff17LPPKiMjQ5LUunXr/b6/7Z588kk5nU7deeedKi4u1tNPP61LLrlE8+bNkyTV1NRo7Nixqq6u1k033aSsrCxt375dU6dOVVFRkVJTU/d6PxQUFGj8+PG68MILdemll6pNmzZyu906/fTTNXPmTF133XXq06ePli1bpmeffVZr167VZ599Zn3/o48+qkceeURHH320HnvsMcXGxmrevHn64YcfNGbMGEnS22+/rSuuuEJjx47VU089pYqKCr388ssaOXKkfv31V3Xp0iXosV1wwQV65JFHlJubq6ysLOvymTNnaseOHbrwwguty66//npNmTJFV111lW6++WZt2rRJL774on799VfNmjXLmlXw0EMP6YknntDJJ5+sk08+WYsWLdKYMWNUU1Oz1/vJ7q233lJpaakmTJigqqoqPf/88zrhhBO0bNkytWnTRpK0YsUKjRgxQu3bt9c999yjxMREffjhhzrzzDP1ySefBDzON9xwg1q3bq2HHnqoURXtiRMnqkWLFrrnnnu0fv16vfDCC4qJiZHT6VRhYaEeeeQRzZ07V1OmTFF2drYeeugh63uvueYavfnmmzr33HN1xx13aN68eZo4caJWrVqlTz/91OfnrF+/Xueee66uvvpqXXHFFfrXv/6lK6+8UoMHD1a/fv00atQo3XzzzfrnP/+p++67T3369JEk62NjbgMADjkGAGCf3njjDUOS8csvvxgbNmwwoqOjjZtvvtn6+rHHHmv069fP+nzTpk2GJOONN94IuC1JxsMPP2x9/vDDDxuSjOuuu866rK6uzujQoYPhcDiMJ5980rq8sLDQaNGihXHFFVdYl/3444+GJKN9+/ZGSUmJdfmHH35oSDKef/55wzAMw+12Gz169DDGjh1ruN1u63oVFRVGdna2cdJJJwUc00UXXdSo++fWW281JBk///yzdVlpaamRnZ1tdOnSxXC5XD6//4QJExp1uxUVFT6f19TUGP379zdOOOEEn8slGZKMBQsWWJdt2bLFiI+PN84666yA3+v000/3+f4bbrjBkGQsWbLEuqxz585B7+cff/zRMAzPY5SdnW107tzZKCws9Lk9//vX3/vvv29IMmbMmGFd9swzzxiSjE2bNgVc3/9YGnt/m8fcp08fo7q62rru888/b0gyli1bZhiGYfz666+GJOOjjz4K+Nn7cuyxxxqSjMmTJ/tc/vbbbxtOp9PnGA3DMCZPnmxIMmbNmmUYhmGsW7fOcDqdxllnneXzPDGM+vuxtLTUSEtLM6699lqfr+fm5hqpqak+l5uPsWnNmjWGJOOFF17w+d4bbrjBSEpKsh6fn3/+2ZBkvPvuuz7XmzZtms/l+fn5RmxsrHHKKaf4PM733XefIcnncQrGfG9o0aKFsW3bNuvyefPmGZKM2267zbps9OjRxoABA4yqqiqf++Too482evToYV1mvj+NHDnSqKur2+vPN4z650X//v2Nmpoa6/KLLrrIcDgcxvjx432uP3z4cKNz587W54sXLzYkGddcc43P9e68805DkvHDDz9Yl3Xu3DnguZ6fn2/ExcUZd9xxh3XZRx995PP6smvsbQDAoYSp4wDQRF27dtVll12mV199VTt37gzb7V5zzTXW/6OiojRkyBAZhqGrr77aujwtLU29evXSxo0bA77/8ssvV3JysvX5ueeeq7Zt2+rLL7+UJC1evFjr1q3TxRdfrIKCAu3evVu7d+9WeXm5Ro8erRkzZsjtdvvc5h//+MdGHfuXX36poUOH+kwvT0pK0nXXXafNmzdr5cqVjbsT/JiVeEkqLCxUcXGxjjnmGC1atCjgusOHD9fgwYOtzzt16qQzzjhDX3/9tVwul891J0yY4PP5TTfdZP0ejfXrr79q06ZNuvXWWwPWnNunLtt/h6qqKu3evVtHHXWUJAX9PRqjqff3VVddpdjYWOvzY445RpKs55FZsf7666/3a311XFycrrrqKp/LPvroI/Xp00e9e/e2nmu7d+/WCSecIEn68ccfJUmfffaZ3G63HnrooYD17+b9+O2336qoqEgXXXSRz21FRUVp2LBh1m0F07NnTx122GH64IMPrMtcLpc+/vhjnXbaadbj89FHHyk1NVUnnXSSz88YPHiwkpKSrJ/x3XffqaamRjfddJPP43zrrbc26T4788wz1b59e+vzoUOHatiwYdZzcM+ePfrhhx90/vnnq7S01DqegoICjR07VuvWrQvYAeHaa69VVFRUo4/h8ssv91n7P2zYMBmGoT/84Q8+1xs2bJhycnJUV1cnqf51cvvtt/tc74477pCkgCUMffv2tZ5zkmemRkPvYw0Jx20AwMFE0AaA/fDAAw+orq4urB3IO3Xq5PN5amqq4uPjrWnE9sv914xKUo8ePXw+dzgc6t69u7XOd926dZKkK664Qq1bt/b59/rrr6u6ujpgPW52dnajjn3Lli3q1atXwOXm1M8tW7Y06nb8TZ06VUcddZTi4+OVnp6u1q1b6+WXXw66btj/95c8IauiokK7du3a63W7desmp9PZpI7HGzZskKR9buu2Z88e3XLLLWrTpo1atGih1q1bW/frvtY/N6Sp97f/c6tly5aSZD2PsrOzdfvtt+v1119XRkaGxo4dq0mTJjX6+Nq3b+8T5CXP823FihUBz7WePXtK8jTFkzz3o9PpVN++fRu8ffO5e8IJJwTc3jfffGPdVkMuuOACzZo1ywqmP/30k/Lz83XBBRf4/Izi4mJlZmYG/IyysjLrZ5j3rf9zqHXr1tb92hgNPV/N5+D69etlGIYefPDBgON5+OGHJSng927s69UU7D1Hkjp27Bhwudvttp4PW7ZskdPpVPfu3X2ul5WVpbS0tH0+/yTPczDY+1hjj3V/bgMADibWaAPAfujatasuvfRSvfrqq7rnnnsCvt5Qky//yqpdsEpUQ9UpYy/rpRtiVqufeeYZHXbYYUGvk5SU5PO5vRp7sP388886/fTTNWrUKL300ktq27atYmJi9MYbb+i9994L68/aV1O2UJx//vmaPXu2/vznP+uwww5TUlKS3G63xo0bFzCD4EBpzPPo73//u6688kp9/vnn+uabb3TzzTdba9j31lhLCv48cbvdGjBggP7xj38E/R7/MLc35v309ttv+6yzNkVH7/105oILLtC9996rjz76SLfeeqs+/PBDpaam+uzh7na7lZmZqXfffTfobTS0Xv5AMX/nO++8U2PHjg16Hf+g29TXa0PPi8a+7zT2dROO97FwvhcCwMFA0AaA/fTAAw/onXfe0VNPPRXwNbOy5b8n8v5WdhvDrPqZDMPQ+vXrNXDgQEmeqq0kpaSk6MQTTwzrz+7cubPWrFkTcPnq1autrzfVJ598ovj4eH399deKi4uzLn/jjTeCXt//95ektWvXKiEhISAkrVu3zqf6t379ernd7gYbagVj3p/Lly9v8P4sLCzU999/r0cffdSnkVSwY21K2D8Q97ckDRgwQAMGDNADDzyg2bNna8SIEZo8ebKeeOKJJt9Wt27dtGTJEo0ePXqvv1u3bt3kdru1cuXKBgeAzPs6MzNzv5672dnZGjp0qD744APdeOON+s9//qMzzzzT53nVrVs3fffddxoxYsReA6t5365bt05du3a1Lt+1a1eTqqsNPV/N56B52zExMWF/vYaqc+fOcrvdWrdunU/Dsry8PBUVFe3X8+9ADnYBQHNg6jgA7Kdu3brp0ksv1SuvvKLc3Fyfr6WkpCgjIyNge6mXXnrpgB2P2cXY9PHHH2vnzp0aP368JGnw4MHq1q2b/va3v6msrCzg+/2nVzfFySefrPnz52vOnDnWZeXl5Xr11VfVpUuXvU4LbkhUVJQcDofPLIDNmzf7dKu2mzNnjs+a55ycHH3++ecaM2ZMQDVs0qRJPp+/8MILkmTdV41xxBFHKDs7W88991zAgIpZZTN/rn/V7bnnngu4vcTEREmBgzPBhPv+LikpsdbfmgYMGCCn0xl0K67GOP/887V9+3a99tprAV+rrKy0umKfeeaZcjqdeuyxxwIq/Ob9NnbsWKWkpOivf/2ramtrA26vMc/dCy64QHPnztW//vUv7d6922fauHm8LpdLjz/+eMD31tXVWY/LiSeeqJiYGL3wwgs+j2uwx3RvPvvsM5811vPnz9e8efOs52BmZqaOO+44vfLKK0F7QYTyeg3VySefLCnwdzZnL/jvCNAYTXn+A8BvARVtAAjB/fffr7fffltr1qwJ2GLmmmuu0ZNPPqlrrrlGQ4YM0YwZM7R27doDdizp6ekaOXKkrrrqKuXl5em5555T9+7dde2110qSnE6nXn/9dY0fP179+vXTVVddpfbt22v79u368ccflZKSoi+++GK/fvY999yj999/X+PHj9fNN9+s9PR0vfnmm9q0aZM++eSTgCZXjXHKKafoH//4h8aNG6eLL75Y+fn5mjRpkrp3766lS5cGXL9///4aO3asz/ZekmfrKH+bNm3S6aefrnHjxmnOnDl65513dPHFF2vQoEGNPj6n06mXX35Zp512mg477DBdddVVatu2rVavXq0VK1bo66+/VkpKikaNGqWnn35atbW1at++vb755htt2rQp4PbMRm7333+/LrzwQsXExOi0006zAohduO/vH374QTfeeKPOO+889ezZU3V1dXr77bcVFRWlc845p0m3Zbrsssv04Ycf6o9//KN+/PFHjRgxQi6XS6tXr9aHH36or7/+WkOGDFH37t11//336/HHH9cxxxyjs88+W3Fxcfrll1/Url07TZw4USkpKXr55Zd12WWX6YgjjtCFF16o1q1ba+vWrfrf//6nESNG6MUXX9zr8Zx//vm68847deeddyo9PT2gSnzsscfq+uuv18SJE7V48WKNGTNGMTExWrdunT766CM9//zzOvfcc9W6dWvdeeedmjhxok499VSdfPLJ+vXXX/XVV18F9FPYm+7du2vkyJH605/+pOrqaj333HNq1aqV7rrrLus6kyZN0siRIzVgwABde+216tq1q/Ly8jRnzhxt27ZNS5YsadqDEiaDBg3SFVdcoVdffVVFRUU69thjNX/+fL355ps688wzg+5bvi+HHXaYoqKi9NRTT6m4uFhxcXE64YQTlJmZeQB+AwA48AjaABCC7t2769JLL9Wbb74Z8LWHHnpIu3bt0scff6wPP/xQ48eP11dffXXAThzvu+8+LV26VBMnTlRpaalGjx6tl156SQkJCdZ1jjvuOM2ZM0ePP/64XnzxRZWVlSkrK0vDhg3T9ddfv98/u02bNpo9e7buvvtuvfDCC6qqqtLAgQP1xRdf7Fd1S/I0vvq///s/Pfnkk7r11luVnZ2tp556Sps3bw4atI899lgNHz5cjz76qLZu3aq+fftqypQp1tR5uw8++EAPPfSQ7rnnHkVHR+vGG2/UM8880+RjHDt2rH788Uc9+uij+vvf/y63261u3bpZgxuS9N577+mmm27SpEmTZBiGxowZo6+++ipgD/YjjzxSjz/+uCZPnqxp06bJ7XZr06ZNQYN2uO/vQYMGaezYsfriiy+0fft2JSQkaNCgQfrqq6+sDulN5XQ69dlnn+nZZ5/VW2+9pU8//VQJCQnq2rWrbrnlFqspmiQ99thjys7O1gsvvKD7779fCQkJGjhwoC677DLrOhdffLHatWunJ598Us8884yqq6vVvn17HXPMMQEdz4Pp0KGDjj76aM2aNUvXXHONT7dt0+TJkzV48GC98soruu+++xQdHa0uXbro0ksv1YgRI6zrPfHEE4qPj9fkyZP1448/atiwYfrmm2+adN9ffvnlcjqdeu6555Sfn6+hQ4fqxRdfVNu2ba3r9O3bVwsWLNCjjz6qKVOmqKCgQJmZmTr88MN9liI0h9dff11du3bVlClT9OmnnyorK0v33nuv1aitqbKysjR58mRNnDhRV199tVwul3788UeCNoDfLIdBFwkAwG+cw+HQhAkT9lnVfOSRR/Too49q165dTao+AuGyefNmZWdn65lnntGdd97Z3IcDADhAWKMNAAAAAEAYEbQBAAAAAAgjgjYAAAAAAGHEGm0AAAAAAMKIijYAAAAAAGFE0AYAAAAAIIx+k/tou91u7dixQ8nJyXI4HM19OAAAAACA3znDMFRaWqp27drJ6dx7zfo3GbR37Nihjh07NvdhAAAAAAAiTE5Ojjp06LDX6/wmg3ZycrIkzy+YkpLSzEcDAAAAAPi9KykpUceOHa08uje/yaBtThdPSUkhaAMAAAAADprGLF+mGRoAAAAAAGFE0AYAAAAAIIwI2gAAAAAAhBFBGwAAAACAMCJoAwAAAAAQRgRtAAAAAADCiKANAAAAAEAYEbQBAAAAAAgjgjYAAAAAAGFE0AYAAAAAIIwI2gAAAAAAhBFBGwAAAACAMCJoAwAAAAAQRgRtAAAAAADCiKANAAAAAEAYEbQBAAAAAAgjgjYAAAgrwzC0bFuxSqtqm/tQAABoFgRtAAAQVku2Feu0F2fqnk+WNfehAADQLAjaAAAgrHYWVXo+Flc285EAANA8CNoAACCsXIYhSTKa+TgAAGguBG0AABBWLrcnYrtJ2gCACEXQBgAAYWUGbRkkbQBAZCJoAwCAsKKiDQCIdARtAAAQVm5rjTZJGwAQmQjaAAAgrFxuz0e3u3mPAwCA5kLQBgAAYUXXcQBApCNoAwCAsHJ7F2cbNEMDAEQogjYAAAgrlxW0m/lAAABoJgRtAAAQVmYzNDdJGwAQoQjaAAAgrKyKdjMfBwAAzYWgDQAAwspFRRsAEOEI2gAAIKzMZmiUtAEAkYqgDQAAwsraR5uKNgAgQhG0AQBAWLGPNgAg0hG0AQBAWJlTx6loAwAiFUEbAACEVR37aAMAIhxBGwAAhJVZySZoAwAiFUEbAACElbWPNkkbABChCNoAACCsXNYa7WY+EAAAmglBGwAAhJU5dZxmaACASEXQBgAAYWVNHW/m4wAAoLkQtAEAQFjVN0MjagMAIhNBGwAAhJWL7b0AABGOoA0AAMLK5fZ8ZI02ACBSEbQBAEBYWVPHm/k4AABoLgRtAAAQVtb2XuzvBQCIUARtAAAQVi4q2gCACEfQBgAAYeWmGRoAIMIRtAEAQFjVdx0naQMAIhNBGwAAhJXZDI0l2gCASEXQBgAAYVVnVrRZpQ0AiFAEbQAAEFZW13FyNgAgQhG0AQBAWJlTxyloAwAiFUEbAACEVX1Fm6QNAIhMTQraEydO1JFHHqnk5GRlZmbqzDPP1Jo1a3yuc9xxx8nhcPj8++Mf/+hzna1bt+qUU05RQkKCMjMz9ec//1l1dXWh/zYAAKDZud2ej8RsAECkim7KladPn64JEyboyCOPVF1dne677z6NGTNGK1euVGJionW9a6+9Vo899pj1eUJCgvV/l8ulU045RVlZWZo9e7Z27typyy+/XDExMfrrX/8ahl8JAAA0J5dBRRsAENmaFLSnTZvm8/mUKVOUmZmphQsXatSoUdblCQkJysrKCnob33zzjVauXKnvvvtObdq00WGHHabHH39cd999tx555BHFxsYGfE91dbWqq6utz0tKSppy2AAA4CCq30e7mQ8EAIBmEtIa7eLiYklSenq6z+XvvvuuMjIy1L9/f917772qqKiwvjZnzhwNGDBAbdq0sS4bO3asSkpKtGLFiqA/Z+LEiUpNTbX+dezYMZTDBgAAB5C9km2QtgEAEahJFW07t9utW2+9VSNGjFD//v2tyy+++GJ17txZ7dq109KlS3X33XdrzZo1+s9//iNJys3N9QnZkqzPc3Nzg/6se++9V7fffrv1eUlJCWEbAIBDlMttD9qSw9GMBwMAQDPY76A9YcIELV++XDNnzvS5/LrrrrP+P2DAALVt21ajR4/Whg0b1K1bt/36WXFxcYqLi9vfQwUAAAeRPWi7DUNOkbQBAJFlv6aO33jjjZo6dap+/PFHdejQYa/XHTZsmCRp/fr1kqSsrCzl5eX5XMf8vKF13QAA4LfDZ+p4Mx4HAADNpUlB2zAM3Xjjjfr000/1ww8/KDs7e5/fs3jxYklS27ZtJUnDhw/XsmXLlJ+fb13n22+/VUpKivr27duUwwEAAIcg/4o2AACRpklTxydMmKD33ntPn3/+uZKTk6011ampqWrRooU2bNig9957TyeffLJatWqlpUuX6rbbbtOoUaM0cOBASdKYMWPUt29fXXbZZXr66aeVm5urBx54QBMmTGB6OAAAvwO2nE3ncQBARGpSRfvll19WcXGxjjvuOLVt29b698EHH0iSYmNj9d1332nMmDHq3bu37rjjDp1zzjn64osvrNuIiorS1KlTFRUVpeHDh+vSSy/V5Zdf7rPvNgAA+O3yb4YGAECkaVJFe19bdHTs2FHTp0/f5+107txZX375ZVN+NAAA+I3wCdqs0gYARKCQ9tEGAADw57tGuxkPBACAZkLQBgAAYeWydx1n7jgAIAIRtAEAQFi5qWgDACIcQRsAAISVvaLNEm0AQCQiaAMAgLBiH20AQKQjaAMAgLBy+3QdBwAg8hC0AQBAWNmnjlPRBgBEIoI2AAAIK7e7/v/kbABAJCJoAwCAsGJ7LwBApCNoAwCAsHKxRhsAEOEI2gAAIGzcfhtns0YbABCJCNoAACBsXH7BmpwNAIhEBG0AABA2LiraAAAQtAEAQPj4B2tyNgAgEhG0AQBA2PhXtAnaAIBIRNAGAABhExC06TsOAIhABG0AABA2gWu0m+lAAABoRgRtAAAQNoFdx0naAIDIQ9AGAABh43b7fU7OBgBEIII2AAAIG/+KtlijDQCIQARtAAAQNm7WaAMAQNAGAADhw/ZeAAAQtAEAQBj5Tx13k7QBABGIoA0AAMLGf+o4ORsAEIkI2gAAIGyoaAMAQNAGAABh5L9GGwCASETQBgAAYRO4jzbBGwAQeQjaAAAgbPynjpOzAQCRiKANAADCxn/qOBVtAEAkImgDAICw8Q/WxGwAQCQiaAMAgLCpc/lPHSdqAwAiD0EbAACETUBFm5wNAIhABG0AABA2gWu0m+lAAABoRgRtAAAQNoFdx0naAIDIQ9AGAABh46aiDQAAQRsAAISP/9Rxg77jAIAIRNAGAABhQzM0AAAI2gAAIIxcbt/PCdoAgEhE0AYAAGHj3wzNv8INAEAkIGgDAICw8W+GRswGAEQigjYAAAibwH20idoAgMhD0AYAAGHjP3WckjYAIBIRtAEAQNgE7qNN0gYARB6CNgAACBv/ijY5GwAQiQjaAAAgbKhoAwBA0AYAAGFUR9dxAAAI2gAAIHz8u44bVLQBABGIoA0AAMLGf6o4ORsAEIkI2gAAIGxcbt/P3QRtAEAEImgDAICwCahos0obABCBCNoAACBs/NdoU9EGAEQigjYAAAgbmqEBAEDQBgAAYUQzNAAACNoAACCMAirarNEGAEQggjYAAAgbl18J2+1u4IoAAPyOEbQBAEDYuAMq2gAARB6CNgAACJvAfbSJ2gCAyEPQBgAAYRMQrMnZAIAIRNAGAABhE7iPNkkbABB5CNoAACBs/JuhEbMBAJGIoA0AAMLG5aKiDQAAQRsAAIRNQEWbnA0AiEAEbQAAEDYB23uRtAEAEYigDQAAwoY12gAAELQBAEAYBXQddxO1AQCRp0lBe+LEiTryyCOVnJyszMxMnXnmmVqzZo3PdaqqqjRhwgS1atVKSUlJOuecc5SXl+dzna1bt+qUU05RQkKCMjMz9ec//1l1dXWh/zYAAKBZ+Tc/I2YDACJRk4L29OnTNWHCBM2dO1fffvutamtrNWbMGJWXl1vXue222/TFF1/oo48+0vTp07Vjxw6dffbZ1tddLpdOOeUU1dTUaPbs2XrzzTc1ZcoUPfTQQ+H7rQAAQLMI3Ee7mQ4EAIBm5DBC6FKya9cuZWZmavr06Ro1apSKi4vVunVrvffeezr33HMlSatXr1afPn00Z84cHXXUUfrqq6906qmnaseOHWrTpo0kafLkybr77ru1a9cuxcbG7vPnlpSUKDU1VcXFxUpJSdnfwwcAAGF2zZsL9N2q+plsD5zSR9cc07UZjwgAgPBoSg4NaY12cXGxJCk9PV2StHDhQtXW1urEE0+0rtO7d2916tRJc+bMkSTNmTNHAwYMsEK2JI0dO1YlJSVasWJF0J9TXV2tkpISn38AAODQEzB1nIo2ACAC7XfQdrvduvXWWzVixAj1799fkpSbm6vY2FilpaX5XLdNmzbKzc21rmMP2ebXza8FM3HiRKWmplr/OnbsuL+HDQAADiD/qeMGq7QBABFov4P2hAkTtHz5cv373/8O5/EEde+996q4uNj6l5OTc8B/JgAAaDqzoh3ldHg/b86jAQCgeUTvzzfdeOONmjp1qmbMmKEOHTpYl2dlZammpkZFRUU+Ve28vDxlZWVZ15k/f77P7Zldyc3r+IuLi1NcXNz+HCoAADiIzIp2tNMhl9tg6jgAICI1qaJtGIZuvPFGffrpp/rhhx+UnZ3t8/XBgwcrJiZG33//vXXZmjVrtHXrVg0fPlySNHz4cC1btkz5+fnWdb799lulpKSob9++ofwuAACgmdmDthS4ZhsAgEjQpIr2hAkT9N577+nzzz9XcnKytaY6NTVVLVq0UGpqqq6++mrdfvvtSk9PV0pKim666SYNHz5cRx11lCRpzJgx6tu3ry677DI9/fTTys3N1QMPPKAJEyZQtQYA4DfODNbRUU5JruY9GAAAmkmTgvbLL78sSTruuON8Ln/jjTd05ZVXSpKeffZZOZ1OnXPOOaqurtbYsWP10ksvWdeNiorS1KlT9ac//UnDhw9XYmKirrjiCj322GOh/SYAAKDZBVS0WaQNAIhATQrajdlyOz4+XpMmTdKkSZMavE7nzp315ZdfNuVHAwCA3wAraEd5gjYxGwAQiULaRxsAAMDOZU4dd3pOMVijDQCIRARtAAAQNi6352OMWdEmZwMAIhBBGwAAhI25JtvcR7sxy84AAPi9IWgDAICwMaeOx0R5TjGI2QCASETQBgAAYeNf0WaNNgAgEhG0AQBA2Lh89tFmjTYAIDIRtAEAQNgE7KNN0AYARCCCNgAACBu3X9A2WKUNAIhABG0AABA29VPH2d4LABC5CNoAACBszH20o53mGm2SNgAg8hC0AQBA2JhdxlmjDQCIZARtAAAQNlYzNKaOAwAiGEEbAACETX0zNM8pBvtoAwAiEUEbAACEjX8zNAAAIhFBGwAAhE0dFW0AAAjaAAAgfMyp4zGs0QYARDCCNgAACBtz6niU1XWcpA0AiDwEbQAAEBaGYVgV7Jgo7z7azXg8AAA0F4I2AAAIC5dt02yzom1Q0QYARCCCNgAACAuXLVSzjzYAIJIRtAEAQFi43fX/j2aNNgAgghG0AQBAWPhUtL3be5GzAQCRiKANAADCwr5Gu76i3VxHAwBA8yFoAwCAsHDbg7bVdZykDQCIPARtAAAQFvap496czdRxAEBEImgDAICwMCvaTofkdLC9FwAgchG0AQBAWJgV7SinQw4Ha7QBAJGLoA0AAMLCZVW0HXJ4LyNnAwAiEUEbAACEhbmPdpTTIW/TcfbRBgBEJII2AAAIizpv0o5y1E8dp6QNAIhEBG0AABAWZvU6KoqKNgAgshG0AQBAWLjMqeMOh2R1HW/GAwIAoJkQtAEAQFhYzdBYow0AiHAEbQAAEBbW1HGHQ2bfcWI2ACASEbQBAEBYmBVte9dxg4o2ACACEbQBAEBYuAxz6ri1RJs12gCAiETQBgAAYeF226aOe5M2a7QBAJGIoA0AAMLC3gzNW9BmjTYAICIRtAEAQFi4bM3QnFZFuzmPCACA5kHQBgAAYeE299F2OmxrtEnaAIDIQ9AGAABhYTVDs1W0ydkAgEhE0AYAAGHhtm3vZVW0WaUNAIhABG0AABAWPs3QzDXa7uY8IgAAmgdBGwAAhEV9MzTZuo5T0QYARB6CNgAACAuXbeo4XccBAJGMoA0AAMLCFWyNNt3QAAARiKANAADCwm3YK9qey8jZAIBIRNAGAABhYTVDczhkrtJ2k7QBABGIoA0AAMLCd4225zJiNgAgEhG0AQBAWFhTxx227b1I2gCACETQBgAAYeHy7pnttFW0WaQNAIhEBG0AABAWLltFm+29AACRjKANAADCwm1boy1rjTZJGwAQeQjaAAAgLKyu405bRdvdnEcEAEDzIGgDAICwqG+GZhW0qWcDACISQRsAAIRFsIq2QTM0AEAEImgDAICwcPls7+W5jJwNAIhEBG0AABAW9mZoZtB2k7QBABGIoA0AAMLCvo+2w7tKm5gNAIhEBG0AABAWLm+Lcc8+2p7LqGgDACIRQRsAAISFtUbb6ZDDWqTdjAcEAEAzIWgDAICwMKeORzmpaAMAIhtBGwAAhIXbCGyGRswGAEQigjYAAAgLax9tR/3UcSraAIBIRNAGAABh4bK295K35zj7aAMAIlOTg/aMGTN02mmnqV27dnI4HPrss898vn7llVfK4R3JNv+NGzfO5zp79uzRJZdcopSUFKWlpenqq69WWVlZSL8IAABoXtbUcYdDTm9Fm6ANAIhETQ7a5eXlGjRokCZNmtTgdcaNG6edO3da/95//32fr19yySVasWKFvv32W02dOlUzZszQdddd1/SjBwAAhwxr6rh9jTZJGwAQgaKb+g3jx4/X+PHj93qduLg4ZWVlBf3aqlWrNG3aNP3yyy8aMmSIJOmFF17QySefrL/97W9q165dUw8JAAAcAoJVtN3kbABABDoga7R/+uknZWZmqlevXvrTn/6kgoIC62tz5sxRWlqaFbIl6cQTT5TT6dS8efOC3l51dbVKSkp8/gEAgEOLvaJtMug7DgCIQGEP2uPGjdNbb72l77//Xk899ZSmT5+u8ePHy+VySZJyc3OVmZnp8z3R0dFKT09Xbm5u0NucOHGiUlNTrX8dO3YM92EDAIAQ+e6jTUUbABC5mjx1fF8uvPBC6/8DBgzQwIED1a1bN/30008aPXr0ft3mvffeq9tvv936vKSkhLANAMAhxj51vH6NdjMeEAAAzeSAb+/VtWtXZWRkaP369ZKkrKws5efn+1ynrq5Oe/bsaXBdd1xcnFJSUnz+AQCAQ4t96nh913GSNgAg8hzwoL1t2zYVFBSobdu2kqThw4erqKhICxcutK7zww8/yO12a9iwYQf6cAAAwAHisiraqq9oN+PxAADQXJo8dbysrMyqTkvSpk2btHjxYqWnpys9PV2PPvqozjnnHGVlZWnDhg2666671L17d40dO1aS1KdPH40bN07XXnutJk+erNraWt1444268MIL6TgOAMBvmNtb0fas0fZeRkUbABCBmlzRXrBggQ4//HAdfvjhkqTbb79dhx9+uB566CFFRUVp6dKlOv3009WzZ09dffXVGjx4sH7++WfFxcVZt/Huu++qd+/eGj16tE4++WSNHDlSr776avh+KwAAcNDV+XQdN6eON+MBAQDQTJpc0T7uuOP2ut7q66+/3udtpKen67333mvqjwYAAIcwq6LtoKINAIhsB3yNNgAAiAzWGm2nQw4WaQMAIhhBGwAAhIWLNdoAAEgiaAMAgDBx2yva5hrt5jwgAACaCUEbAACEhbWPtsNhbe9FRRsAEIkI2gAAICzcbs9Hzxptz//J2QCASETQBgAAYWE2Q3M6HHI62N4LABC5CNoAACAs7M3Q6puOk7QBAJGHoA0AAMKivhmarIq2m5wNAIhABG0AABAWPs3QvJcZzB0HAEQggjYAAAgL36njVLQBAJGLoA0AAMLCmjpu295LoqoNAIg8BG0AABAW1tRxZ33XcYnO4wCAyEPQBgAAYWFOE49y1q/RlkTfcQBAxCFoAwCAsKhzuyX57qMt1U8pBwAgUhC0AQBAWHhztqKcDslnjXbzHA8AAM2FoA0AAMLCXKMd7XTIaQvaVLQBAJGGoA0AAMLCZdj20ba3HQcAIMIQtAEAQFi4bftoU9EGAEQygjYAAAgLs6Id5ZTsfcfJ2QCASEPQBgAAYWHto+1wyEFFGwAQwQjaAAAgLOxTx+1Bm5gNAIg0BG0AABAW9mZo9n20DXdzHREAAM2DoA0AAMLCvo+2vee4QU0bABBhCNoAACAs6puh+Va03eRsAECEIWgDAICwaKgZmkEzNABAhCFoAwCAkLltZWtPMzQq2gCAyEXQBgAAIXPZqtZR3pBtZm3WaAMAIg1BGwAAhMxlK1s7vWcX5jptZo4DACINQRsAAITM5Td1XJLVeZygDQCINARtAAAQMvvUcbOSbX50k7QBABGGoA0AAELm3wxNklXSJmYDACINQRsAAITMZ+q4VdH2fO6m7TgAIMIQtAEAQMjMqeMOh+S01mg79vYtAAD8bhG0AQBAyNxuz8co2/7ZVkWbNdoAgAhD0AYAACEzK9pmNVuSHGzvBQCIUARtAAAQMnMdtr2i7aCiDQCIUARtAAAQMrMZWpS9ou39SMwGAEQagjYAAAiZNXXc1v/MnEZuUNEGAEQYgjYAAAiZe28VbXI2ACDCELQBAEDIzIq2PWg7vYu02UYbABBpCNoAACBk5hptZ5BmaAartAEAEYagDQAAQmbtox1key/zawAARAqCNgAACFl9M7RgXcepaAMAIgtBGwAAhMzlLVsHW6NNMzQAQKQhaAMAgJC5gk4d93wkaAMAIg1BGwAAhKy+GVr9ZfVdx0naAIDIQtAGAAAhM8N0tDPw1IKYDQCINARtAAAQMquibV+j7T3LoKINAIg0BG0AABAys+t4lO3MwiGaoQEAIhNBGwAAhMztrWhHOexdxz0fDZI2ACDCELQBAEDIgk0dd5jbezXLEQEA0HwI2gAAIGTmOmx7Rdv8r1ntBgAgUhC0AQBAyMx9tH0q2t6PxGwAQKQhaAMAgJC5glS02UcbABCpCNoAACBkVjM0Z+DUcUraAIBIQ9AGAAAhC7qPtlXRbpZDAgCg2RC0AQBAyOqnjgd+zaCkDQCIMARtAAAQsmBTx6loAwAiFUEbAACErM6cOh5key+DZmgAgAhD0AYAACGz9tEOUtEmZwMAIg1BGwAAhCxYMzSros0abQBAhCFoAwCAkJlBO8pn6rh3jba7WQ4JAIBmQ9AGAAAhM6eOR9sr2t6P1LMBAJGGoA0AAELm8latfffR9nx0s0gbABBhCNoAACBkVjO0IFPHydkAgEhD0AYAACEL1gzNyfZeAIAI1eSgPWPGDJ122mlq166dHA6HPvvsM5+vG4ahhx56SG3btlWLFi104oknat26dT7X2bNnjy655BKlpKQoLS1NV199tcrKykL6RQAAQPOxmqHZziwc3lXaxGwAQKRpctAuLy/XoEGDNGnSpKBff/rpp/XPf/5TkydP1rx585SYmKixY8eqqqrKus4ll1yiFStW6Ntvv9XUqVM1Y8YMXXfddfv/WwAAgGYVfOq479cAAIgU0U39hvHjx2v8+PFBv2YYhp577jk98MADOuOMMyRJb731ltq0aaPPPvtMF154oVatWqVp06bpl19+0ZAhQyRJL7zwgk4++WT97W9/U7t27UL4dQAAQHPY6z7a5GwAQIQJ6xrtTZs2KTc3VyeeeKJ1WWpqqoYNG6Y5c+ZIkubMmaO0tDQrZEvSiSeeKKfTqXnz5gW93erqapWUlPj8AwAAhw5XkIq209xHm6QNAIgwYQ3aubm5kqQ2bdr4XN6mTRvra7m5ucrMzPT5enR0tNLT063r+Js4caJSU1Otfx07dgznYQMAgBC5rTXagRVtAAAizW+i6/i9996r4uJi619OTk5zHxIAALAJvo82FW0AQGQKa9DOysqSJOXl5flcnpeXZ30tKytL+fn5Pl+vq6vTnj17rOv4i4uLU0pKis8/AABw6AjWDM1EzgYARJqwBu3s7GxlZWXp+++/ty4rKSnRvHnzNHz4cEnS8OHDVVRUpIULF1rX+eGHH+R2uzVs2LBwHg4AADhI6tyeknbwinazHBIAAM2myV3Hy8rKtH79euvzTZs2afHixUpPT1enTp1066236oknnlCPHj2UnZ2tBx98UO3atdOZZ54pSerTp4/GjRuna6+9VpMnT1Ztba1uvPFGXXjhhXQcBwDgN8qcOh5sey+DkjYAIMI0OWgvWLBAxx9/vPX57bffLkm64oorNGXKFN11110qLy/Xddddp6KiIo0cOVLTpk1TfHy89T3vvvuubrzxRo0ePVpOp1PnnHOO/vnPf4bh1wEAAM2hvhla/WVmRZucDQCINE0O2scdd9xeR6YdDocee+wxPfbYYw1eJz09Xe+9915TfzQAADhEmdt7+eyj7f1oiKQNAIgsv4mu4wAA4NBmVrSjfbb3Yo02ACAyEbQBAEDIrIp20DXazXFEAAA0H4I2AAAImctao23vOu75yD7aAIBIQ9AGAAAhs/bR9lmj7W2G1ixHBABA8yFoAwCAkJkVbfvUcaf3LIPtvQAAkYagDQAAQmbtox2sok3OBgBEGII2AAAImTV1PEgzNNZoAwAiDUEbAACEzJo6HmR7L3I2ACDSELQBAEDI6puh1V9G13EAQKQiaAMAgJAFa4bmaOjKAAD8zhG0AQBAyOqC7qPt+T8VbQBApCFoAwCAkLndgc3QzJI2ORsAEGkI2gAAIGQuI7AZWn1Fu1kOCQCAZkPQBgAAIQtW0Tb/Z4ikDQCILARtAAAQMpfR8Bptpo4DACINQRsAAITM5fZ89N1H2/PRIGkDACIMQRsAAITMnDoe7RO0WaMNAIhMBG0AABAyqxmaI1hFuzmOCACA5kPQBgAAIXMH3Ufb+zWSNgAgwhC0AQBAyOqbodVf5vD2HSdmAwAiDUEbAACEzOUOnDrupBkaACBCEbQBAEDIgk0dd7C9FwAgQhG0AQBAyPbWDI012gCASEPQBgAAITP30fapaLNGGwAQoQjaAAAgZG6DruMAAJgI2gAAIGR13pJ2sKnjlLQBAJGGoA0AAELm7YXmV9F2eL9G0gYARBaCNgAACJm5vVeUraIta3uvZjggAACaEUEbAACEzOo6bjuzqK9oN8cRAQDQfAjaAAAgZEH30fZ+NFikDQCIMARtAAAQMrOibZ86bla0mToOAIg0BG0AABASwzCsMO1T0XbUfx0AgEhC0AYAACFx2RZh+wZt1mgDACITQRsAAITEZatYO1mjDQAAQRsAAITG7a7/f7A12lS0AQCRhqANAABCYq9oB1+jfbCPCACA5kXQBgAAIbGv0Xb6VLQ9H2mGBgCINARtAAAQEvc+m6ERtAEAkYWgDQAAQuLTDK0+ZzN1HAAQsQjaAAAgJGZF2+mor2JLkkM0QwMARCaCNgAACEmdN0nbp41LtjXabO8FAIgwBG0AABASl1XR9g3aTB0HAEQqgjYAAAiJ2ewssKLt+Zyu4wCASEPQBgAAITEr2lF+FW0Ta7QBAJGGoA0AAEJiVrSdDVW0D/oRAQDQvAjaAAAgJC6356P/1HGzwM0+2gCASEPQBgAAIWmoGZr1OTkbABBhCNoAACAkZsU6moo2AACSCNoAACBErgb20XZYXccP+iEBANCsCNoAACAkLqsZmu/lZuymog0AiDQEbQAAEBJ3A9t70XUcABCpCNoAACAkVjO0BtZoG1S0AQARhqANAABCYk4dD6xoez6SswEAkYagDQAAQuJucB9tz+es0QYARBqCNgAACInVDM2vom1+RswGAEQagjYAAAiJy1vS9q9oO62K9kE/JAAAmhVBGwAAhMTlnTpOMzQAADwI2gAAICQua3sv38ut7b3I2QCACEPQBgAAITGbnQU2Q/N8NFilDQCIMARtAAAQEmsfbf9maOYabfdBPyQAAJoVQRsAAISkwYq29yMVbQBApCFoAwCAkFhrtOk6DgCAJII2AAAIUUNB28FG2gCACEXQBgAAIbGmjjv8K9q+XwcAIFIQtAEAQEga2kfbXKVNzAYARJqwB+1HHnlEDofD51/v3r2tr1dVVWnChAlq1aqVkpKSdM455ygvLy/chwEAAA4SFxVtAAB8HJCKdr9+/bRz507r38yZM62v3Xbbbfriiy/00Ucfafr06dqxY4fOPvvsA3EYAADgIHA3uEbbW9EmZwMAIkz0AbnR6GhlZWUFXF5cXKz/+7//03vvvacTTjhBkvTGG2+oT58+mjt3ro466qgDcTgAAOAAsvbRDug67vlokLQBABHmgFS0161bp3bt2qlr16665JJLtHXrVknSwoULVVtbqxNPPNG6bu/evdWpUyfNmTOnwdurrq5WSUmJzz8AAHBoqG+G5nu5OZOcmA0AiDRhD9rDhg3TlClTNG3aNL388svatGmTjjnmGJWWlio3N1exsbFKS0vz+Z42bdooNze3wducOHGiUlNTrX8dO3YM92EDAID91FBF22Hto03UBgBElrBPHR8/frz1/4EDB2rYsGHq3LmzPvzwQ7Vo0WK/bvPee+/V7bffbn1eUlJC2AYA4BBR5w7eDM3aRpucDQCIMAd8e6+0tDT17NlT69evV1ZWlmpqalRUVORznby8vKBruk1xcXFKSUnx+QcAAA4NDTVDc1oV7YN+SAAANKsDHrTLysq0YcMGtW3bVoMHD1ZMTIy+//576+tr1qzR1q1bNXz48AN9KAAA4AAwt/cKnDru+UgzNABApAn71PE777xTp512mjp37qwdO3bo4YcfVlRUlC666CKlpqbq6quv1u2336709HSlpKTopptu0vDhw+k4DgDAb5S7ganjTrb3AgBEqLAH7W3btumiiy5SQUGBWrdurZEjR2ru3Llq3bq1JOnZZ5+V0+nUOeeco+rqao0dO1YvvfRSuA8DAAAcJGZFO2Afbe9Hg77jAIAIE/ag/e9//3uvX4+Pj9ekSZM0adKkcP9oAADQDFxuz0enfzM01mgDACLUAV+jDQAAft+sfbT9zipYow0AiFQEbQAAEJKG9tFmjTYAIFIRtAEAQEjMoB3dUNfxg31AAAA0M4I2AAAIiTV1PKDruO/XAQCIFARtAAAQkoamjpt9x8nZAIBIQ9AGAAAhoaINAIAvgjYAAAhJQxVtB83QAAARiqANAABCYu6jHRXQddzzke29AACRhqANAABC0tDUcYe5RvugHxEAAM2LoA0AAEJS1+DUcc9H1mgDACINQRsAAITE7TYr2r6XW/tok7MBABGGoA0AAEJiNkMLXKPt+dxN0AYARBiCNgAACInL2PvUcVZpAwAiDUEbAACEpH7qOBVtAAAkgjYAAAhRgxVt70e29wIARBqCNgAACImrgYq2g4o2ACBCEbQBAEBIrH20G1ijTUUbABBpCNoAACAk++o6Ts4GAEQagjYAAAiJ2+35GFDR9n4kZwMAIg1BGwAAhMRqhtZg13GiNgAgshC0AQBASBqaOl6/RvtgHxEAAM2LoA0AAEJS3wzN93IzaFPRBgBEGoI2AAAIiVnR9p86bm7vRcwGAEQagjYAAAhJw13HPR8Pte29al3u5j4EAMDvHEEbAACExAra/hVtHXrbe+WVVGnw49/q3v8sa+5DAQD8jhG0AQBASKyu4w1UtA+lNdpLtxWrpKpOszfsbu5DAQD8jhG0AQBASNwNTB03N9I+dGK2VFhRI0kqrqxt5iMBAPyeEbQBAEBI9rWP9iFU0FZxhSdgF1fWWgMEAACEG0EbAACExO3tLRawj7bt/4dKQzSzom0YUml1XTMfDQDg94qgDQAAQtJQMzR7hftQKR4XVtRPGS9h+jgA4AAhaAMAgJDUN0Pzvdyeuw+VinZxZY3t/wRtAMCBQdAGAAAhaagZmuNQrGiX14drgjYA4EAhaAMAgJCYFe2AfbTtFe1DpPd4USVBGwBw4BG0AQBASFwNVLTta7QPkZnjKqpg6jgA4MAjaAMAgJA0OHXc9v9DJWgX/s6C9tq8Ui3bVtzk73O7Df24Jl8FZdUH4KiwLwu37NHm3eXNfRgADiCCNgAACMm+9tGWJPchkLSral2qqnVbn//Wg7bbbeiCV+bovFdmq6yJW5VNX7dLV73xix74bPkBOjo0JL+kSudNnqOrpvzS3IcC4AAiaAMAEGE+X7xd502erbySqrDcXoP7aPus0W5+RRW+wfq3ELQLy2t04atz9NaczQFfK6mqVWFFrapq3cotrmzS7W7c5ammLt2Pajg83pm7RRe9OlclVU17HuUUVshtSJsLyq1lF+H22a/bdenr81Rcceg/x4HfK4I2AAAR5t15W/XL5kJ9vSI3LLdnNUPbS9A+FCraRbatvaTfRtD+aW2+5m7co4c+X6Fpy30fL/ue4AVlNf7fulf5pZ5Blu1FlaqoaVo1PBQbdpVpS8HvY8r0lNmbNWdjgWav392k7zM73xuGb8+AcHG7Df3ly1WauX63vluVF/bbB9A4BG0AACLMnnLPyf2mMKwRNQzDqsr5Tx136NBqhmbf2kuSSn4DQXtXaf0a6js+XKz1+aXW5+bjKEkF5U0LbPbbNavbB1pVrUtnvjhLZ06apVqXe9/fcIjb7V3fnlvctJkheyr2/3FrjF9zCq3Hdzdr8IFmQ9AGACDCFHpP7sPRjMk+8zWw63j9/41DIGn7Vw9/CxVtMzA5HFJ5jUvXvbVQ1XUuSb6/jxnYDMPQ3R8v1fPfrWvU7UrS+vyycB92ULnFVSqtrlNhRW3Yli00l1qX21qKkFvStDBrf9wORBC2z3wgaAPNh6ANAEAEcbsNq/P25oKKkG/PvsY0cB/tQ6uibe6hnZYQI+m3FbSvG9VVaQkx2ri73Ooy7lPR9gaqTbvL9cGCHD33/dq9NkhrjqBtD307m1gFPtTYp+o3dX38HtvMij1hrmgbhqFptiUhTV1SACB8CNoAAESQ4spaqwqds6dCdSFO4bWvvXb6nVU4D7E12uYAQ+dWiZICm6MdinZ5w2nvrGR1zfActxlY7cdvBrZcb6XYMKSVO0oavF176D14Qbs+9O0oalo4PdTY77/cJlbnfWYihDkIr9pZqpw99fftLiraQLMhaAMAEEHs60Pr3Ia2FYYWeHwq2gHN0GwV7ZB+SniYHZg7pydI8nTtdh+grs/hYlaeWyfFq1VSnKT6wLonSGCzV6qXbQ/eUbzO5fZZG7x+V/iCdkFZtW56/9egDcJ+TxVt+++S18Sp46Gsrd8Xs5qd2sIza2M3FW2g2RC0AQC/K2XVdT5hA778p6qG2hDNZa9o+00dl+o7jx9KFe0urTxB2zCk0ibuP32wmc/lzJQ4ZVhB26xo2wOb5zL72uflDQTtPeU1PlP5N+8uD1tzsq+W5+qLJTv0yoyNAV/zCdpBKto1dW5tK9y/5QwFZdUHdSnAbp+p41VN6kFQ5NMtPvC9qqrWtd9rq7/2rs8+d3AH73H+dt8Ly6vrrO74vwXFlbVBH0/sXWWN6zffs6EhBG0AwO/K2S/N0vF/+6nJe9tGinAHbfdeKtqS6vuON3/OtrbDykyJV1y05xToUO48XlPnto65dVKcWifFSqoPT75rtD3/t1dXl24rCnq7+d7wnpEUp4TYKNW5DW0Jw3p9z8+v8vloZw9924sCv37fp8s08qkftXBLYZN+ZkVNnU74+3Sd9sLMg9Z0z/67VNa6VFLZ+AEb+0yEYGu0b/n3rxr51A9Nbla4taBCa/JKFe106PwhHa3bP9RnbTTk/Ffm6Ninf7KaNx7KDMPQqS/8rBP+Pl2VNa7mPpzflCv+NV/HPPWjdjax18FvAUEbAPC7UVJVq7V5ZSqrrtOGg7Tu9LfG/8R+c4h7Gu+tGZpUX+U+FM71zanjaQkx1tTaQ7khmhnmYqIcSm0Ro4xkT0XbDNWFQdZo59u37dpdHrQhmrluNzM5Tt1aJ0kK3zrtvQVt+3rkYCfVM9bukiQtySlq0s/ckF+u4spabd1T4XOfHEj+lcumrNPe2xptwzA0c91uVdW6NbOJ+3P/muMZoOjfPlVdW3vW87vchtUE8LekqtalFTtKVFnr0rogz831+WV64LNlh0wFOa+kWjl7KlVcWRvye+rB8taczXp33pagX1u4pVCPfrFCVbUHdtDA7Ta0OKdINS63Fm8tOqA/qzkQtAEAvxs5e+qrcjuCVMx+a1xuI+yVeTOQxUZ5TgHCOnU8WEXbe5GxHyXtooqakJu12ZlTx1smxB6QoL2nvMZn4CFUu2yVZ6fToVaJvlPH7ZW+PRWen20PuA01RLPWfSfHqXumJ2hvCNM6bbOiXlhRa21DZtrbGu28kiprkKCpfQO22l73+zv1vKn81z43NmgbhuEzGGBO+TftKqtWubcianaXbyzz+gM7pComyml11/8tTh+3N8sL1jhv8vQNemfuVr3004aDeVgNsr+PNvb563IbYe8631h5JVV66PMVuv/T5UEHKx757wq9MWuz/rd05wE9jl1l1arxvscfrKaMBxNBGwDwu2EP2r+HaWh//2aNBj36jX7d2rSptHtjntj1b58iKfSKttubg4NNG5fqG6I1NX/uLK7U0L9+r+veXhjK4fmwb+8V7qC9Pr9UR/7lO932weKw3J7kG4glKcOaOm5WtOtP0g3DMzBhfk9Lb8gK1hAtWNAO10muvaLu3yvBHk73lNf4VMvsoXJ7UdPCsj1obw+xuV9j+YfXvEY2dyupqvMZjPFvhrZ5d/3v0lAzu4aY1+/fPlWS6tf0/wZ7Vmy3B+0g7+VbvUsdZjWx6n+g2N9HtzdysOeODxfryL98p3V5pQfqsBq0amf9AJz/86y8uk4rvV+3v7YOBPugRDibMh4qCNoAgN+Nrb+jirZhGPp44TYZhjR7Q0HYbtesgg7u3FKSJ5j4Vx6bwqxoNxi0vR+bunZ28dYi1dS59cumPft9bHaGYVhTdtMSYn320i6tqtXjU1fqu5V5+3378zcVyuU29PO6XWFbJ2xO8W7tDUzm1PHdZdUBlVHJE9rMivbxvTIlBW+IZjVY28+p48u3F+vJr1YHnVaab6vs+nfj9g989kql/WQ/WEWwuKJWT361WmtyA0OJb0X74ARt8z5slxovqfFd1P3XGxdV1PrM2rCvy16bVxpwH+8srtTjU1dqi98AmdttaIV39sIAb9BulegdmPkNrHH2Z38cdwZ5LzdnLqzOLT0kGqY1taJtGIZmrNstl9vQ3I37//6+dFuRnpi6UqVNnPlkfx35v0cs2VZkDQaF8nrasKtMT361OujyFZN9BgoVbQAAwqTO5Q7rNFvJ94T7YFa0DcMI+++yPr9sv6fS7o1ZQevRJlmJsVFyG74zAZrKbLQUbH22VL9Gu6nZ03wsS6vrwlJ1Lq9xqdblOYiWCTFKsVW0P/t1u/5v5iZd89YCXffWgv3a49msaBVW1Iat631ARds7dby0qk67y+qnqbdPayFJ2lJQoQrvtOPRfdpIanxFe8OuskY1zXK5Dd343iJNnr5Bny/e7vO1Wr9tw3bZAlBVrcvq8G5WWu3h1H6yvz3I/f+XL1dq8vQN+se3awK+Zn/+BvvefXG7jSYPjpi/Zz9vqG3s1HFzFkLb1Hhrn3l7c7SNtsBW5zYCBhbemrNF/zdzkyZP9+3qvrnAsx4/LtqpHt7H1BqY+S1WtO1B2++9vNbl9rm/54RxIHJ/2YN2Y56Du8qqrdlFG3bt/6yiZ75eo9dnbtJni3c06ftW255X/u8RCzfXz6Bq6uwSu6enrdbk6Rv0WpAdCOpvv/6+2rirvFka91XVusL+99tE0AYAHHRut6FLXp+noyZ+H9Y1yFv37H1d34Hy2s8b1fOBr7Rgc3iqr5J8GiGFc92peaLfKjFWXTI8DZM27d7/2zdPUBqeOu75uL9BWwrP729Ws2OjnWoRE+UzdXyJbdryNyvzdPqLs6zGaY1lP9FeFaTquj/8g3ZKi2hrbf26fM/PaBETZQVtczpoUly0hmanS/IE6HK/ipL9dju3SlC006GKGlejlhF8uzJXm73Tdv0rUP4DDPaKdoGtN0DvrGRJDVe0iypqfapg6/NL9fHCbUF/phTac2XexgJ1u/9LvTUneFOoYNy2tbX923mCdmO3J7Jef0mxapngqTjbG6L5dxr3D0Hm1+1Tf+3X69suRdHe50hrv+3gfkvsj6N/h/rc4iqfpSgz1zX/9PHNTaxor95Z/x4RSiV3rXfauf/zYZ8/36ei7fu9C21LlUIZ5F2S43lO7m16v/32K2tdQZcJHEglVbUa+dQPuvi1uQfk9gnaAICD7qe1+Zq3aY92lVZreRMb/uzNVltQ2NHIqZyNNW35Tutk39+Xy3Llchv675KmVRX2xn7yuD9VumnLd+rrFbkBl5sn9em2oN3UbYTszKnjDeRsW9fxpiXtcK+7NfcuTmsRI4fD4RO0zWrqXeN6qV1qvHaXVevn9buadPv2+3BNrufEtarWpUk/rm/0/WsYht6Zu0XzvFNJ/YO2w+FQK+86bfPkPD0x1rrMPNnOTIlT6+Q4ZaXEexqi+Z2E26ekx0Q5NbxbK0meBlP7Oj77/tj+AzT+YdP+uVlVbZUUaw0MmBXtfG8jNKdDSoyNkuT7mP/t67VWsMrZU+lTfapzuX1eH8GCwfLtxXp1xgbV1AU21vtuVZ4MQ0167RZW1M8m6Nsuxed32ef3lnuehy0T6h83e0Msc7Cjb9sU69jtzNfF2rxSn+qfeT1z2rhUv6bfv7P5b4H9MfWvaPs/xjPX7z5o27oF43Ib2tLEWRX2mQr7G7RLqmqtwazVQYJ2Va1LL3y/zgrjplqXW+vz6y/bXlRpPQfdbkOLbNvr5RZX7VdDyl2l1dasg19zihqc2u7/3n6wp48vySnS7rIazdu0J2BAMhwI2gCAg+4V27THTWHaCsXlNnxOwHaXVQc9sd4fa/NKdcO7i3TnR0sCOgG73YZ1IrPANuUuFLUut8+6ve2FlU06kSwoq9aE937VDe8uCuhqa1bU0hNj1dWsaIfwGLj3VdH2fmzqaXBOiOtu/e8vM2ibVUQzaOeXVFnbB519eAeNH9BWUtOaLLn89qE2q1VvzdmsZ75eo8enrmzU7cxcv1sPfLZcN77/qwzDCFijLckKZ+vyPMeclhCj9ES/oO0N5gM6eELXIr99qf0D/O0n9ZQkfbxw214bMy3YUqhfbVvw+FfA8/0q2vbPze7arZJi1TbNXNfseVzNamz3zCRr8MesaP66tVDTVuTK6ZCinQ7VuNw+lfCdxVU+wTvYoMwDny3XX79crdd+DpzCag4WrNxR0ujpo2ZTt5YJMerQ0jNoEKyiHew1a3/9mY+bWXF2uw3rPj39sHaSfCvahmFYTcAqalzKsVV9/RuhSVKr33BF2/44FlXU+uxNbT43juzSUrHRTu0srvKZcn+w7SiqVE2d23oP3FNeo4qavYe2Vbn1wTi3pKrJa6wl+WxhuTYvcOnHO3O36O/frtX1by9UrS0sb9pdrlqXoaS4aGV7X2/m82f9rjKVVNWpRUyUop0O1bkN5e3H0gP7AJHLbWjexuCzvczH0mze2NigHa6p3vaZBRtDmMLfEII2AOCgWpJTpHm2BlehVFPtdhZXqs5tKCbKodhopwyj8dM59+VvX6+xKmrvzd/q87Wcwvp1satzS/ba+KWxluQUqbzGpbSEGDkdUnWdO2A7ob1Ztr1YLrdn3fhCW8iqqnVZx5qeGKsurTwnWWv3MdX5xzX56vPgNE1bHrjVyz6boXkvbkpF23/QpKkV/c8Xb1efh6bp+1X1zc0KrUZonhM6M2jP37RHLrehjKQ4tUmJ08juGZKkn9c1vkq2o6jS2qJGqp+WOWOtJ6z/snlPo9YefrXcMwNhV2m1NhdUBARiqX59szl13FPR9lxmVtXapHiC7PCunkr1LNsa1oqaOus5at7u4Z1aamy/NnIb0t++CVwDbTIHyI7p4bmPthZU+Jzw5u+1ol1jHX+7VE84NacEL91WHxLN4Go+5s9+t06SdM4RHWxLHerfM8wKr1kl91/T73Ib1gDE5J82BDQjM4NtZa0rYIuzqlqXxj47Q1dP+cXncjO4tkryzBqQPOHK3lRw5rrd6v3gNL0913dKun2LOfNxMwfD8kqrVFXrCWzj+2dJ8lQ+zYZoxZW11jp3SVrlDQlut2FN//WtaP82g7Z9Dbb5tmKfUmw+N7pnJmmIt6ljc3YfN59DXVolKCU+WtK+Z+H4r73fn3Xa9lBaVl0X8D45zft+sml3uT5ckGNdbr4eerZJsp4vZjA2B4sP65imdt7X1P7MKPJf8hBsT3jDMKxjPqZHa0n73mYwZ0+Frnpjvvo9PM3nb5tp+fZiDXjkaz377VrrstkbdqvvQ9OCzkizT6Ffvyv83d8J2gB+l5bkFAU06sGh4VXv1FNzimgo64PtzBPuDi0TrE7A4VinvWhrob6xdaP+7+LtPmF6lW1E3G14umWHyjwpGdE9wwpNTVl7aq8m2E9GzBP6mCiHkuKiNaRLSzkdnkrlor1sIfbRghxV1rr0eZCGO3Uuc+r43rf3asrMzh1FnkETU1PX3X7663ZV1br1z+/XWZcVNRC0S6o8j+WA9ilyOBwamp2uaKdD2worG721jXminRTnOclen+9ZFz3fu2a/pKrO2rpmT3mNnvturSZ+uUoTv1xldTp3uQ19s6L+ebZg8569Bm3zJDstIdbqLm3ex2ZFe6Q3EM/fVGCFNTPwxsc4reOVpD+P7SWnQ/p6RV7Q58L6/DJ95x24eOjUvoqNcgZUl80Ktlkls6/ZNqvzGUlx9RVt7/fapz23T0uQ5JnFUFXr0pwNntfCH4/rZt2uvZJuPkY92yRZ94P9+bK5oFzV3pktpdV1PtPjXe76CrFUH/jtn6/JK9X3q/N99hrebf0unu71cdGe0+l825r0L5fvVHWdW099tdpnVske+9TxRN+p3eYAQqf0BHVKT1DLhBifhmj+z0fz8mCN0Mzj8xzvb2vquLkGOy7aqa7ervj2zuPmIFz7tBYa4R0Ysy+1MQxDH/6SEzBl+kAxB4uzMxLVvmX987chdS63NYvGHCBqqJLrdhv6fPF2fbUscJDTfzsse2jML6nyWWv9/HfrrFkB5vOmd9sUK2gv3VYkqf7vxZAuLa1j29v77+z1u4PutW0G7SO7NDwQUlBeo6patxyO+sG7vVW035qzWSc9O10/rtmlqlq3flydH3CdV2dsVGlVnd6bv9UaKH1/fo4qalxBl4ests0sOBDT1gnaAH536lxuXf3mL7rl34sDpvmieW0tqNBX3qrorSd6pqtu2h2eP27mVONO6Qlq662YhdpYxTAMPfXVaknS+UM6qGtGosprXPrC9gfbvzIRbJS9qesHzZOSkd0zrJOdplR1l/kE7frZA+YJf3pirBwOhzq3StS5gztIkp76anXQ4zSM+qp4sK2VzKplfExU0GMxK1JNuQ/8u6A35Xc3DMMKbku2FVv/b2jquMk84UyMi9YRnTwnh8GqMMGYJ9rDstOVGBulGpdbHy3I8Vm6YFaKnv9urZ77bp1embFRr8zYqOvfWagNu8q0aGuhT+VxxrrdqvSG44ykwKBthqf0hBhrOrnJHJzpkZmk1slxqqp1W+F5V5nn8WqdHGcNgkhS98zkvT4XXvdOuz6xTxv1aJOsTq08gcJeXTafC+b0ZZ+Kti1ot/Nbo73MFrStinZhpZZtL1aty1Dr5Dh1zUi0grb9Z5pT9julJ/h8r8mcGmoOKkyZvdmasu4/E8F/PfSa3OB7DZv3fUaS5z7MCrLFl/laKauu00s/rrcuNwd8WibGqJW3i7zZKM78vbq0SpDD4bDuR/Nn+wdtMySYX+/Ttr4Rmnl8nuOtbtY1zHsT7LjMKfHt01pYzxX7gI75+HZomWDNQJm7scC6relrd+muT5bq5vd/bdLP3V/mYHGXVonWc3DbXt6zNheUq6bOrYTYKB3Xy1PJDRbyVueW6NzJs3XLvxdrwnuLAmaMbMj3PF+ivW+y9nXa36z09B7o3z5FHVq2UH5ptd6Yvcl7u96gnZVsPcfMGRHm+8QRnVsGfT3Z7Smv0ZVTftGE9xZp9gbf90rztXTdqG5yOKR1+WUBM8zM281MjlMfb0+ChsLuurxSPfT5ClXVuq0BpNV+f4/2lNdYVfxdpdXWdPrZ3vdx++tZ8h3w2NvPDgVBG8DvzvzNe6wTob1V6X7LJk/foBFP/uBTjfkt+L+ZG+U2pFE9W2ucd2qkf3Oj/bXVFrTrT85Cmzo+a32B5m3ao9hop249sacuGtpJkvTevPrp4+bJbmdv8FiwxXct2o+r8zX0r9/rxR/WqTGKK2qtdbAju2fUn7g1YfqevYvskm3FVuAzg7YZNiXPgEdstFPzNu3R9LWBDcC2FVZaDXc2FZT7rJWUZE1JPKF3ZtBjsSrajT76+scyy6rmN/53zy2p8qngve+d6m/uOZ3qV9E22de2mlUy/yrMfxZt0+DHv9V8v729zRPt7IxE9fR21H5j9mZJ9VPnF24plNttaJq3Qd2Zh7XTgPapcrkN/eObtdYJolm9/sFbPU6MjVKirfKc4Req0xLq1/qaMr33m8PhsIKI+btYVXJbeDfd0sBzIb+0Sv9Z5JkhdP2xXSXJWnZgry6bz5MB7T0nzYUVtdZ06gIrnMZaU8fLquu0JKfIaoTWt12K2resr6KZgxODO7WUw+GwfqY9aJuDMh3TE2zfW/98MU+uTxnQVkOz01Vd59aLP6wPuB0pcLrrqgb2GrYPGkj1AxvmdGfD8N2W6605W6zBIvtrMN1qVua5PXPAxpwi7z+t13xdmDMWzJ9hVuIHdqh/DtuPr7rOHZYlLfvj6xW5GvLEt1bYMbndhv49f6uG/vV7PfLfFT5fMwNY+5Yt6mcnBZk63r5lC/Vtl6LYaKdKquqs+2eR9/1zdW6pcv2a1C3aWqjTXpipcc/9HPBetr/MweIuGYkNVoHfmbtFR/7lOy3csseaBdUrK9mageAf8mav361T/znT+l3chjTLL8ya06zN96vVtgq+2Qjz1IHtdMcYz6D2yz9t0M7iyvqKdlaK+nlfq9uLKvX2nM3Wa+KITi3VYR/V+U8WbrP+tjw9bY01eLGrtFo7i6vkcEhHd2ulgd7nsX93+G22AZNurZPkcHjeMwqCLHUwl9WM6tlaL1x0hOf39QvO/1m0zWfgbOb63VqdW2oNZOWVVPssHTEHPEwEbQBohK+X13daDraH7KHC7Tb0n0XbGlxHPHv9bp+GWCbDMPR/Mzdpe1Glvlgavi7X4ZJfWqUPf8kJ2LarsLxGHy7wrJG6flRXtUtrEXT66b5U1XqmgG3xa8Rkbu3lCdq+zZZ8jyEnaJM0wzD0xZIdPoMXZvX93MEd1C6thc4Z3EGxUU4t215szZYwT1ou9obwxVuLrIGD/y7ZoWvfWqBdpdV6f36OGuOVGRtU5zbUOyvZJzw0dp1cQVm1dSKaHB+tmjq3VuzwHKu9om1ql9ZCVwzvLEl6atqagLXE9sEqw6hfGyx5pid+t8ozfc8chPBnVrSbskbbPGE2u2EXVdQ2uiOs+bjEx3hOcT5fvEPl1XX1lcSGKtq2kGJOuZ69ocB6LF1uQ3//Zq0Kymv0xqxNPt9rrdHMSFTvLM+Jq1lpPW2gp6nVwi17tHhbkfJKqpUUF62nzh2oZ84bKIdD+t+y+o72t3lnepR7Q4B92rjkW92WPI+l/2WZtu8xg/bM9Z73kvwg09FN7dNa6PKjPM+Fp23PhTdnb1aNy63DO6VZa2K7tg4MveZt92iTbG1DZgZ7ezhtERtlTeG/9q0FkqSjurZSQmy0zxpt+zRWz/3rOfHfHGSNtqeinWB9r2mVNU02WROO7y5J+sE75dR83MymgP4N0dY0sNew2UHdHPRo6w2Ded5Qt62wUmXVdYqJcmhol3TVuNx6zrtm1D6zIiPRt+u4fcBGkgZ2SJMka+DNHFQ4qa9nj/RN3injX3qnFZtbuplaxEZZS3R2l9VobV6pvgmyE8G+mO+NK3cE30Jq5Y4Sn34Idm/O3qzdZTV6Z179WvVthRW64NU5uuc/y7SrtFofLsjx6WxdH8BaWLOTzKnjLrdh/b3o0LKFYqKc6uMd3DIfo2XeadBS/QBTTZ1bD362XOe8PFvLtnuWBMzd1LT9t+tcbv1n0baAARpzu7uuGYkNVoHfnL1Zu0qr9fB/V1hrpHtnJat7pufY/dcmT/ppvercho7pkaFzjvDMNJm5rv54q+tc1t/AUwZ6GjiaFe2iihprb/Gx/bJ0xqD2GtA+VaVVdbp6ygLr9dGrTbJS4mOs5/+Dn3sGPE7sk6nUFjH1f3uC/H02DMMaxJSkxTlF+tq79MUcGOqakajEuGhrIODndb4DueYe3e3TWqhFbNRep9GbA5GnDmyrPm0999m2wkqriZxhGFb/lJ5tPIMXs9bvDhgstVfBzf+bA7pbCip8msaFA0EbwO+K221Yb/ZS4FTAQ8lHC3N0+4dLdP+nywK+lldSpcv/NV+XvD4v4HdYl19mnbwGm6bcnAzD0LVvLtBdnyzViX+fri+X7bRGud+eu0WVtS71a5eio7u1UpTTEXT66d7MXr9b45//WTe//6uue2uhz9fMrb062qaO7/SraD/83xW66+OlQbsPT1ueq5ve/1U3vr/Iusz8I318L0+1Nj0x1qrEv//LVlXWuKyO3Wcc1l6JsVEqra7T2rxSvTdvq27596/WWuPtRZUBwd9ffkmV/uUNcXeM6SVJQcPD3iyzneQM8554m8+TYEFbkm44rruS46K1ameJJtmmuUqBndTtXVo/WrhNLrehwZ1bqpf3ZDdQ09dom+Gpb9sUKxA39fc/dWA7dWmVoLLqOl3/9kJrfZ4ZSlNsQTvD1tRKkgZ1SFVSXLSKKmqtcPHzul3WMfy0Zpe15lmqf/52zUi09og23XSCJ9xtLqjQu3M9J4In9M5UXHSUemel6KzD20vyNLpqEROlsw5vry7e14W076CdlhBjrfU1tbH9LuZJ7rJtRSquqA267ttuwvGe58LKnSX6YqlnkOId73FfP6qrNUPBqmjbg7Z30DArJV6ZKZ7bN6vc/lVg8zWaX1qtjKRY/f38QZKkDt412rvLajTfG4SO8IZ7M4DmFFZaJ8Tmc6Vzq+DVRDMs98pK1pFdWirK6dDO4irtKKq0HrcTemcqITbKpyGaf1XavgzJrJCZv0uWX0XbPIHvnpmse0/uLUn6ZNE2FZbXaI996niS79RxM/ibv+dg7++9Nr9UxZW11u96RKeWapUYK8OQXpuxUTuLq9QyIcYK4HYZ3sd5Z3GlLn19nq57e2GTZ3pNnr5RN73/qy79v3kB3bHrXG5d8cZ8Xf3mgoCZHpU1Luv9wz5odf+ny/XL5kIlxEYpLtqpihqXTwCyKtZpLaxBU7OinV9apTq3oWinQ5nJnq/Zp9gbhqFlthk95nv4G7M26e25W2QY9QNRs5q4//Zfvlyl2z9coj+9s9D6u1bnclsDIF1sQdteBc6z7WywfHuJFQh7Z6Wou7eivaWg3Jr9sXl3uWatL5DDIU08e4D1HjFz/S7r527eXSG3ISXHRWuUt5HYpt3lqqp16ftV+dZgbXZGopxOh1665AilJcRYW/21S423ZvcM6pgmSYqNdur2k3pq0iWeinGHlsGr85I0b9MebdxdrsTYKF01oosk6ZmvV6vO5fZZCiLVNzr7bPEO3f7hYqtivc02c0GSdV/4rz3fWlChlTtLFOV06MQ+bZSWEKs23vcXcx3+/E17tHFXuRJio/TEmQMkeZYT/LTWM6hmziyyV8HNv2XH9mytxNgo1fntHhEOBG0ggkxfu0vHPvOjHv1iRaO2kthdVq3TXpjp073xULd0e7FyS6qsasravNKwTQ/zV1pVq7fmbNYp//xZV/xrfpNHQn9c7Rndnbl+t0+3Wkn6ZkWu6rxdo+/+ZKnPaL99+pU5HfVgWL69WCf87SdN3UsV/avluVriPSHNL63WDe8u0tVvLtD6/DK96Z1Ke12wk/W9bC+Vs6dC/zdzk85/ZY4ufn2edXK8Jq/UZy9Qe2XLbLZkD2dVtS6rmdOXQRrLTPVetnRbsbYWVChnT4U2F1QoyunQUV3rK0Vm5fbzX7drcU6RDENqlRirrNR4HdYpTZL04GfLdd+ny2QY0iXDOll74u5rYOT579epqtatwZ1b6sQ+nnDfmIY0dubATP/2qRrcuXFBu2VirB48ra8k6R/frdUPq+sHq8zvNY/DPCF2u+srGhc3UM2WAivaVbUuXT3lF1382lxrZkFVrUuXvD5Xt/zbs62Vtd6+VUKTf3/zJG9gh1TrsZq5frfq3IZO6ttGY/t5wkh8TJTVxMpshGaKjnLqKG/H7m9Weiop9uUClbUuzfBOrfY/0bYH7R6ZSerRJtmqsPznV0/V2hyskTwV7Jgoz88+rldrtYiNsh43SVaYMPmvx05PjFVaQqzsvejsFe2s1Hh1z0yS25DmbNxtmzrue7umlomxum6UZ3r47R8u0eGPf6viylp1aZWgk/rWH7dVXfaemNbUua3AmJkcZx2DGb6tdc3JnuNv732NRjsdmnTxEVbwTmkRrWTvVPmSqjrFRjvVv53nhL1NcrxaxERZXemLK2qtDuMd01sEdCwvq66fTtw7K0UJsdHWa3HBlkJrkKBr6yT18+6HbU7DNqvS5vrXHcVVVkBoaOq4OZBmTlfvnZWswzu1VM82nvt/9oYCn5kV6VYztGqfxmzm+2Lr5Dh1bpUgw/Bsc1Y/qJBgDWyZzd3OHdxBcdGBfRLMY/zglxxrxsFPaxq/R/z0tbv09NeePhV7ymv02s++szl+2VxoPafes1WtJc8yGnMqb1FFrVbsKFZRRY0Vfj/509HW68z+3mi+1ju0TAhYo22Gs3ZpLaydDuxT7PNKqn16Hcxcv9vnveqR0/rqgVP7Wl/z9/HCbRr51A8B79X/WbRNb8zaLMnzHmhO6d5W6GncGBftVFZKfNCBUfP3NV+j5qyGXlnJapMSp6S4aLkNT3iWPIO4kicAdmiZoCFdWiou2qm8kmprIMis+nbLTFKblDilJcTIbXgu/8zbCHZsv/rXa8f0BL1w0eHW+7F9YPSW0T004fhumnbLMbp5dA/redTetgTL/zzDvD9PP6y9bjupp9ISYrRhV7ken7pSC7z3nTkAclTXdF17TLYcDuk/i7brpGdnaNPucttae2/Q9ja+e/jzFerz4DRd+vo8lVTVWtPgh2WnW68Zc+aQ+ffIPJ4zDmunIZ1bKj0xVhU1Ls3yzuQ5sY/nfX9NkIp2n7bJ6mabwp9fUqVxz83QxC9XKVQEbfyu5eyp0LTluT4hJVJt3FWmG99dpC0FFXpj1mad9I8Z1lSchnz263Yt216sydM37HNPyEOF+TuN6ddGGUmxchuyRnDDZW1eqR78bLmO+uv3eujzFVqxo0TT1+7Sv39p3NRgyTP9zWweUlXr1qItRT5fn2ab3rdiR4n+b2b9yY19KlRxZa02hqmZ2L78a+Ymbdxdbq1vlDwB6atlO1VcUas6l1t/+9qzNdAfj+2mm0f3UEyUQz+sztdJz05XQXmN2qe10MnefYql4NNPJc/v9dx3azX++Z91zNM/6vGpKzV/0x45HNLlwztb2xaZj3dJVa21BrdTqwRrDai9OdHMdbutra1W7CjxabhVVevy6WD69Ypc6/E5rGOakuPrq59HdU23mqI94z0BNU9azIBknmj86bhueuLM/lbn1WBBe+WOEr0xa5NenbFBH3ifQ3eP620FP/tUxMY08LFXE8yK2IIthTIMw6qm+QdtSTp/SEdddlRnGYZ0y/uLtXFXmcqq66wKwEVDO0qqrwjMXL9b2worlRIfbU1dDMY8uTQMT5Xwgc+W6/vV+Zq9ocAKsdOW52rW+gJ9vniHFucU+U0HDj4Vc+WOkoAKmr0RWv/2qTp3cAe1TY1X29R4vXLZYL12+RCfx9Ksltu3RDKdPMBzkvryTxv0v6U79b33+WF2xzVfo/4n2uYJoFRfTTYfB8PbSfnYnq2t63RMT9Cfjusuh0O6eFgnn+tL+65ot0yIVZTToXTvlPikuGifNd1S/fTxt+du0eKcoqC3a/eHkdnq0LKFXG7DGgy55cQePlu4WdXlPZ7plma4iYlyqGVCrBU+80urVedyW9tamQ3ARnTPUJTToUdO76dh3tez5FlXbla4JM/sgljvgIjT6bB6IWzeXW41zcpIilNCbHTAGm2z2pWZHGc95837dtGWQmuQoEtGgga0T5NUP1BVX5VOsqbWmq8tc+q4OehhVuIWbPYMfNqbTXnuf8/j/fWKXNV6u/S3TIi1pp6XVNV51ou63IqNclrhUvKsT5c8FUSz50Sn9ATreWZ2VG9o6YY528HewLGxW2FtKSjXTe8tkmHUv0Ze/3mjT5D92va36svluT5rYP3X5M5cv9un2tqnbYr1eNjfG+1rsNvaGs0ZhlG/ftt2H1kV7W3FVvfsrhmJiot2Kr+0Wm/N2azNBRVKiovW+Ud21AjvkpTVuaU+nfGLK2r12BcrtK2wUg//d7kVLpdvL9a9//HMPDMfM3PgbZO1tZencmwe167SamvWi3k/XH5UZ5/ZJ72zkuVwOHxCXk2dWx97l1iZj2l8TJSO7JLuc1tm0O6emSSHw2E91x7+7wr9vG63op0OnTaonc/9f0yP1rr/lL5yOqTRfepnP3TJSNSfx/a2Oryb2qbGK8q7d/0u22NeUFatr5Z5HveLh3ZSSnyM7jjJs+TlzTlbrEFIc+mDw+HQ/af01ac3jFCPzCTtKa/RU1+t9ukeL3nWXzsdUp3bUGWtSzPX79Zt/16sL71LuOwDlObva25/Z+4Mcv6QjnI6HTq6W/17SkZSrM7w7ku/yidoe/6W9cpKsUL+hl1lemvOFq3OLdUrMzYG7VvSFARt/G7tLK7UWS/N0h/fWajTX5xlnVxEotKqWl339kKVVtdpQPtUdW6VoNySKv3xnYW69q0FDa6PNUNMdZ1b05swAt5cDMOw9vkd1z/L1k0z9OnjtS63/rd0py54ZY7GPDtDb8/dovIal7q2TtSp3pDxz+/XNXpAYtn2YmtbIckzJcxUWF6juRs9AeJG75rCZ79bqy0F5ap1ua112+YJt//U3gOhps5tVYNX55ZalaDHp67Un95dpNH/+El3f7JMG3eXKz0xVhOO76bbT+qpr24ZpaHZ6da04T+MzFaMrStusOZG1XUuXfnGfD333Tqt2lkip8MTbh86ta9+vut4PXZGf515uOePprlMwAzNrRJjlRQXbU03LK6stR6TaX5rE+0niPYQbl7XXNNqhiWTw+GwToDMqoZ50jvEFpDuGtfLCsxHBDmZlKR5Gwt0+osz9egXK/XXL1erzm3o+F6tfdZamifd5TUuqxKyN9Z+uh1SNbBDqmKiHNpVWq1thZXaU9Zw0JakB0/tqyO7tFRpdZ2ue3uhZq7bLbfhCfujvOFwdW6pZz2c90Tz7CM6NNhxXKrf9sswPEHPvpepWYWwV4tfmb7RGjQJ1uCquKJW9326TCf/82dd8OocLbG9t5uN0KKcDvVtm6JWSXGa/ufjNfueE3yqOyZz6q55Qmh31uHtdcrAtqpzG5rw3iK53IaGdG6pm07oIUn6bmWeal1u60TbnKKZmhBjnTiaodxeoT6mR+uAIHzbiT204tGx1hRLc02yFBiI0xNjZcu7aul9LM3H1JyybVffEK3ACoFmgAkmMS5a391+rH6+63j9fNfx+uX+E3XW4R18rtMmOV7xMU7VeavLZq+J1klxcjodVkU7r6RKeypqZBie2Q3mcV41IlvLHxmrS71rwu062IK2/b6T5NN5vH5AxnN9834vqqj1DBLZmk7V357nvp27scD6/uyMRA3o4HkNm2HarEr3aZtird9f7p2abO86LknDuqYrOS5a+aXV+jWnyLqPzZ87sofnpN98D42PcapFbJRS4mOswQtzMLVLRoLPgMZg73Nh6tIdcnkHdFonx/nMnDiqa3pASDKZU8ftBcnFOUX7nNVWXl2n695aqJKqOh3eKU0f/XG4BnZIVUWNyxpsdbsN6zyhRUyUaurc+mRR/evbrBgf7p3pM2v9but9eIz39egftF1uw1ryY1+jXVHjUkllnVXttg/G9PT2BCipql+vfkTnltb76FPTPAPAZx7eTgmx0WqVFGfNbLB3y355+gbr7/Ly7SX6cvlOFZRV6/q3F6q6zq3RvTM1+dLBkjyPR3FFrT71Ngk0B43TEmKsdfE7ijyDo+b9MLZflm70LiVplxqvNO/gmBny1ueX6ZuVuSoor1FmcpxPg0lrGzPvbZnTq81BHvNvkHk/PnhqX+trdlePzNbyR4O/7vxFRzkDGlL+uCZfZ0yapRqXW/3b1782LhveRa9eNth6XzGbG9od1jFNL11yhJwOz99YszpvzgIY1bO1Fj5wkn6+63i9e80wxUU79f3qfKtHwRjbjJre3nXaq3eWWn+/26XG6zDvNPiRtr/bI7pnWPfP2txSud2GyqrrrN+pd1Z9RXt1bqnPnuP3/WdZo/uDBL0P9/s7gUNYVa1Lf3x7ofXHcOXOEp310ixdMbyL7hjT06ei8Xvndhu648MlWp9fpqyUeP3ryiOVHB+tF39Yr8nTN+jblXmatX63/nH+II3rX1+V8t+DcdqKXI0f4Fu1evCz5dq0u1wvXny49Qdjfy3JKdK9/1nmM2oqeao/Fw3tpGuP6WpVNYLZVVqtt+du0eaCCsVGO3Vcr0ytzS3VT2t2BTRE+3Zlnl78cb1uP6mnVVn64Jet+uf36306VtpV1risrq1Oh6cZzeXDu+jobq1U6zK0ZFuRcvZU6o1Zm62GO5L09pzN+njRdj1wSh9rRFqqryjExzhVVevWzPUF+vNYz9e+W5Unl9tQn7YpumNMTy3aWqjZGwp036fLdMvoniqvcSk9MVbnDemgl3/aoIVbCnWhrZqxOrdEt3+wRNeN6qozvWu7GmvSj+s1bXmuJhzfTWP7ZVlV1bkbC3wGBr5ekauLh3XSp796TjJ2l9VYJ1gTju9uvca6Zybpg+uO0ueLd2jT7nJdepRv1cW/uZFhGHr48xX6dWuRUuKj9eCpfTW6T5uAYHhinzZyOpZp2fZibSussEb3O6Z7bi85PkbJcdEqra7TjqIqdW6VYJ3knjwgS18uy9W05bm65hjPFFnz5G9cvyxNW5GrRVsLtdZ7sjzSL2hL0jmDO+iZr9dYz5f6ylWGbjqhu3plJevUgfXVhCHex37FjhJV1NQpITZaO4oqdcO7i1TnNjSwQ6o6pSeoRUyUbh7dw+dnxcdEqXVynHaVepqctWwgJEueqZ1mNahfuxTFx0SpX7tULc4p0vxNe/Za0ZY8a/QmXXKETn9hltbnl+nOj5ZI8pwM98hMltPh+Rkrd5ZY92dDlTSTGRku+9c8lXin+V41ooumzN6sWesL9N3KPGu/aan+sTAHTazOt0WV2ry7XOe9MseqQhmG9O68LdYaQ3MdbY/MJCv87+19476Te2v2hgJrix2f43Y49My5A7Uhv8wKThcP66TBnT3rYwvKazR3Y0F9p2jvoJEkPXXOQC3ZVmSt7bdXqO1VGfvPSoitPyXr3jpJKfHRKqmqC+gOHuV0KD0x1vr71tK7zrJVUqzW5ftOGzcd3ztTfzqumzUg1TY1PmAAyV98TJT1egrG6fR0ATcH3szXgtnxPNNW0Tb37k5PjPUJkS1igw/Q2KuV9vtOqu/IvWl3ufWe3Mn2uk9tEaPiylptL6z0Ccv+t2c+pi1iotQmOd6q2K7cUaKaOrdV+eqVlaxop0OfL96hZduLVVpdZ/2uZtCOi47SCX0y9fniHfrv4u3WwKF5cj80u5WinQ5rMM+cfeD0Ppa7SqutwSbzPcn/eHNszR4dDocVNKS9vwbtMyCO6ZFhLYmZu3FP0DXdkud9+K5PlmpNXqlaJ8dp8qWDFR8TpbvH9dYlr8/Tu/O26LLhnVVaVafckiolxkbp9jG99PjUlXp//lZdPTJbhRW1WuHtb3DX2N666LW5+mVzofV+MM4btA/rmCano76HhWHIZw22+XzfU16jHcWV1vubfTAmNtqpPm2TtWRbsb70Bv8B7VPVPTNJP9u2ybPfTyN7ZGjlzhLNWr9bZxzWXrnFVVaTw+FdW2nOxgL97es1ykqN1/aiSnXNSNSzFx6m5Lho9WqTrDV5pfrDm79o4ZZCRTkdumpEtqT6GRlr88q0rdCzo0Z+abXiop06onNLHZmdrtKqOus9S6oPyy9PXy+H9x46f0hHn0Hpkd0z9JSkuRv3qNblrq9otzaDdv3z4ZwjOujy4Q0Haft7zb60b9lC24sqta2wQp8v3q635niWB7RPa6G/eNdCm8b0y9LR3TP0r5mblJkcZ22pZ9ejTbLOOaKDPlq4zepfYn+9t0yMVcvEWHVMT9DEswfo9g89f4MO65hmbaMnSb3amFPHS6yO5GNs5ywj/IJ2l1YJiot2qrLWpa17KqxlLm1S4tQyMVbdvPfjtOU7VesylJEUq7joKG0vqtQ/vl2rB73LDZqKijbCprrOpWnLd+qjBTn79e+H1Xlh2eLHMAw9+NlyLdlWrLSEGH16w9E66/D2MgzP/pkn/mO6pi3f2agpmAdbzp4KfbMiV9sKK8J2fC/+uF7frMxTbJRTky8brNbJcYqPidKdY3vpy1uO0ZDOLVVR49IN7y7yGcUz92A0O8P+sCrfZx3xz+t26e25WzRz/W7d/O/FAY9dRU2dvl2ZZ62f25v8kipd+9YCrdxZol2l1T7/thVW6pmv1+i0F2b67AcseR7rBZv36Ob3f9XRT36vf37v2T7prMPaKykuOmhFe+WOEt30/iItySnSDe8s1Pr8Us1Yu0v3/meZthdVBvx8819ZdZ0ykuJ00wndNfPuE/TKZUM0onuGHA6HYqOduuMkT+OqydM3WFPnvluZpwc/X6ElOUW67P/m6ac19VOTzelf5h9ns1GRVF9pHef9o/HXswYoLtqpWesL9NDnyyV5tswINh3ZDKord5booc+XW7fZGJ/+uk3PfL1Gy7YX64/vLNK1by2wtkYxw4/5fJi2Ilf/XbJDFd6q/p1jPNsC9WyTFBCmHQ6Hzjzcs47Lfw2hf3Oj9+Zv1b9/yZHDIf3zosN13pCOQUNhq6Q4a+Di3XlbNfFLzxTuw2wnL+Y67R1FlZq/aY+KKmrVKjFW953cx3O/bS30NNZx1VfrrxzRRYd1TJNhSKXVdUqIjfK5TVN6YqzG9g8cXXc6HbpjTC+fkC15qhdZKfFyuQ0tySlWVa1Lf3pnoQrKa9SnbYo+uG64Xrz4CD1z3qCg4SbYOuVal1s/rM5Tfmn99Hh7IzRzsMOsqr4xe5O1xjR9LwNjmcnxevnSIxQb5bSCzJDOLdUiNsoKk09MXaW6fTZB8zC3uyqqqJXb8JwEPnRqX2uQ67YPFkvyDJ6Ya5ml+kGT+t+9UhO/WqVdpdXqmpGo+72P4xdLdlod7pf7NeHZl2N6tNbd43r77D1slxAbrVcvG6KMpFhr2UOU06Ex3nXe/5q5ST96Z/uYAVDynMRPOL67nE6zF0GC+rVLUWZynE7qEzzc2DmdDp3UN0tOh++2YyZz+nVstFMtvAMK5mX2RmimKKdDd4/rrRcvPkIvXnyE7j+l714HIBrLPiPFXIttNikyjyOvpEoF5b5rmvfFHFyRAoN2tvdnztqw21qfbH+N2hs4WWG5Tf1ztF1a/ZZRkme9s9PpUHZGkjKS4lRZ69KHC3JsWyD57jVsThtPjI3yGSgwg+O/f8mRy20oLSHGui+S4qKtqq4kn4Fp+1TiS4Z10vlDOvr8vj0zk60161L9oELPNslqn9ZCXTMSgw7emOzbwV0yrFODW9fZvTzds1wiJsqhly85wnosR3TP0LE9W6vWZeiPby/UJ97ZKcf3ztT5QzooITZKG3aVa/6mPValuHdWso7qmq6slHjV1LlVXedWp/QEq3N0Yly0NRCycEuhFaTta7DNKumOosqA6cYm8zEylzr0b5/qM0g6qGOa+rUL3MJv5rrdMgxDz3+/TtV1bg3p3FKvXTFErRJjrQGJxNgovXLZYKXEx3hnNHW0jleSHjilj88sJPu2WGYFemh2uuJjohQT5dTNo3v4LB8xd1eoqnWrstalhNgoXTTM9+9o33YpSkuIUVl1nV7+aYM2+lW0h3drpZgoh47olKa/nNXfp+dEKDp47+cXf1ivt+ZskdMhXTMyW9/cNspnsMCUFBetm0f38Bn893frST2t95+MpNgGB9zOPqKDrj3Gc450wZG+r4tumYmKdjpUUlVn9Y2xvw46pidoaJd0pSXE6PhemYqOcqpHm/qq9Wqrj4LnuWfej+bSjnMHd9QTZ/WX5Gmkt2Q/Z8VS0UZYzN3oqbZt3NW4zsENOaxjmv561oCA6SZN8c7cLfpo4TY5HdILFx2uwzu11OGdWuqcIzro/s+WaUtBhf74ziKd2CdTj57RP+DNurlsK6zQGZNmWc2KMpJiNbBDmgZ2SNWgjmka1CGtwSpUQ75fladnv/M0MnvizP4BgaFnm2R9cP1w3f/pMv37lxzd9fFSlVXV6Q8js62wd92orpoya7PyS6s1e0OBju+VKbfb0NPeqViSNGPtLv39mzW6a5ynu2qty60r//WL5m/eoxYxUTrz8Pa6fHhnn6qCqabOrT+9u0j5pdXqkZmkZy84zJpqKknLdxTrya9Wa01eqc55eY4uHtZJN5/QQz+sztfbc7dY22RInulplw/vrFMGeEKOOaVpXX6Zqmpdqqxx6bq3F6iq1rMOrrzGpWveXKCiyvoAcPXI7KD3pdMpdc1IavDk9PRB7TR5+gatzi3V6ZNmasJx3fWX/3kaaZjVyGvfWqDnLjhcJ/TOtP5Anze4g75ZkasNu8o1Z2OBRvbI0AxvCDf/aHTJSNRtJ/XUk1+ttqowx/TI0BHetXsbd5drT3mN0hNjNX3tLs3zrlstqarT5BkbdLf3cdmb5duLdc8nnjVow7u20oIte/Tdqnxt2DVXn95wtL7xTtF+4JS++vPHS/Tr1iLruXrx0E665piuumpEtpwOR9CGPA0xmxtV1rr0+eId1n6qfx7bS8f1Cr4vs2lc/yzN27RHL//kOdnu1jrR2i9U8nQ1XptXpp3FldZ06pP6tlGHlgka1DFNS3KK9O3KPGW3SrRC+JFd0jWuf5a11GRYdnqDj/nFQzvpiyU7FOV0qEfm3sOmw+HQ4C4t9b+lO7Vwyx59smibNRj46mWDGzzRMHVo2UKLc4qsk8xftxbqvk+Xa9XOEiXFRevPY3upU3qCHvqvZyDGvlXVVSOy9caszT57a6cn7f295PBOLfX4mf10t/c5YU5975WVrI27Pc9Vad/VbEl67fIhWp9fJsPwzOAwp7heNLSTflqzS6XeMH/JsE7aUlCuR75YKak+UJjBadWOEi3JccvpkF65bLC6ZybpwwU5Wpdfps8X79BlR3WuX5/eoXFBuzE6tUrQj3ceJ6fDYVXJx/bL0vvzc6yQLdVPHQ3G4XDokz8drTq3EbTKE8zT5w7UfSf3tqa322Ukx2pNnmfAxDyhNqeYZ+1lSni4Zbeub2aY4h3YMZu31TdDq29O5d/IrSHmIEvXjMSAv3vmzzTPN47u1spnGmyn9ASt2FGiv3y5Svnejuf26q/keT7vWOqZYmwO9kU5Hbrx+G565IuVev77ddb7W++sFCXGeR737UWV+vPHSyVJbfzu52N7tVZctNNaM92rTbJP2BnRPUO/eJf52H+n1slxWp1bqsGdW+rh0/oF3BdOp0OHd25prXs175v4mCh9d/uxMmTs9T3XDMkZSXEa3aeNdxbI1qCNwPJLqvToFyv1P+/064dP62fNxjE9c95AnfbCTK3LL7M6aY/rn6Xk+BidPqid/v1Ljv707iLrdWsOSI/skWEtGxnXP8vnvhnSuaVW7CjxVIf9elNInvfyFTtKtKO4ytZAy3dA0j645nR4diyIi3Za1fCLh/oGtaFd0hUb5dSO4ir9Ycov1mv57vG9lRQXrZtO6G69F/39/MPUwzZYc9YRHTTxq9WqrnPr7CPa68qju/jctvne9cIP66zXxd5mkBzWMU1z7x1tPefapMQFvO6jnA6N6Jah/y3bqX94G9TGRTut+6lzq0T9cv+JSoqLbnDgcH+Yt28+1vef0rfB86TGMrcRfH3mpoDH0d/9p/TVtaO6BszsiYuOUtfWiVqbV6bqOrf199vurauHqtbltgade2elaPn2Eq3YUWydJ5nvDZ1bJSja6bCq7BcN7ajOrRJ1xmHt9PniHbr7k6X64qaRPrMMGqNZg/akSZP0zDPPKDc3V4MGDdILL7ygoUOHNuchIYiCsmot3VasJduKtCSnSJW1Lv3x2G46rlemCstr9NcvV+kj75tnRlJs0NH3fTEMz8jg4pwinfbiTF0zMlu3nNijSdNbJOmXzXv0qPeN8e5xva31bpKnwvD1raM06UfPlOnvVuVr9obpuv2knrry6C77/caUV1Klb1fm6btVeaqqden4Xpka2y/Lqm7Uutx6/edN+nF1vvq3T9WYfm00pHNLn59XVevSH99ZqD3lNUptEaPy6jrtLqvRD6vzrf0+JU9X1WN7ttbYflkalt0qIABU17m0emeplm4r0uKcYn29IleGIV12VGed7zcaaIpyOjTx7AFKjo/Waz9v0mNTVyq3pMrag3F8/7baWVSlt+du0dfLc3V8r0x9uXynlm0vVmJslP48tpce+WKlXvppg1JbxOjqkdl6YupKzd/saVxVWevS+/O36v35WzWkc0tdNryzxvdvq9hop4oqanT/p8u1cEuhkuOj9erlQ6yTHlPfdik6qU8bTfxqlT5csE3vzdvqs54zPsapMwa112XDOwc897JS4pWR5Jli+e3KPL01Z7O2FVaqU3qC3rjqSF32+jyrGc6gjp5R4L2tNd0bp9OhZ84dpOvfXqCcPZW6x9s4ZWiXdE35w5G66+Olmrp0p256f5HOPqKDalxutUuNV3ZGokZ2z9CGXeX6ed0urc8vVU2dW9kZiT7VvWtGZuuLJTusqXgjumcoLSFW3TOTtD6/TAu3FGp070xrLdphHdO0OKdIb8zapMuHd9b3q/L13yU71CMzSWP6ZWl41/rnz69bC3Xje7+qus6t43u11utXHKmNu8p05Ru/aNPucp3/yhztLqtWSny0Th/UTu/P36qFWwq1xTtN39zj03/daWPvt86tErQ6t1R3f7JULrehkwdk6U/Hdtvn947tl2W93pPjPM8f+7IQc532U9PWWGuszCr0uH5ZWpJTpCe/Wm394TypbxtFOR0a2y9LT37lqZCP7BE4pdh0VNd0/Xlsr72OyNsN7uQJ2q/P3KSiilo5HdKLFx2x1+m5JnM94urcUj30+XJrm5oop0Nl1XV62DtAIXmq5/blC+neLtL/sO0esLeKtumCIzupssalwopaaz1j76wUa5pecny0TvFbThJMTJQz6CDb6N6ZykyOU35ptdqnedaAl1W1tE5g/YO2OV33nCM6WCe9Fw3tpMemrtR787bquJ6trQGS/fk7tDf+y42O6dFaV4/MttYYtkqM0/i9VBUlNfm9JcrpCBqypfrKsDnDRJIuPaqzKmrq9toBPtzM6vLCLYVWk7KAinZplRZ711g2tqI9uk+mrhmZreN7Bw622afot09roRcvPsLn7+kNx3XXL5sLrSAe5XQErFUd0rmlpnqDtn0mwsXDPCf/5oCWWZV2OBzqmpGojbvLtXBLoeJjnLrTu/2eKSE2Wsf2bG01ZfJ/zh/TI0PPfbfOul3TzaN7qHOrBN0yumeDg3pDbEG7k+39ojHvO8f3ytSVR3fR6D6Ziolyani3VnI4POuBc4urlJ4Yq7kbPY0JP/91h0qr67yDDt11ybDA51JmcrwmXzpYF7wy19O8zbtUS/I0zFu0tVBr88qs0GhWlUd2rw/a/v0SjujcUm/O2aL/LNpuzYK7zDZ4Yr6X/+ObNdbX7UFc8n3N98hMtu6biWcP0MIthQE9Bjzd/VtqzsYC/bhml5wO6cYTelhh7eJhnbWtsFI92iQFzBhIbRGjp84ZqKXbinXXuF4B1eM/jMjW96vzlLOn0mrIGWwJkl1Wavw+B8luGt1dLrehKu/swvH9s3ye+6Eu4QvGvhb+zMPa6Q/erbxCdcuJPVTnNqzZQXvjv/OCqXdWitbmed6Dzb/fdvExUT7vu+b0+ldnbFR1nVsJsVHWDJKYKKe6ZCRqfX6ZRnbPUGfv+8xDp/bVjLW7tDq3VK/O2Ojzt7Uxmi1of/DBB7r99ts1efJkDRs2TM8995zGjh2rNWvWKDNz71UM07crc5WYFFoFFYEMw7NNjhmut/l1epU8a0RO6J2pxTm2qtawTrp7XG+ri2tT5RZX6dEvVuir5bl6ZcZGTV26UzeP7t7o26tzG3rkvytV5zZ06sC21vYkdvExUbpjTC+dPqid7vt0mX7ZXKgn/rdKn/66XdeN6mpt9dIYG3eX65sVeQFN1uZu3KOJX61WzzZJOqF3G/24Ol9rzH3+Nu/Rv2ZtUnpirEb3ztSI7hmKj3HqiyU7tXx7idITY/XFTSPVKjFWq3aWaElOkZZuK9bibUXauKtcOXsq9c7crXpn7lYlx0frhN6ZGty5pdbnl2lJTpFW7SwNWGM8NDt9n2tLHA6H7ju5j1JbxOhv36zVqzM8ewz3auPZg3Fsvyy9PXeLvlmZp+N67dTfv/GcsF87qquuHJGtHcVVenXGRk38arXem7/V2ofw1cuGKCU+Wm95Q/qCLYVasKVQjyet0ikDsvS/ZTu1u6xGTof0zwsPDwjZppaJsXr63EE6+4gOuv/TZdqwq1xdWiXo0qM667zBHa29IIP9Xv3bp+qnNbt00/u/SpISYqP06uWD1a11kiZfNlgXvjpXKfExesW7Bi0UAzqk6tvbj9Wz367Vv2ZtUlZKvCZdcoQSYqP1/IWHKzk+Wu/Pz7FONsyR/hHdM/TmnC161zaAcM4R7QO2G3ry7IE6d/Js9c5KtkaBB3dqaW3nsXx7sVbtLFFyXLTeuPJIXfvWAi3YUqgxz85QqXd99fxNe/TuvK1KjovW8d69Yz9YkCPD8FR2nrvwcE+Ftk2yXrlssM55ebb1h2x0nzaKjXZqbL82VkX+5P5Ze10z3BjZGZ51ni63oV5tkvXMuYMaNe2tXVoLjejeSnM37tGzFxxmrbEyDeqQpvfn5/hUCcxOpKcObKtnv11r3S+SrPXs2RmJGpqdrqXbiqwttoJxOBxN+qNrToE1G5rdM763RvbY+8mXyXy87Y3Ezjmig+4Z31vTlu/U09PWqLymTn8Yka3bTuoZMOhx9chsvTl7s7UurbGP2ZUjfCsXvfzWATbmRL8h0VFO/WFktp78arWuGtFFUd5GYhcN7aQpszdbUzFTW8QoKS5aZdV1io1y6taT6mctnH1Eez05bbVW7SzR6L9PV43Lrczk+kZHB0qU07Hfa/bCwZwmbq+Mds9M0tPnDjqoxzGkS0tFOx1asaPEGgT0r2gXVdTqTe+6TnMWzr7ERDmtLZj8ZSTFqmtGonJLqvTKZYMDKt4DOqTq+zuO1dPTVuvdeVt1RKe0gIqvvcFati24x0Y7dceYnrrtA8+6UHtVemSPDG3cXa7je7XWY2f0DzpANrZflhW0/ZdUDOyQZj2P7cd8ZJf0gEqcP/v0+U6NGJizi4126pHT6yvlaQmxGtg+VUu2Fev6dxZqY36ZNatE8gw6//Ws/j7TrP0d3qmlnjizv+76ZKnG98+yZmm0TW2hqTcdo9dnbtTz361Ti9go63V8TI8MpbbwDFwc7je7zvz9zBB9/aiuPj1hBnVIk7TFapKYmRwXEErNhmieJl31xz62X1bQRoiSp7I+Z2OB+rdP0cSzBvrMhImNbvg5KHn+XjTUA6VTqwR9c+ux+ucP6/TajI1qmxYflvek3lkpmnzZ4JBvpykO79RSDodnxsDEsweGbUp6cnyMz/Nyf/TKSpY8L9UGH+OA66u+U//fzxvkc97gKXqU6epj6v/utUqK0wOn9NUdHy3R89+vU9vUeBk1jd9r22E000LVYcOG6cgjj9SLL74oSXK73erYsaNuuukm3XPPPXv93pKSEqWmpqrjrR/KGde0Nxzsn26tEzXIO415655KTZm9yepg2bNNkiaePSCgM+j++m5lnh7+7wqfPQibondWsv5zw9H7rIa73YY+XJCjv365yqfJ0/44vFOaxvTNUmJclL5dmac5Gwqs6SeS52To+lFdtTavTN+vzgvaOTjK6dA7Vw+z1ur4K6mq1YLNe/Ttyjx9uzLPaoTjLy0hRoM6pGlQh1QN7JCmUT1bN2kt3pRZm6zpUjeP7qHbT+qpWpdbQ574zme9davEWE2/63jP/o9uQx8syNFE231564k9dOuJ9SfEeSVVVmU7r6S+4Vn3zCT99awBPuub9qamzq2Nu8vUMzPZWv+4N//4Zo3+6e2QOrRLuv56dn91t03z3VNeo/gYZ5NnT+xLXkmV1VXWZBiGJn612hrIeO6Cw3Tm4e1VUlWrwx/7Vi63oRYxUbpjTMOzLPJKqpQYF22d2Hy4wDPl3+7OMT114wk99MvmPTpv8hxJnnVT14/qqp3eGRj2LU0kT2C5/+Q+ARW0/yzaZjUjmXzpYI3rn6UtBeU69pmfJEkfXHeUz9Y8++Ppaav10k8blBIfrS9uGmmNJDdGRU2diipqfbbDMRmGoZU7S1Re7Rn9756Z5HOCu62wwtouJz0x1qfqVV5dp/LqOquhUzjUutwa+Mg3qqx16fRB7fT8hYc1+qTlpzX5uvKNXyR5BgL+cmZ/HW2rkBRV1Ki8xrXXpTDmazu1RYyWPDxmv34H+2M/7dZjfLay2h+GYWjT7nJlZyRa94XLbWhHUaVPkBn33Aytzi3V1SOzAwLubR8stpryHdU1XX89a0CDHZh/LyZP36Anv1qtUwe21YsXH9GsxzJ7w27d/+lyqwHYm38YqmN7tpZhGOr94DRV17mt97WrRmQHVJ32R0lVrWrq3PuskG8rrFDLhNiAgac6l1sDH/1GFTUuffTH4T5B1+U2dMo/f9bq3FJdeXQXKwzUutzauqdCXW3PVX9FFTUa8sR3qnMb+vSGo3W438DCNW/+ou9W5Qf8fdyX8uo6DXz0G7nchr69bZTPNOb9Yb7nmlonx+mkvm00pm8bHdOjdaMfo5w9FVbfF38FZdVyGYZPNXJ3WbVio50+fxclz/vA8Ik/KLekSsf0yNCUq4b6HINheLZMMwdGe2QmBR0sPOPFmVqyrViPnNY3YJAwGMMwtGGX5/0nHM/LYHKLqxQf4zwg1eaDZVthhTKT48PS1yGcflidpz9M+f/27jyuqjKPH/iH9XJRllgEDERNUdRRB0cTnXRUhBwztzFSLGwss1zKypRfbvQbx5py1PZNRWyBrNTREiNBM0FcApQlQFJB2czhsirb/f7+6MeZrqCi3QW5n/frxesF53nOeZ7nni/nnu895zz3BDqrrHFyZdBNH1u7VFWHoWu/AwAsGHMPloboPlZX3/jr15hd+z4qInh0yzEc/v+P9WnralG48SFUVFTA0fHG74EmSbTr6+thb2+PL774AlOmTFGWh4eHQ6PRYPfu3Tr16+rqUFf3v5PCyspK+Pj44MH138JG3fYTMmo7t84qDPRxwmBvZwzwdmpxUMy4WIG3E89gkI8z/j6yh97/+WrqGvHOwTNI+fm/N6/8Gx6Odlg+oW+bbsVsdqmqDhu/y9X5Evu2cLa3wZi+XRDk79Fi8pmKKw04mFOGxJ/K4NZZhQVjeilvCo1NWhw/V479mSXILKpQbv8MH9Fd5/uFb6RJK0grLMe3maX4qaQKvbt0xkAfZwz2doaPi/p3f+K491QR9qYX4/9OGaA897cz9QI+SymEVgRWlhZ44r6eCLpmxtJLVXV4MyEPnVTWWBrcp9VEuKFJi/isUuxMvYjBPs43nU3897pQXot/7M3G2L5d8Lch3m1Kzg1JRLD96HmkFmiwbtoflBOUD7//GTmlVXg2qPdNn1n6req6Riz74pTy1Tp336XGK9MGKlca3z2YjwvltVg4tpfyNSlarSDtggbfZpaisLwWYcO66SRt19ryw1nklVXj5cn9ldus3zl4BjV1jXghuOVtc7eq8L+1WLcvG4+N7HHTKzt3uk9TCnD6ogYrH+h3Sx/uXG1oQsRXp9HTrROeGNXztu6+qG/U4p/fZKOvp8MNJ6q5mX/H58LOxhJP/+XWbqH7Pb7NLMF32aV4aWK/Fnc5XdRcwav7fsIoP/cWd4J0VEWaK1j7dTYeG9m9xTO0pnC1oQkfHf4Z+ZdqdI5rHx3+GbmlVVg87taOa8bwxckLyCqqxIqJ/i3eFzKLKvBOYj6WhvTRubW8LT5JOY+zl2rwf/7acrtphRq8f+jXeTNudbvbk8+huOIqlob8/mNu87PY3i5qBPfzxB99nE3+3rgnvQiJOWVYObHfbd8ldeTML/jqx4tY82A/s/p2GXPV0KRF5J5MDO3ugsmD2/YNK28cyENNfSNeDOl7Sx+uFGmuYMWuDFReaUDDlRr85/ng9ptoFxUV4e6770ZSUhICAwOV5S+++CIOHTqElJQUnfpr1qxBZGRki+20ZYBEREREREREv1fzndVtyUPb1z0A1xEREYGKigrlp7Cw8OYrEREREREREZmASSZDc3Nzg5WVFUpLS3WWl5aWwtOz5cPsKpUKKlXbZqokIiIiIiIiMiWTXNG2tbXFkCFDcODAAWWZVqvFgQMHdG4lJyIiIiIiIrrTmOzrvZ577jmEh4fjT3/6E4YNG4aNGzeipqYGjz32mKm6RERERERERPS7mSzRDg0NxaVLl7Bq1SqUlJRg8ODBiIuLg4fHzb+4nIiIiIiIiKi9Mtn3aP8etzLbGxEREREREdHv1eFmHSciIiIiIiK6UzDRJiIiIiIiItIjJtpEREREREREesREm4iIiIiIiEiPmGgTERERERER6RETbSIiIiIiIiI9YqJNREREREREpEdMtImIiIiIiIj0iIk2ERERERERkR4x0SYiIiIiIiLSIybaRERERERERHrERJuIiIiIiIhIj6xN3YHbISIAgMrKShP3hIiIiIiIiMxBc/7ZnI/eyB2ZaFdVVQEAfHx8TNwTIiIiIiIiMidVVVVwcnK6YR0LaUs63s5otVoUFRXBwcEBFhYWet320KFDcfz4cb1usz22aap2jd1mZWUlfHx8UFhYCEdHR6O1C5jH62tObZoqlszl9TVVu+ZyTOI+7XhtmlMsmUubpmjXnOLIVO2aS5vmEksigiFDhiA3NxeWljd+CvuOvKJtaWkJb29vg2zbysrK6AmZKdo0VbumGqujo6NZjJVtGp6xY8mcXl9zGqs5xJGp2jWXNpuZQyyZS5umbNcc4shU7ZpLm83MIZZsbW1vmmQDnAythQULFphFm6Zq11RjNQVzeX3NpU1TMafX15zGamzcpx2vTVMxl9fXnP5nTMGcXl9zadNU2vPre0feOk7UVpWVlXByckJFRYXJPtmjjoGxRPrAOCJ9YSyRPjCOSF8YSy3xijZ1aCqVCqtXr4ZKpTJ1V+gOx1gifWAckb4wlkgfGEekL4yllnhFm4iIiIiIiEiPeEWbiIiIiIiISI+YaBMRERERERHpERNtIiIiIiIiIj1iok1ERERERESkR0y0qd37/vvvMWnSJHTt2hUWFhbYtWuXTnlpaSnmzJmDrl27wt7eHvfffz/y8vJ06uTn52Pq1Klwd3eHo6MjHnroIZSWlurU+fHHHzF+/Hg4OzvD1dUV8+bNQ3V1taGHR0aybt06DB06FA4ODujSpQumTJmCnJwcnTpXr17FggUL4Orqis6dO2P69Okt4qSgoAATJ06Evb09unTpgqVLl6KxsbHVNo8cOQJra2sMHjzYUMMiEzBmLL399tvw9/eHWq1Gnz59EB0dbfDxkXHoK44WL16MIUOGQKVS3fRYc+bMGTg4OMDZ2VnPoyFTMWYcff755xg8eDDs7e3h6+uL1157zVDDIhPQRyylp6dj5syZ8PHxgVqthr+/PzZt2nTdNjv6eRITbWr3ampqMGjQILz99tstykQEU6ZMwc8//4zdu3cjNTUVvr6+CAoKQk1NjbJ+cHAwLCwskJCQgCNHjqC+vh6TJk2CVqsFABQVFSEoKAi9evVCSkoK4uLikJmZiTlz5hhzqGRAhw4dwoIFC3D06FHEx8ejoaEBwcHBSpwAwJIlS7Bnzx7s2LEDhw4dQlFREaZNm6aUNzU1YeLEiaivr0dSUhK2bduGqKgorFq1qkV7Go0Gjz76KMaNG2eU8ZHxGCuW3n33XURERGDNmjXIzMxEZGQkFixYgD179hh1vGQY+oijZn//+98RGhp6w/YaGhowc+ZM3HfffXofC5mOseJo3759CAsLw/z585GRkYF33nkHGzZswFtvvWWwsZFx6SOWTp48iS5duuDjjz9GZmYmXnrpJURERLQaJ2ZxniREdxAAsnPnTuXvnJwcASAZGRnKsqamJnF3d5cPP/xQRET2798vlpaWUlFRodTRaDRiYWEh8fHxIiLy/vvvS5cuXaSpqUmpc+rUKQEgeXl5Bh4VmUJZWZkAkEOHDonIrzFhY2MjO3bsUOpkZ2cLAElOThYRkW+++UYsLS2lpKREqfPuu++Ko6Oj1NXV6Ww/NDRUVqxYIatXr5ZBgwYZfkBkMoaKpcDAQHnhhRd02nruuedk5MiRhh4SmcDtxNFv3exY8+KLL8rs2bNl69at4uTkpO/uUzthqDiaOXOm/O1vf9NZ9sYbb4i3t7dotVr9DoLahd8bS82efvppGTNmTIvl5nCexCvadEerq6sDANjZ2SnLLC0toVKp8MMPPyh1LCwsoFKplDp2dnawtLTUqWNrawtLy//9S6jVagBQ6lDHUlFRAQBwcXEB8OunsA0NDQgKClLq9O3bF926dUNycjIAIDk5GX/4wx/g4eGh1AkJCUFlZSUyMzOVZVu3bsXPP/+M1atXG2MoZGKGiqW6ujqdYxvw63Hp2LFjaGhoMOiYyPhuJ47aKiEhATt27Gj1zjDqWAwVR9c7Hl24cAHnz5/XQ8+pvdFXLFVUVCjbaGYu50lMtOmO1vwPHhERgfLyctTX1+PVV1/FhQsXUFxcDAAYPnw4OnXqhGXLlqG2thY1NTV44YUX0NTUpNQZO3YsSkpK8Nprr6G+vh7l5eVYvnw5ACh1qOPQarV49tlnMXLkSAwYMAAAUFJSAltb2xbPLnp4eKCkpESp89vEqLm8uQwA8vLysHz5cnz88cewtrY28EjI1AwZSyEhIfjoo49w8uRJiAhOnDiBjz76CA0NDfjll18MPDIyptuNo7a4fPky5syZg6ioKDg6Ouqz29TOGDKOQkJC8NVXX+HAgQPQarXIzc3F+vXrAfA8qSPSVywlJSUhNjYW8+bNU5aZ03kSE226o9nY2OCrr75Cbm4uXFxcYG9vj8TEREyYMEG5Ou3u7o4dO3Zgz5496Ny5M5ycnKDRaBAQEKDU6d+/P7Zt24b169fD3t4enp6e6NGjBzw8PHSuclPHsGDBAmRkZCAmJkav221qasKsWbMQGRkJPz8/vW6b2idDxRIArFy5EhMmTMDw4cNhY2ODyZMnIzw8HAB4XOpgDBlHTzzxBGbNmoVRo0bpfdvUvhg6jhYuXIgHHngAtra2GD58OB5++GEAPB51RPqIpYyMDEyePBmrV69GcHAwAPM7T+J/Bt3xhgwZgrS0NGg0GhQXFyMuLg6XL19Gz549lTrBwcHIz89HWVkZfvnlF2zfvh0XL17UqTNr1iyUlJTg4sWLuHz5MtasWYNLly7p1KE738KFC7F3714kJibC29tbWe7p6Yn6+npoNBqd+qWlpfD09FTqXDtTa/Pfnp6eqKqqwokTJ7Bw4UJYW1vD2toaL7/8MtLT02FtbY2EhATDDo6MypCxBPx6W+aWLVtQW1uLc+fOoaCgAN27d4eDgwPc3d0NODIypt8TR22RkJCA119/XTkmzZ07FxUVFbC2tsaWLVv0NQwyMUPHkYWFBV599VVUV1fj/PnzKCkpwbBhwwCA50kdjD5iKSsrC+PGjcO8efOwYsUKZbm5nScx0aYOw8nJCe7u7sjLy8OJEycwefLkFnXc3Nzg7OyMhIQElJWV4cEHH2xRx8PDA507d0ZsbCzs7Owwfvx4Y3SfDExEsHDhQuzcuRMJCQno0aOHTvmQIUNgY2ODAwcOKMtycnJQUFCAwMBAAEBgYCBOnz6NsrIypU58fDwcHR3Rr18/ODo64vTp00hLS1N+5s+fjz59+iAtLQ333nuvcQZLBmWMWPotGxsbeHt7w8rKCjExMXjggQd4BakD0EcctUVycrLOMenll1+Gg4MD0tLSMHXqVL2Nh0zDWHHUzMrKCnfffTdsbW3x2WefITAwkB/8dRD6iqXMzEyMGTMG4eHhWLt2rc42zO48yZQzsRG1RVVVlaSmpkpqaqoAkH//+9+Smpoq58+fFxGRzz//XBITEyU/P1927dolvr6+Mm3aNJ1tbNmyRZKTk+XMmTOyfft2cXFxkeeee06nzptvviknT56UnJwceeutt0StVsumTZuMNk4yrKeeekqcnJzk4MGDUlxcrPzU1tYqdebPny/dunWThIQEOXHihAQGBkpgYKBS3tjYKAMGDJDg4GBJS0uTuLg4cXd3l4iIiOu225Fn0zRXxoqlnJwc2b59u+Tm5kpKSoqEhoaKi4uLnD171pjDJQPRRxyJiOTl5Ulqaqo8+eST4ufnp7xfXvtNCM0463jHYqw4unTpkrz77ruSnZ0tqampsnjxYrGzs5OUlBSjjpcMRx+xdPr0aXF3d5fZs2frbKOsrOy67Xbk8yQm2tTuJSYmCoAWP+Hh4SIismnTJvH29hYbGxvp1q2brFixosUJxrJly8TDw0NsbGykd+/esn79+hZfR/HII4+Ii4uL2NraysCBAyU6OtpYQyQjaC2GAMjWrVuVOleuXJGnn35a7rrrLrG3t5epU6dKcXGxznbOnTsnEyZMELVaLW5ubvL8889LQ0PDddvtyG8g5spYsZSVlSWDBw8WtVotjo6OMnnyZPnpp5+MNUwyMH3F0ejRo1vdzvU+kGGi3bEYK44uXbokw4cPl06dOom9vb2MGzdOjh49asSRkqHpI5ZWr17d6jZ8fX2v225HPk+yEBHR80VyIiIiIiIiIrPFh7yIiIiIiIiI9IiJNhEREREREZEeMdEmIiIiIiIi0iMm2kRERERERER6xESbiIiIiIiISI+YaBMRERERERHpERNtIiIiIiIiIj1iok1ERERERESkR0y0iYjILK1ZswaDBw9W/p4zZw6mTJli8HYtLCywa9cug7fTHnTv3h0bN240aBsHDx6EhYUFNBrNLa1nTvuBiIiMj4k2ERG1O8nJybCyssLEiRON1uamTZsQFRWlt+1dm8g3Ky4uxoQJE/TWTmuioqJgYWEBCwsLWFpawsvLC6GhoSgoKDBou9c6fvw45s2bZ9Q2DeV6+5OIiKg1TLSJiKjd2bx5MxYtWoTvv/8eRUVFRmnTyckJzs7OBm/H09MTKpXK4O04OjqiuLgYFy9exJdffomcnBzMmDHD4O3+lru7O+zt7Y3aJhERUXvARJuIiNqV6upqxMbG4qmnnsLEiRNbXGVuvlX466+/xsCBA2FnZ4fhw4cjIyNDqRMVFQVnZ2fs2rULvXv3hp2dHUJCQlBYWHjddq+9dVyr1eJf//oXevXqBZVKhW7dumHt2rVK+bJly+Dn5wd7e3v07NkTK1euRENDg9J+ZGQk0tPTlSvLzeO49pbl06dPY+zYsVCr1XB1dcW8efNQXV3dol+vv/46vLy84OrqigULFihtXY+FhQU8PT3h5eWFESNGYO7cuTh27BgqKyuVOrt370ZAQADs7OzQs2dPREZGorGxUSnXaDR48skn4eHhATs7OwwYMAB79+5Vyn/44Qfcd999UKvV8PHxweLFi1FTU6OU//bW8VmzZiE0NFSnjw0NDXBzc0N0dLTymq9btw49evSAWq3GoEGD8MUXX+is880338DPzw9qtRpjxozBuXPnbvg6AEBeXh5GjRoFOzs79OvXD/Hx8S3q3O7+1Gg0ePzxx+Hu7g5HR0eMHTsW6enpN+0TERF1bEy0iYioXfn888/Rt29f9OnTB7Nnz8aWLVsgIi3qLV26FOvXr8fx48fh7u6OSZMm6SSftbW1WLt2LaKjo3HkyBFoNBo8/PDDbe5HREQEXnnlFaxcuRJZWVn49NNP4eHhoZQ7ODggKioKWVlZ2LRpEz788ENs2LABABAaGornn38e/fv3R3FxMYqLi1skmQBQU1ODkJAQ3HXXXTh+/Dh27NiB7777DgsXLtSpl5iYiPz8fCQmJmLbtm2Iioq6pdvcy8rKsHPnTlhZWcHKygoAcPjwYTz66KN45plnkJWVhffffx9RUVHKhwlarRYTJkzAkSNH8PHHHyMrKwuvvPKKsn5+fj7uv/9+TJ8+HadOnUJsbCx++OGHFn1vFhYWhj179uh8iLB//37U1tZi6tSpAIB169YhOjoa7733HjIzM7FkyRLMnj0bhw4dAgAUFhZi2rRpmDRpEtLS0vD4449j+fLlNxy7VqvFtGnTYGtri5SUFLz33ntYtmxZi3q3uz9nzJiBsrIy7Nu3DydPnkRAQADGjRuH//73v23eP0RE1AEJERFROzJixAjZuHGjiIg0NDSIm5ubJCYmKuWJiYkCQGJiYpRlly9fFrVaLbGxsSIisnXrVgEgR48eVepkZ2cLAElJSRERkdWrV8ugQYOU8vDwcJk8ebKIiFRWVopKpZIPP/ywzf1+7bXXZMiQIcrf126/GQDZuXOniIh88MEHctddd0l1dbVS/vXXX4ulpaWUlJQo/fL19ZXGxkalzowZMyQ0NPS6fWkef6dOncTe3l4ACABZvHixUmfcuHHyz3/+U2e97du3i5eXl4iI7N+/XywtLSUnJ6fVNubOnSvz5s3TWXb48GGxtLSUK1euiIiIr6+vbNiwQUT+ty+jo6OV+jNnzlTGcfXqVbG3t5ekpKQW7cycOVNERCIiIqRfv3465cuWLRMAUl5e3mo/9+/fL9bW1nLx4kVl2b59+3T2Q2vasj8PHz4sjo6OcvXqVZ3l99xzj7z//vvX3TYREXV81ibL8ImIiK6Rk5ODY8eOYefOnQAAa2trhIaGYvPmzfjLX/6iUzcwMFD53cXFBX369EF2drayzNraGkOHDlX+7tu3L5ydnZGdnY1hw4bdsB/Z2dmoq6vDuHHjrlsnNjYWb7zxBvLz81FdXY3GxkY4OjreynCRnZ2NQYMGoVOnTsqykSNHQqvVIicnR7mC3r9/f+VKMgB4eXnh9OnTN9y2g4MDfvzxRzQ0NGDfvn345JNPdG59T09Px5EjR3SWNTU14erVq6itrUVaWhq8vb3h5+fX6vbT09Nx6tQpfPLJJ8oyEYFWq8XZs2fh7++vU9/a2hoPPfQQPvnkEzzyyCOoqanB7t27ERMTAwA4c+YMamtrMX78eJ316uvr8cc//lF5ve69916d8t/GQWuys7Ph4+ODrl273nCd29mf6enpqK6uhqurq87yK1euID8//4brEhFRx8ZEm4iI2o3NmzejsbFRJykSEahUKrz11ltwcnIySj/UavUNy5OTkxEWFobIyEiEhITAyckJMTExWL9+vUH6Y2Njo/O3hYUFtFrtDdextLREr169AAD+/v7Iz8/HU089he3btwP49Vn4yMhITJs2rcW6dnZ2N30Nqqur8eSTT2Lx4sUtyrp169bqOmFhYRg9ejTKysoQHx8PtVqN+++/X9keAHz99de4++67ddYz9ORxt7s/q6ur4eXlhYMHD7YoM8bEekRE1H4x0SYionahsbER0dHRWL9+PYKDg3XKpkyZgs8++wzz589Xlh09elRJ6MrLy5Gbm6tzFbWxsREnTpxQrl7n5ORAo9G0uNLamt69e0OtVuPAgQN4/PHHW5QnJSXB19cXL730krLs/PnzOnVsbW3R1NR0w3b8/f0RFRWFmpoa5ar2kSNHYGlpiT59+ty0n7di+fLluOeee7BkyRIEBAQgICAAOTk5SjJ+rYEDB+LChQvIzc1t9ap2QEAAsrKyrrt+a0aMGAEfHx/ExsZi3759mDFjhvIhQr9+/aBSqVBQUIDRo0e3ur6/vz/+85//6Cw7evToDdv09/dHYWEhiouL4eXl1eo6t7s/AwICUFJSAmtra3Tv3v2G/SAiIvPCydCIiKhd2Lt3L8rLyzF37lwMGDBA52f69OnYvHmzTv2XX34ZBw4cQEZGBubMmQM3NzedWcNtbGywaNEipKSk4OTJk5gzZw6GDx9+09vGgV+v6C5btgwvvvgioqOjkZ+fj6NHjyp96N27NwoKChATE4P8/Hy88cYbyu3uzbp3746zZ88iLS0Nv/zyC+rq6lq0ExYWBjs7O4SHhyMjIwOJiYlYtGgRHnnkEZ2J1/TBx8cHU6dOxapVqwAAq1atQnR0NCIjI5GZmYns7GzExMRgxYoVAIDRo0dj1KhRmD59OuLj43H27Fns27cPcXFxAH6dpTspKQkLFy5EWloa8vLysHv37utOhtZs1qxZeO+99xAfH4+wsDBluYODA1544QUsWbIE27ZtQ35+Pn788Ue8+eab2LZtGwBg/vz5yMvLw9KlS5GTk4NPP/30ppPCBQUFwc/PD+Hh4UhPT8fhw4d1Emrg9vdnUFAQAgMDMWXKFHz77bc4d+4ckpKS8NJLL+HEiRM33ylERNRxmfohcSIiIhGRBx54QP7617+2WpaSkiIAJD09XZkMbc+ePdK/f3+xtbWVYcOGSXp6ulJ/69at4uTkJF9++aX07NlTVCqVBAUFyfnz55U6N5oMTUSkqalJ/vGPf4ivr6/Y2NhIt27ddCYPW7p0qbi6ukrnzp0lNDRUNmzYIE5OTkr51atXZfr06eLs7CwAZOvWrSIiLSbhOnXqlIwZM0bs7OzExcVFnnjiCamqqrpuv0REnnnmGRk9evR1X8vm8V8rOTlZZ0K4uLg4GTFihKjVanF0dJRhw4bJBx98oNS/fPmyPPbYY+Lq6ip2dnYyYMAA2bt3r1J+7NgxGT9+vHTu3Fk6deokAwcOlLVr1yrlv50MrVlWVpYAEF9fX9FqtTplWq1WNm7cKH369BEbGxtxd3eXkJAQOXTokFJnz5490qtXL1GpVHLffffJli1bbjgZmohITk6O/PnPfxZbW1vx8/OTuLi4FvvhdvdnZWWlLFq0SLp27So2Njbi4+MjYWFhUlBQcN3+EBFRx2ch0sp3phAREbVTBw8exJgxY1BeXn7d52CjoqLw7LPPQqPRGLVvRERERABvHSciIiIiIiLSKybaRERERERERHrEW8eJiIiIiIiI9IhXtImIiIiIiIj0iIk2ERERERERkR4x0SYiIiIiIiLSIybaRERERERERHrERJuIiIiIiIhIj5hoExEREREREekRE20iIiIiIiIiPWKiTURERERERKRH/w+O4zzdY8Q91AAAAABJRU5ErkJggg==",
      "text/plain": [
       "<Figure size 1200x600 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "df[\"Application Received date\"].groupby(df[\"Application Received date\"].dt.to_period(\"M\")).count().plot(figsize=(12, 6), title=\"Number of applications received per month\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "id": "f7492dcb",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Application Received date\n",
       "2011-01-01    276\n",
       "2012-05-01     27\n",
       "2014-08-01     21\n",
       "2013-11-01     20\n",
       "2010-03-01     18\n",
       "             ... \n",
       "2016-11-08      1\n",
       "2016-11-07      1\n",
       "2016-11-01      1\n",
       "2016-10-18      1\n",
       "2026-01-14      1\n",
       "Name: count, Length: 790, dtype: int64"
      ]
     },
     "execution_count": 11,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df[\"Application Received date\"].value_counts()"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.12.3"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
